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ABSTRACT
Acquired expression of transcriptionally active p73 
in hepatocellular carcinoma cells
A. Emre Sayan
Ph.D. in Molecular Biology and Genetics 
Supervisor: Prof. Dr. Mehmet Ozturk 
2002, 127 pages
P53 gene is the most common mutated tumor suppressor gene during tumorigenesis. 
From its description till 1997, p53 gene was thought to stand alone in the human 
genome. In 1997, p73 gene and in 1998, p63 gene was identified which are encoding 
functional homologues of p53 protein. Unlike p53, the knock out mice for p73 and 
p63 genes did not yield a tumor prone phenotype and the mutation frequency of these 
genes is very low compared to p53 gene. There is also extensive alternative splicing 
and changes in the expression pattern of p73 and p63, unlike p53. Thus the new p53 
homologues were considered as non-classical and non-Knudson type tumor 
suppressor genes. A codon specific, aflatoxin ingestion related p53 mutation was 
shown to be important in the ethiopathology of HCC so loss of p53 function is a 
major factor during HCC development. The rate of p53 functional inactivation was 
determined by lots of studies in HCC but the knowledge for new p53 homologues is 
scarce. We aimed to define the probable function of the new p53 homologue, p73 in 
HCC development. For this purpose, we have analyzed the 3’ alternative splicing and 
expression pattern of p73 in a series of HCC derived cell lines. Our results showed 
the alteration of splicing and expression in HCC cell lines compared to normal liver. 
After the completion of human genome project, the contig harboring the p73 gene 
was entered to the public database. With the hints of the presence of an alternative 
promoter in the p63 gene and the description of the alternative promoter in mouse 
p73 gene, we have made an in silico analysis to identify the probable promoter and 
exon within p73 gene. Our studies revealed the in vivo description of a new human 
p73 encoded transcript. The proposed protein product of the transcript was lacking 
the transactivation domain so it was named as Dominant Negative p73 (DN-p73) and
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the former p73 was renamed as Transactivating p73 (TA-p73). Since the promoters 
of these two transcripts are different and probably under the regulation of different 
transcription factors, we studied the expression pattern of them by semi quantitative 
RT-PCR method. We have shown the presence of only DN-p73 in normal in normal 
liver. HCC derived cell lines and primary HCC tumors also express DN-p73 
together with the acquired expression of TA-p73 in most of the cell lines and some of 
the primary HCC tumors. The promoter of TA-p73 was shown contain E2F1 
transcription factor binding sites. The Retinobastoma protein (pRb) is the most 
potent inhibitor of the E2F1 transcription factor and the dysrégulation of the Rb 
pathway components is a common event in HCC development (Rb gene mutations 
and proteolytic dysrégulation of pRb and mutational and epigenetic inactivation of 
p i6). We have shown the expression of TA-p73 in some of the HCC derived cell 
lines and primary HCC tumors so the acquired expression of TA-p73 in HCC cells 
might be the indicator and the effect of of Rb pathway dysrégulation. We tested this 
hypothesis by analyzing the expression of pRb and p i6, together with the 
endogenous E2F1 transcription factor targets such as cyclin E, p i4' ’^^  and TA-p73. 
Our results showed a 75% inactivation of Rb pathway components and a partial 
correlation of TA-p73 expression in HCC cells. The acquired expression of TA-p73 
in HCC cells is unfavorable during tumorigenesis since TA-p73 mimics the pro- 
apoptotic and cell cycle regulatory, function of wild type p53. Mutant p53 proteins 
were shown to inhibit the pro-apoptotic fliction of wild-type p53 and TA-p73. We 
have analyzed the p53 protein status of 15 HCC derived cell lines and defined the 
presence of mutant p53 or no functional p53 protein in 87% of the HCC derived cell 
lines. As a summary, we have identified the human homologue of mouse DN-p73 
and defined the 3’ alternative splicing and 5’ differential promoter initiation products 
of p73 gene encoded products in normal liver versus a series of HCC derived cell 
lines and primary tumors. Moreover we have correlated the expression of TA-p73 
with Rb pathway inactivation and expression of mutant p53 proteins.
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ÖZET
Karaciğer kanseri hücrelerinde p73’ün transkripsiyonel olarak aktif
formunun edinilmiş ifadesi
A. Emre Sayan
Doktora Tezi, Moleküler Biyoloji ve Genetik Bölümü 
Tez yöneticisi: Prof. Dr. Mehmet Öztürk 
2002, 127 sayfa
P53 geni tümör oluşumu sırasında en sık mutasyona uğrayan gendir. 
Tanımlanmasından 1997 yılına kadar, p53 geninin insan genomunda yalnız olduğu 
düşünülüyordu. p53 proteininin fonksiyonel homologları kodlayan p73 ve p63 
genleri sırasıyla 1997’de ve 1998’de bulunmuştur. p53’ün aksine, p73 veya p63 geni 
olmayan farelerin tümör oluşumuna yatkınlıklarında bir değişiklik olmadığı gibi, bu 
genlerde görülen mutasyon sıklığı da p53’e oranla çok düşüktür. Aynca yine p53’ün 
aksine, p73 ve p63’te kapsamlı bir alternatif kırpılma ve gen ifadesi değişimleri 
bulunmaktadır. Bu sebeplerden dolayı, bu yeni p53 homologları atipik ve Knudson 
hipoyezine uymayan tümör baskılayıcı genler olarak değerlendirilmektedir. 
Aflatoksine bağlı, bir kodona özgül p53 mutasyonunun HCC etiyopatolojisindeki 
önemi, p53’ün fonksiyonel kaybının HCC gelişiminde önemli bir faktör olduğunu 
vurgulamaktadır. p53 mutasyonlarının HCC’deki önemi ile ilgili pek çok çalışma 
olduğu halde, p53 homologları ile ilgili çalışma çok azdır. Bu nedenle biz, yeni p53 
homologlarından biri olan p73’ün HCC gelişimindeki olası rolünü araştırdık. Bunun 
için p73’ün 3’ alternatif kırpılma ve ifade profilini bir seri HCC kökenli hücre 
hattında araştırdık. Sonuçlarımız, p73’ün normal karaciğere kıyasla HCC hücre 
hatlarında kırpılma ve ifade değişimlerine uğradığını gösterdi. İnsan genom 
projesinin tamamlanmasının ardından p73 genini taşıyan kontig databaza sunuldu. 
p63 geninde bir alternatif promotorun varlığı ve fare p73’ünde bir alternatif 
promotorun tanımlanması üzerine p73 genininde olası bir promotor ve ekson 
tanımlamak üzere in siliko bir analiz yaptık. Çalışmalarımız sonucunda insan p73 
geninden kodlanan yeni bir transkripti in vivo olarak tanımladık. Bu transkriptten 
oluşacak olası proteinde transaktivasyon bölgesi olmayacağından bu proteini
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‘Dominant Negatif p73’ (DN-p73) ve önceden bilinen p73 formunu da ‘Transaktive 
Edebilen p73’ (TA-p73) olarak adlandırdık. Bu iki transkriptin promotorları farklı 
olduğundan ve muhtemelen farklı transkripsiyon faktörleri tarafından regüle 
edildiklerinden, bunların ifadesini yarı-kuantitatif RT-PCR metoduyla çalıştık. 
Normal karaciğerde sadece DN-p73 ifadesine rastlarken; HCC kökenli hücre 
hatlarının çoğunun ve primer HCC tümörlerinden bazılarının DN-p73 ifadesini 
korurken, TA-p73 ifadesini edindiklerini gösterdik. TA-p73 promotorunda E2F1 
transkripsiyon faktörü bağlanma noktaları bulunmaktadır. Retinoblastoma proteini 
(pRB) E2F1 transkripsiyon faktörünün en güçlü inhibitörlerinden biridir ve Rb yolu 
bileşenlerinin regülasyonundaki bozukluklara HCC’de sıklıkla rastlanmaktadır (Rb 
geni mutasyonları ve pRB proteini yıkımıyla ilgili bozukluklar ile p lö ’nın 
mutasyonları ve epigenetik mekanizmalar ile inaktivasyonu). Biz TA-p73’ün bazı 
HCC kökenli hücre hatları ve primer HCC tümörlerinde edinilmiş ifadesi 
gösterdiğimizden, bu ekspresyonun Rb yolu regülasyonundaki bozuklukların 
indikatörü ve sebebi olabileceğini düşündük. Bu hipotezi pRb, pl6 ve endojen E2F1 
transkripsiyon faktörü hedeflerinin (cyclin E, pl4'^^ and TA-p73) ifadesi analizini 
yaparak test ettik. Sonuçlarımız Rb yolu bileşenlerinde %75 inaktivasyon ve TA-p73 
ifadesi ile de kısmi bağdaşma olduğunu gösterdi. TA-p73, p53’ün pro-apoptotik ve 
hücre döngüsü düzenleyicisi fonksyonlarmı taklit ettiğinden, aslında TA-p73’ün 
HCC hücrelerindeki edinilmiş ifadesi tunıor gelişimini desteklememektedir. Mutant 
p53 proteinin, p53 ve TA-p73 proteinlerinin pro-apoptotik fonksiyonlarını 
engellediği bilindiğinden, 15 HCC kökenli hücre hattında p53 proteininin durumunu 
kontrol ettik. Bu hücre hatlarının %87’sinde mutant veya fonksiyonel olmayan p53 
olduğunu tesbit ettik. Özetle, fare DN-p73’ünün insan homoloğunu tanımladık ve 
p73 geninden sentezlenen 3’ alternatif kırpılma ve 5’ farklı promotor sonucu oluşan 
değişik gen ürünlerinin, normal karaciğere kıyasla primer tümörler ve HCC kökenli 
hücre hatlanndaki ifadesinin analizini yaptık. Ayrıca TA-p73 ifadesini Rb yolu 
inaktivasyonu ve mutant p53 expresyonu varlığı ile bağdaştırdık.
VII
ACKNOWLEDGEMENTS
Firstly, I would like to thank to my supervisor, Prof. Dr. Mehmet Ozturk 
for chosing me as his Ph.D. student and making me his collègue. He opened up 
my vision, thought me how to make research and how to make science. Dr. 
Ozturk is the scientist that I have taken as a model and want to be in the future. 
He is also my model in humaniterian aspect as being modest, patient, diligent and 
reliable. I have great intentions to be his collègue again.
I would also like to thank to my wife, Berna, for being the person she is. 
Without her, this thesis will not come into existence. She helped me a lot in my 
and it is impossible to be inaffirmative when she is around. She is a very “handy 
minded” person so she makes life and experiments easier.
I would also like to thank to my parents Erol and Esin Sayan for 
supporting me to be a scientist from the beginning of my education. I also would 
like to thank to Keriman Ozcelik as my new mother in Ankara. I can never forget 
the support of “Erkilic Family”, especially Ali, Revman, Cenan, Saide and 
Burhanettin. My .special thanks go to Eser, Korean and Aysin as sisters and 
brother. They are ready when I ask their help.
I would like to express my deepest regards to the Bilkent MBG department 
faculty sharing their experiences with me. They have supported and positively 
critisized me, so helped me to evaluate and improve my scientific thinking.
The junior members of the Molecular Oncology Group, especially Esra, 
Tolga, Nuri and Ozgur made my time memorable here. I would like to thank to 
them for their great friendship, help and support.
I specially want to thank Ahmet Ucar and Abdullah Yalcin for being my 
friends. I have my best times in Bilkent University with them.
VIII
Special thanks to Tuba, Ebru, Cemaliye, Hani and Belhaj as friends and grad 
students of MBG Department. I also wish to express my deepest graditudes to Tulay, 
Fusun Hn, Sevim Hn, Abdullah bey and Yavuz bey for supporting MBG depatment 
and for their constant efforts.
IX
TABLE OF CONTENTS
ABSTRACT.............................................................................................  iii
ÖZET..........................................................................................................  vi
ACKNOWLEDGEMENT........................................................................  viii
TABLE OF CONTENTS.......................................................................... x
LIST OF TABLES...................................................................................  xiv
LIST OF FIGURES..................................................................................  xv
ABBREVIATIONS..................................................................................  xiv
Inroduction.................................................................................................. 1
Chapter I
1-1 Cancer........................................................................................ 2
1-2 Hepatocellular carcinoma.........................................................4
1-2.1 Etiology ofHCC...................................................... 5
1- 2.2 Genetics ofHCC.......................................................6
1-2.2.1 Oncogenes.....................................................7
1-2.2.2 Tumor Supressor Genes.............................  8
1-3 Retinoblastoma Pathway......................................................  11
1- 4 p53 Pathway........................................................................  İ4
Chapter II The p53 homologue p73
2- 1 Identification of p73..............................................................İ7
2-2 Mutation detection studies of p73.......................................... 21
2-3 Knock out studies of p73.........................................................29
2-4 Functional Studies of p73........................................................31
2- 4.1 TA-p73............................................................. 31
2-4.2 DN-p73............................................................. 32
2-5 Inhibition of p73 by p53 mutants............................................34
PAGE
X
Aim and Strategy of the study................................................................  36
Chapter III Aim and Strategy of the Study............................................  37
Materials and Methods..............................................................................  39
Chapter IV Materials and Methods..........................................................  40
4-1 Tissue Culture Studies..............................................................40
4-1.1 Defrosting cells......................................................... 40
4-1.2 Subculturing of cells................................................. 41
4-1.3 Freezing cells............................................................. 42
4-2 Protein Studies.......................................................................... 42
4-2.1 Protein Extraction from Cells or Tissues...........  42
4-2.1.1 Protein Extraction from Cultured Cells... 42
4-2.1.2Protein Extraction from Tissues................. 43
4-2.2 Bradford Assay for Protein Quantitation..........  43
4-2.3 SDS-Polyacrylamide Gel Electrophoresis
of Proteins..............................................................  44
4-2.4 Transfer of Proteins from SDS-Polyacrylamide.. .49
Gels to Solid Supports........................................  50
4-2.5 Staining proteins immobilized on solid surfaces with
Ponceau S............................................................... 50
4-2.6 Immunological detection of immobilized proteins50 
4-2.7 Detection of proteins immobilized on membranes by
using the ECL Western Blotting kit.....................  51
4-3 Extraction of RNA from Cells and Tissues...................  51
4-3.1 RNA extraction by conventional method...........  51
4-3.2 RNA Isolation with TriPure Reagent.....................53
4-3.2.1 Phase Seperation Step................................. 54
4-3.2.2 RNA Isolation Step......................................54
4-3.3 RNA Isolation by Nucleospin-II kit....................... 55
4-3.4 Formaldehyde Containing RNA Gel and
RNA Electrophoresis.............................................  55
4-4 Extraction of DNA from Cells and Tissues........................  56
4-5 cDNA Preparation from Total RNA.................................... 56
4-6 PCR Amplification Using cDNA............................................57
XI
4-7 Defining the Fidelity of Reverse Transcription and Genomic
DNA Contamination in the cDNA........................................ 58
4-8 Expression analysis of RNA using cDNA........................... 59
4-8.1 Comparison with GAPDH.................................... 59
4-8.2 Equalizing GAPDH............................................  59
4-8.3 PCR amplification of selected transcripts using the
optimized cDNA......................................................60
4-9 CLONING for SEQUENCING............................................ 61
4-9.1 Growth of E. coli strains.........................................61
4-9.2 Preparation of competent bacteria.......................  62
4-9.3 Ligation................................................................ 62
4-9.4 Transformation of plasmid DNA in bacterial cells63
4-9.5 Isolation of plasmid DNA from bacteria : Small scale
preparation of plasmid DNA................................ 63
4-9.6 Restriction enzyme analysis.................................. 65
4- 10 Analysis of DNA using agarose gel electrophoresis........65
Results........................................................................................................ 66
Chapter V The description and analysis of p73 gene encoded transcripts 
and proteins................................................................................................ 67
5- 1 RNA isolation by conventional method..............................  67
5-2 cDNA preparation and P-actin PCR results............................ 67
5-3 Description of 3’ end alternative splicing forms ofp73 transcripts
by 2 round PCR amplification..................................................68
5-4 Identification of consistantly amplified smaller bands as new
transcript isoforms and cloning of the new transcripts......... 70
5-5 Sequencing results and the description of exon-exon boundries
of alternative splicing products............................................  72
5-6 Identification of a new exon and a promoter region within intron
3 of p73 gene.........................................................................  73
5-7 Description of the transcript from the new promoter containing
the new exon.........................................................................  74
5-8 Cloning and sequencing of the new transcript...................  74
5-9 RNA isolation by TriPure reagent and purification by MN
XII
Nucleospin Π kit from 15 HCC derived cell line, 7 primary 
HCC tumor, 1 correspoding non-tumor liver
and 1 normal liver................................................................  75
5-10 cDNA preparation and GAPDH PCR results....................  77
5-11 Description of 3’ end alternative splicing forms of p73 inl5 
HCC cell lines compared to a normal liver by
semi-quantitative PCR........................................................  79
5-12 Densitométrie analysis of the p73, 3’ end splicing isoforms
compared to normal liver................................................  81
5-13 Description of TA and DN-p73 transcript isotypes by 
semi-quantitative PCR in 15 HCC cell lines and 
primary HCC samples.........................................................  84
5- 14 The description of the presence of endogenous DN-p73 protein
in a HCC derived cell line....................................................  87
Chapter VI The status of Rb pathway components and the evidence
for the activity of E2F1 transcription factor...................  89
6- 1 Description of pl6 transcripts by semi quantitative PCR in
15 HCC cell lines..................................................................... 90
6-2 The description of Retinoblastoma protein in HCC cell lines91
6- 3 The description of endogenous E2F1 targets, pl4ARF and
Cyclin E.................................................................................  93
Chapter VII The protein ststus and codon 72 polymorphism of
p53 gene...........................................................................  98
7- 1 Western Blot for p53 protein for 15 HCC cell lines........  99
7-2 Genotyping the codon 72 Arg/Pro polymorphism of p53 from
HCC cell lines.........................................................................  99
Chapter VIII The summary of results....................................................  101
Discussion and Future Perspectives......................................................... 103
Chapter IX Discussion.............................................................................  104
XIII
Chapter X Future Perspectives................................................................  112
References.................................................................................................  113
Chapter XI References............................................................................. 114
Appendix: Publications of the author during the progression of this thesis
XIV
LIST OF TABLES
NUMBER/NAME PAGE
Table 2-1: Summary of the studies defining the LOH at lp36, 
mutation of p73 gene, polymorphisms of p73 gene and the
expression of p73 RNA or protein................................................................. 23
Table 2-2: The summary of all identified mutations and
polymorphisms of the p73 gene with references..........................................  26
Table 4-1: The cell lines used in this thesis................................................... 41
Table 4-2: Effective range of separation of SDS-PAGE gels................    44
Table 4-3: Solution of preparing resolving gels for Tris-glycine
SDS-PAGE...............................................................................................................47
Table 4-4: Solution of preparing 5% stacking gels for Tris-glycine
SDS-PAGE....................................................................................................... 48
Table 4-5: The primary antibodies used in this thesis..................................  51
Table 4-6: The reagents of a common PCR reaction...................................  57
Table 4-7: Synthetic Oligonucleotides Used In This Study......................... 60
Table 5-1: The probable product size of a and b specific second round
PCR reactions.................................................................................................... 70
Table 5-2: The densitométrie analysis of p73, 3’ splicing isoforms in
numeric form compared to normal liver.........................................................  83
Table 6-1: Correlation of TA-p73 induction with E2F1 target gene activation 
and the retinoblastoma (RBI) pathway inactivation, in HCC cell lines...... 97
XV
LIST OF FIGURES
NUMBER/NAME PAGE
Figure 1-1: Common effected pathways during tumorigenesis....................  4
Figure 1-2; Cell cycle and cell cycle regulators........................................ 13
Figure 1-3: The activation and effects of p53 protein................................ 14
Figure 1-4: The anti-mitotic effect of p53 on uncontrolled division....... 15
Figure 2-1: p73 gene encoded transcripts and their alternative splicing
Products.......................................................................................................... 19
Figure 2-2: The alignment of p73 and p53 proteins.................................... 20
Figure 2-3: The schematic representation of all identified mutations 
and polymorphisms of p73 gene together with corresponding domains
of p73 protein....................................................................................................... 28
Figure 2-4 : The mouse p73 gene and transcription initiation architecture... 29 
Figure 5-1: The RT-PCR picture of P-actin of 10 HCC cell lines and
a normal liver........................................................................................................  68
Figure 5-2: The schematic representation of the approach: Two round PCR
based detection of 3’ alternative splicing products of p73 transcripts...........  69
Figure 5-3: Second round PCR results of p73a specific PCR of 10 HCC
cell lines and a normal liver............................................................................. 69
Figure 5-4: Second round PCR results of p73p specific PCR of 10 HCC cell lines
and a normal liver.......................................... ; ................................................. 70
Figure 5-5: A representative miniprep results of several p73 alternative splicing
products.................................................................................................................  71
Figure 5-6: Restriction of miniprep results of several p73 alternative splicing
products with EcoRI............................................................................................. 71
Figure 5-7: The sequencing results of the plasmid clones containing the different
splicing products of p73.....................................................................................  72
Figure 5-8: The analysis of the contig, covering a putative promoter, 
binding sites for transcription factors, a putative exon,
XVI
transcription and translation initiation sites and a splice donor site...........  73
Figure 5-9: The PCR result of exon 3’-exon 4 which is specific for DN-p73
butnotTA-p73.................................................................................................  74
Figure 5-10: The sequencing result of a DN-p73 clone...............................  75
Figure 5-11: RNA electrophoresis of purified RNA from 15 cell lines and
normal liver.......................... ..........................................................................  76
Figure 5-12: The purified total RNA of the 7 archival HCC tumors
and 1 corresponding non-tumor tissue............................................................  76
Figure 5-13: The strategy of semi-quantitative PCR optimization...............  78
Figure 5-14: Cycle optimization of GAPDH RT-PCR................................. 78
Figure 5-15: The 24 cycle GAPDH PCR results from all cell lines and
the normal liver.................................................................................................  79
Figure 5-16: The GAPDH PCR results of archival tumors and the non-tumor 79
Figure 5-17: Cycle optimization of p73a semi-quantitative RT-PCR...........  80
Figure 5-18: Cycle optimization of p73p semi-quantitative RT-PCR...........  80
Figure 5-19: Semi quantitative PCR results of p73a specific PCR...............  81
Figure 5-20: Semi quantitative PCR results of p73p specific PCR...............  81
Figure 5-21: The densitométrie analysis three representative HCC cell
lines of p73 3’ end alternative splicing isoforms compared to normal liver... 82
Figure 5-22: Cycle optimization of TA-p73 semi-quantitative RT-PCR.....  84
Figure 5-23: Cycle optimization of DN-p73 semi-quantitative RT-PCR....... 84
Figure 5-24: Semi quantitative PCR results of TA-p73 specific PCR for
15 HCC cell lines and a normal liver................................................................ 85
Figure 5-25: Semi quantitative PCR results of DN-p73 specific PCR for
15 HCC cell lines and a normal liver................................................................  85
Figure 5-26: Semi quantitative PCR results of TA-p73 specific PCR for
7 primary HCC samples and a non-tumor liver..............................................  86
Figure 5-27: Semi quantitative PCR results of DN-p73 specific PCR for
7 primary HCC samples and a non-tumor liver................................................  86
Figure 5-28 : Western blot using the ER13 antibody, which recognized an
epitope against the carboxyl-end of the p73 protein........................................  88
Figure 6-1 : Cycle optimization for p i6, semi quantitative RT-PCR...........  91
Figure 6-2 : Semi-quantitative pl6 PCR results of 15 HCC cell lines...........  91
XVII
Figure 6-3 : Anti-p33INGl western blot results of 15 HCC cell lines........... 92
Figure 6-4 : Anti pRb western blot results of 15 HCC cell lines...................  92
Figure 6-5 ; Cycle optimization for cyclin E, semi quantitative RT-PCR......  94
Figure 6-6 : Cycle optimization for pl4, semi quantitative RT-PCR.............  94
Figure 6-7 : Semi-quantitative Cyclin E PCR results of 15 HCC cell lines
and a normal liver..................................................................................................95
Figure 6-8 : Semi-quantitative cyclin E PCR results of a non-tumor liver
and 7 HCC tumors............................................................................................. 95
Figure 6-9 : Semi-quantitative p 14 PCR results of 15 HCC cell lines
and a normal liver.................................................................................................  95
Figure 6-10 : Semi-quantitative pl4 PCR results of a non-tumor liver and
7 HCC tumors.....................................................................................................  96
Figure 7-1 : Anti p53 western blot results of 15 HCC cell lines...................  99
Figure 7-2 ;The restriction products of p53 PCR revealing the R/P
status of codon72.............................................................................................  100
Figure 9-1 : Linking the Rb pathway and p53 pathway components through 
P 14'^^’’ and TA-p73.........................................................................................  106
XVIII
ABBREVIATIONS
ARF Alternative Reading Frame
BSA Bovine Serum Albumin
CDK Cyelin Dependent Kinase
CKI Cyclin Dependent Kinase Inhibitor
CO2 Carbon Dioxide
C-terminus carboxy terminus
DNA deoxyribonucleic acid
HBV Hepatitis B virus
HCC Hepatocellular Carcinoma
HCV Hepatitis C virus
HRP Horse Reddish Peroxidase
LB Luria-Bertani media
MDM2 Mouse Double Minute 2
MMLV Murine Maloney Leukemia Virus
MMP Matrix MetalloProtease
MTS Multiple Tumor Suppresor
N-terminus amino terminus
0/N Over Night
OD Optical Density
PAGE polyacrylamide gel electrophoresis
PBS Phosphate Buffered Saline
PBS-T Phosphate Buffered Saline with Tween-20
pRb Retinoblastoma protein
Rb Retinoblastoma gene
RNA ribonucleic acid
S/N Supernatant
SDS Sodium Dodecyl Sulfate
SDS-PAGE SDS- Polyacrylamide Gel Electrophoresis
TBS Tris Buffered Saline
TBS-T Tris Buffered Saline with Tween-20
TEMED N,N,N,N-tetramethyl-l ,2 diaminoethane
XIX
TGFp Transforming Growth Factor beta
Tris tris (hydroxymethyl)-methylamine
TSG Tumor Suppressor gene
UV Ultraviolet
VEGF Vascular Endothelial Growth Factor
XX
INTRODUCTION
CHAPTER I
1-1 CANCER
Cancer is the clonal expansion of a cell that gained specific properties to serve 
for replicate its DNA, in an uncontrolled manner. This phenomenon is achieved by a 
multistage process involving the inactivation of tumor suppressor genes (TSGs) and 
activation of proto-oncogenes. Thus each step in carcinogenesis can be directly (genetic 
changes) or indirectly (epigenetic changes) linked to the genetic material, DNA. In this 
scheme, oncogenes act as dominant players of the game, since their mutations serve as a 
dominant phenotype, whereas TSGs act as recessive players, as the loss of both alleles 
is necessary to produce the loss of function phenotype.
The risk of cancer can be directly associated with occupational (Vinyl chloride, 
asbestos), environmental (aflatoxin Bl, UV light) and being willfull to the exposure 
(smoking, alcohol consumption, tanning) to chemical or physical carcinogens (Hussain 
and Harris, 2000). On the other hand, some viruses interrupt the normal cellular 
processes to favor cell replication or resistance to apoptosis. Carcinogens, viruses or 
combinations of them produce a series of changes to favor the best adopting and fast 
dividing cell to be selected among others. These changes produce gross phenotypic 
results, which can be summarized as below:
GROWTH FACTOR INDEPENDANCY: Growth factors are essential for a 
cell to replicate, and more importantly, to survive. As a first step in carcinogenesis, a 
cell gains a phenotype to divide and survive without the need of a extracellular stimuli. 
For obtaining this phenotype, the cell surface receptors (EGF-R, HER2) or the 
downstream pathway molecules (ras, MAP kinase pathway elements) must be mutated 
(Hanahan and Weinberg, 2000).
UNCONTROLLED DIVISION: Most of the cells in an organism is in 
quiescent state, which is GO. Under appropriate conditions these cells divide, but return 
to the quiescent state. The negative regulators of cell cycle progression, such as Rb, 
pl6iNK4A must be inactivated or positive regulators, such as cyclins and cyclin
dependent kinases, must be activated so as to abolish the control over cell cycle 
(Hanahan and Weinberg, 2000). Continuous replicating eukaryotic cells face a problem 
of telomere shortening, which leads to a crisis, so that, chromosomes are lost, 
recombined or rearranged. The cell must overcome this problem, firstly, by 
overexpressing the components of telomerase enzyme complex, which contains RNA 
and proteins. Most of the time the RNA subunit of the complex, tERT is expressed to 
activate this enzyme. One in a million cell overcomes this crisis by tERT expression, so 
now inherited the ability of uncontrolled division (Drayton and Peters, 2002).
RESISTANCE TO APOPTOSIS: Together with uncontrolled division and 
growth factor independancy, the apoptotic mechanisms begin working to eliminate the 
cell that is dividing in an infinite manner. Pro-apoptotic genes, such as p53, 
bax, bak, apafl and CD95 and anti-apoptotic genes such as bcl-2, mdm2 and PTEN are 
mutated in favor of a cell to be resistant to apoptotic signals (Hanahan and Weinberg, 
2000).
ANGIOGENESIS AND METASTATIS: Tumor cells can replicate without the 
need of extracellular stimuli, but can not live without enough metabolites. The 
metabolite source for a cell is a blood vessel, so tumor cells attract blood vessels to 
their vicinity, by expressing angiogenic factors like. Vascular Endothelial Growth 
Factor (VEGF). Without angiogenesis, a tumor can only get as big as 2-5 mm in 
diameter, but after getting enough nutrients, it can grow bigger. The blood vessels also 
serve for a tumor cell to migrate through it, get into the blood circulation and settle in a 
new tissue, a process, collectively named as metastasis. For a tumor cell to make 
metastasis, the expression of Matrix Metalloproteases (MMP) is essential as well as the 
modulation in the levels of adhesion molecules like integrins and cadherins (Hanahan 
and Weinberg, 2000).
Every year millions of people develop cancer, for which there is no well defined 
cure for now. Figure 1-1 summarizes the common pathways that are dysregulated 
during tumorigenesis. Blocking any of the steps that is described above is a probable 
cure for cancer development.
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Figure 1-1: Common effected pathways during tumorigenesis.
The red names indicate either a tumor suppressor gene or an oncogene that are mutated 
in human cancers. (Hanahan and Weinberg, 2000)
1-2 HEPATOCELLULAR CARCINOMA
Hepatocellular carcinoma (HCC) is the sixth most common cancer of men and 
eleventh most common cancer of women world-wide (Hussain et al., 2001). However, 
because almost every individual who develops liver cancer dies of the disease, HCC is
the third most common cause of the cancer deaths in men and seventh most common in 
women (Hussain et al., 2001). The major causes of HCC are chronic Hepatitis C Virus 
(HCV) and/or Hepatitis B Virus (HBV) infection, chronic alcohol intake and exposure 
to some chemicals, such as aflatoxins. At diagnosis 60% of cases, the liver contains 
multiple nodules of cancer. In 30% of cases there is a large single mass of cancer often 
with surrounding satellite lesion, and in the remaining cases, the liver is diffusely 
infiltrated. Common symptoms of patients affected with HCC include abdominal pain 
(91%), weight loss (35%), weakness (31%), fullness and anorexia (27%), abdominal 
swelling (43%). If untreated, HCC leads to the death of the patient in 6-12 months after 
diagnosis (Hussain et ah, 2001).
1-2.1 ETHILOGY OF HCC
There are several major risk factors, clearly defined for HCC development. 
These factors include chronic alcohol consumption, being infected with hepathotrophic 
viruses such as HCV or HBV and being exposed to the hepatocarcinogen aflatoxin В 1. 
The heterogeneous geographical distribution of HCC has been instrumental in the 
identification of major risk factors. Sub-Saharan and Eastern Asian populations are 
under high risk for HCC (104 men in Mozambique, 29 in South Africa, 168 in Haimen 
City in China per 10 000) (Hussain et ah, 2001). The high risk of HCC in these regions 
of the world is closely associated with a fungal toxin, aflatoxin B1 intake with 
contaminated food (Bressac et ah, 1991). Aflatoxins are mycotoxins produced by the 
Fungi Aspergillus flavus and Aspergillus parasiticus. Aflavus mould and aflatoxin can 
be found in a variety of stored grains, particularly in hot, humid parts of the world 
where grains such as rice are stored in unrefrigerated conditions. Aflatoxin B1 is the 
first carcinogen defined to hit a hotspot in the human genome. Specific p53 mutations 
were shown to correlate with aflatoxin related HCC (Bressac et ah, 1991, Hsu et ah, 
1991). Data on aflatoxin exposure by contamination of food correlates well with 
incidence rates in Africa and to some extent in China. In hyperendemic areas of China, 
even farm animals such as ducks have HCC (Hussain et ah, 2001).
Chronic Viral Hepatitis is another major cause of HCC. 85% of all HCC cases 
are seen in Sub-Saharan and Eastern Asia populations, where chronic infection with 
HBV is endemic in these regions (Brechot et ah, 2000). The HCC patients without
chronic HBV infection and not being exposed to aflatoxin B1 are mostly infected by 
HCV. HCV infection is also seen in developed countries since there is no available 
vaccine against this virus. It is a major source for HCC in Japan, USA and Western 
Europe. Chronic infection with both of these hepathotrophic viruses is also seen 
occasionally (Koike et al., 2002).
Chronic alcohol consumption produces cirrhosis, which may lead to HCC, but it 
is not closely associated with HCC development alone, since USA and Western Europe 
countries, where alcohol consumption is high, HCC incidences are low (1.8 per 10 000 
for men and 0.7 per 10 000 women in USA and Britain) (Di Bisceglie AM, 1997). 
Alcohol intake and HCC development are closely linked with concomitant chronic HCV 
infection. Patients with alcoholic liver disease have a higher sero-prevalence of HCV, 
but not of HBV disease. Patients with chronic hepatitis C drinking 60 gm of ethanol or 
more daily for five years have higher titters of serum HCV RNA and lower levels of 
serum neopterin, a marker of activation of cell mediated immunity, linking impaired 
cellular immunity in chronic alcoholics to severity of viral infection (Oshita et al., 
1994).
As a result, African and Asian countries are under high risk of HCC, since viral 
hepatitis is endemic in these regions. Moreover, the environmental and food storage 
conditions favor the growth of aflatoxin B1 producing fungi, which is a carcinogen for 
liver.
1-2.2 GENETICS OF HCC
Initial genetics studies relied on gross chromosome gains or losses during HCC 
development, which gave a brief information about the locus of tumor suppressor genes 
(TSGs) and oncogenes involved in this pathogenesis. After the development of 
Comperative Genomic Hybridization (CGH), Restriction Fragment Length 
Polymorphism (RFLP) and Micro Satellite Analysis (MSA) techniques, DNA gains and 
losses as small as 10 Kb are detected. The ethiopathology of HCC is very well defined, 
so the minimal DNA gains or losses are being refined every day. Now, there is a clear 
picture for at least a minimum set of chromosomal arms that are affected in most of the 
cases (Buendia MA., 2000). Common chromosomal losses associated with HCC are Ip, 
2q, 4q, 6q, 8p, 9p, lOq, 13q, 16p, 16q and 17p. Common chromosomal gains include Iq,
6p, 8q and 17q. Some of the candidate genes for HCC development are listed below 
under the headings “oncogenes” and “tumor suppressor genes” with their proposed 
functions and chromosomal locations.
1-2.2.1 ONCOGENES
B-Catenin; P-catenin gene was localized to chromosome 3p21, which is a 
somatic effected chromosomal region for different cancer types (Kraus et al., 1994). P- 
catenin is a member of the ‘armadillo repeat’ family of proteins and a central player in a 
number of important but distinct cellular processes. Through its central armadillo repeat 
region, P-catenin forms mutually exclusive complexes v/ith adhesion molecules like 
cadherin, transcription factors such as members of the LEF/TCF-family, and the tumor 
suppressor gene product APC. Recent studies showed that expression of APC decreased 
the stability of p-catenin while the Wnt-1 proto-oncogene had the opposing effect. The 
mutations in the P-catenin gene, that increased the half-life of the protein, were 
identified in human cancers (reviewed by Polakis et al., 2001). Mutation detection 
studies showed that P-catenin is a very important mutation target for Hepatoblastoma 
and HCC development. A review of literature by Ozturk M. and Cetin-Atalay R. had 
revealed that a total of 97 out of 485 (20%) HCC tumors and 45 out of 79 (58%) 
Hepatoblastomas displayed P-catenin mutations (Ozturk M. and Cetin-Atalay R., in 
press). The mutations of p-catenin generally occur at the exon 3 of the gene, affecting 
the serine-threonine phosphorylation motifs, so the degradation of p-catenin protein. 
When accumulated, P-catenin translocates to the nucleus and become a transcriptional 
co-activator of LEF-TCF family of transcription factors which in turn transactivate a 
series of cell cycle progression genes such as cyclin D and myc (Calvisi et al., 2001).
Mouse Double Minute 2 (MDM2); The mouse homologue of human MDM2 
gene was identified as a genomic DNA segment producing minichromosomes in mouse 
cancers (Cahilly-Snyder et al., 1987). Later the protein product of this gene was defined 
to be an interacting protein of p53. The main function of this protein was defined to 
control p53 protein levels by binding and ligating p53 protein to ubiquitin proteasomes 
(Honda et al., 1997). The overexpression of human MDM2 (hMDM2) was reported to
be present at 5-40% in different cancer types, especially soft tissue sarcomas (Oliner et 
al., 1992). An immunohistochemistry based study reported 26% positivity of hMDM2 
in HCC samples, which correlated with poorer prognosis (Endo et al., 2000).
Cyclin genes; Cell cycle regulatory kinases, cyclin dependent kinases (CDK) are 
tightly controlled by cyclin family of proteins throughout the cell cycle (Ho and 
Dowdy, 2002). Cyclin genes are candidate proto-oncogenes for this purpose. Their 
expression is increased usually during carcinogenesis, but few of them were proven to 
be oncogenes. Cyclin A2 gene is the first cyclin gene found to be mutated in HCC 
(Wang et al., 1992), which was altered by an integration of HBV genome to the 
promoter of cyclin A2 gene in a single tumor. Cyclin A gene amplifications were 
reported to occur at 19% of HCCs (Ozturk M., 1999). Cyclin D is another target altered 
during HCC development. Cyclin D amplification is seen at 10-13% of HCCs. (Ozturk 
M., 1999, Nishida et al., 1994).
1- 2.2.2 TUMOR SUPRESSOR GENES
MTS locus encoded genes; The chromosomal localization for this locus is 9p. 
Multiple Tumor Suppressor (MTS) locus encode for a cdk inhibitor protein (p 16*’^ ’^ '''') 
and a p53 regulating protein (p i4' '^^ )^. These two genes share 2 exons (exon 2 and 3) 
and a portion of the promoter region. The first exon of p i i s  named as exon la  
and pl4'^’^  ^ named as exon Ip (Serrano M., 2000). pl4^* '^' protein is translated in a 
different frame so the protein products of these two gene isoforms are totally different. 
MTS locus is a hotspot for mutations and epigenetic regulations since it harbors two 
TSGs (Serrano M., 2000). Up to 60% of HCC tumor samples were shown to have either 
genetic or epigenetic (méthylation) defects at MTS locus, proving the evidence that the 
loss of these proteins is very important in HCC development (Jin et al., 2000).
Retinoblastoma (Rb); The Rb protein (pRb) is the universal inhibitor of the cell 
cycle progression and a gatekeeper of G1 (Nevins JR., 2001). The inactivation of Rb is 
a key event in tumor progression. The Rb gene is localized to chromosome 13q, which 
is a common deletion site for different types of cancers including HCC (Ozturk M. 
1999). Rb mutations are also observed at 15% of HCCs (Ozturk M., 1999).
Retinoblastoma protein is a target for ubiquitin dependent degradation and the 
degradation mechanism was shown to be dysregulated in HCCs by overexpression of a 
pRb specific ubiquitin ligase, gankyrin (Higashitsuji et al., 2000).
Transforming growth factor receptor beta (TGF-B) Type II Receptor;
TGPpi is a negative regulator of cell proliferation for some cell types, including 
hepatocytes. In a study by Furuta et al. (Furuta et al., 1999), frameshift mutations at a 
poly-A tract of TGF-P Type II Receptor gene was described at up to 50% of HCC 
samples of different differentiation status, increasing through dedifferentiation. Such 
studies must be done to confirm the role of TGF-P Type II Receptor in HCC 
development.
Insulin-Like Growth Factor Type 2 Receptor Gene (IGF2R); IGF2R gene, 
also so called mannose-6-phosphate receptor, M6PR gene) was localized to 
chromosomal region, 6q24 (Rao et al., 1994). The LOH at this chromosomal region was 
shown to be 50-80% by several studies (De Souza et al., 1995, Kishimoto et al., 2001). 
IGF2R plays a crucial role in regulating cell growth by facilitating the activation of the 
growth inhibitor transforming growth factor beta (TGF-p) and inactivating the growth 
stimulator insulin-like growth factor-II (IGF2). Aberrations of this gene are therefore 
predicted to result in both increased cell proliferation and reduced apoptosis, consistent 
with the M6P:IGF2R protein, functioning as a tumor suppressor (Dennis and Rifkin, 
1991, Komfeld S., 1992). The description of mutations by several reports at frequencies 
of 18-30% also supported the role of M6P:IGF2R gene in HCC development (see the 
review of Ozturk M. and Cetin-Atalay R.).
d53: p53 gene is the most mutated tumor suppressor gene known for all cancer 
types (Hanahan and Weinberg, 2000) and localized to chromosome 17p, which is a 
common site for deletion. The protein product of p53 gene is activated by different 
stimuli such as oncogenic activation, DNA damage, decrease in nucleotide pools and 
oxidative stress (Blagosklonny MV., 2002, Wang XW., 1999) and induce cell cycle 
arrest or apoptosis, depending on the cell contex (Blagosklonny MV, 2002. The 
frequency of p53 mutations in HCC is 28% worldwide (Ozturk M., 1999). There is a 
strong correlation between p53 mutations, large tumor size, and poor differentiation
State (Ng et al., 1994). Consequently, patients with p53 mutations have a poor prognosis 
and experience a short tumor free survival following surgery. A HCC specific p53 
mutation was found (Bressac et al., 1991, Hsu et al., 1991) and ethiologically associated 
with aflatoxin B1 ingestion. This finding is a proof for the importance of p53 mutations 
in the development of HCC.
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Above, I have mentioned the genes commonly mutated in human tumors. This 
information provided by geneticists was correlated with in vitro and in vivo studies that 
were done by molecular biologists so that the individual tumor suppressor proteins and 
onco-proteins are now members of pathways that are dysregulated during 
tumorigenesis.
The results proposed in this thesis revealed a partial correlation with 
transcriptional regulation of p73 with Rb pathway dysrégulation, so I also want to 
mention about the Rb pathway under a separate heading. The main subject of this thesis 
is the contribution of p73, the new p53 family member to liver carcinogenesis so I want 
to mention about p53 pathway specifically. The components in a pathway are mutated 
in a mutually exclusive manner and when the mutation frequencies of these two 
pathways (p53 pathway and Rb pathway) are added up, the sum is nearly 100%, 
indicating most, if not all cancers have lost the regulation on the components of these 
two pathways.
1-3 Retinoblastoma Pathway
Cellular senescence and quiescence is strictly controlled by the balance of 
proliferative and anti-proliferative signals that a cell acquires. The study of senescence 
and quiescence and their related aspects of cellular life-span uncontrolled division and 
immortalization have a great importance in understanding tumorigenesis. The molecular 
machinery that controls cell division is based on the sequential activation of a family of 
protein kinases, known as cyclin dependent kinases (CDKs) (Sherr and Roberts 1999). 
These kinases require to be associated with an activating protein which is named cyclin 
so as to phosphorylate their substrates. The expression of cdks are generally ubiquitous, 
whereas the transcriptional induction of cyclins govern the association with a specific 
CDK and progression of cell cycle. When quiescent cells are stimulated, first CDK4 and 
CDK6 are activated by association with D type cyclins. The activation of CDK4 and 
CDK6 were followed by the subsequent activation of CDK2 by cyclin E and cyclin A, 
which in turn initiates DNA replication. As DNA replication process finishes, CDKl- 
cyclin B complex is activated leading to mitosis. Thus the uncontrolled activity of CDK 
family proteins and cyclins may lead to tumorigenesis, which in turn makes them 
potential oncoproteins. This hypothesis was proven to be true by the description of an
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activating mutation in CDK4 and the description of overexpression of CDK4 and cyclin 
D (reviewed by Ortega et al., 2002).
The process of sequential association of cyclins with their kinase parthers was 
strictly controlled by 2 families of proteins, both regulating the kinase unit of this 
partnership so they are collectively named as cyclin dependent kinase inhibitors (CKIs). 
First group of CKIs is the INK4 family. This family is composed of 4 members 
(pl6iNK4A^  pl5iNK4B^  and p i h a v i n g  negative effect on CDK4 and
CDK6, so regulating the Gl-S transition of cell cycle mainly. The second group is 
Cip/Kip family of CKIs, which is composed of 3 members (p21^‘*’‘, p27'^'’’’ and 
p^7Kip2) Interestingly, this group of CKIs have an activating effect on CDK4/6-cyclin 
D complex by facilitating and stabilizing the association of cyclin and CDKs. In 
contrast the effect of Cip/Kip family of CKIs is negative on CDK2 and cyclin E/cyclin 
A complex, so they are effective on late G1 to G2 phases of cell cycle. Since the 
Cip/Kip family of CKIs have both positive and negative effects on cell cycle 
progression, inactivating mutations in this family is unexpected. Mutations of CKIs or 
epigenetic downregulation of CKI expression yields in a loss of the control on cell cycle 
thus the CKIs, especially INK4 family are potential tumor suppressor genes (TSGs). 
The positive and negative regulators of cell cycle are described in figure 1-2.
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Figure 1-2 : Cell cycle and cell cycle regulators (Collins et al. 1997)
The Retinoblastoma protein (pRb) is the major substrate for CDK4/cyclin D and 
CDK6/cyclin D complex. In unphosphorylated or hypophosphorylated form pRb is 
bound to E2F family of transcription factors, so silencing their transactivation 
functions. The E2F family of transcription factors activate the transcription of several 
important cell cycle proteins such as cyclin E and cyclin A. pRb must be 
phosphorylated by CDK4/cyclin D so as to free E2F1 transcription factor, which in turn 
transactivates cyclin E gene and induces DNA synthesis (Collins et al. 1997).
The major components of Rb pathway are cyclins (cyclin D, cyclin E and cylin 
A), cyclin dependent kinases (CDK4, CDK6 and CDK2), celt cycle inducing 
transcription factors (E2F1, E2F2, E2F3, and E2F4 and E2F5), CDK inhibitors of INK4 
family and of course the key holder Rb. Frequently altered tumor suppressor genes and 
oncogenes in HCC were summarized at part 1-2.2.1 and 1-2.2.2. In these sections.
pl6 INK4A (as a MTS locus encoded transcript) and Rb genes were defined to be
frequently altered tumor suppressor genes and cyclin D gene was defined to be a 
frequently altered oncogene in HCC development. These data suggests that Rb pathway 
inactivation is a key and a frequent event in HCC development.
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1-4 p53 Pathway
The p53 tumor suppressor protein is inactivated in approximately half of human 
cancers. The inactivation of p53 protein is most of the time a result of missense point 
mutations in p53 gene, but functional inactivation of p53 protein by rapid degradation 
or by viral oncoproteins is also present in some cancer types. In normal conditions p53 
is expressed as a latent transcription factor with a short half life. DNA damage or 
oncogenic activation provokes p53 protein to be post-translationally modified, thus 
stabilized. The modification mechanisms include phosphorylation at N-terminal 
residues and acetylation at C-terminal residues. The modifications not only induce an 
increased half life of p53 protein but also cause conformational changes to be 
competent for oligomerization and DNA binding (Giaccia and Kastan 1998). Upon 
activation, p53 protein transactivates several target having roles in cell cycle control 
(p21^'’’’) and apoptosis (Bax). The activation of p53 and the probable effects of p53 are 
schematized in fig 1-3.
IRAJV Hypoxia Redox Oncogenes
I
pl4 ARF
p53
Adhesion
Phosphorylation/
Acetylation
Differentiation Cell Cycle Apoptosis
Figure 1-3 ; The activation and the effects of p53 protein
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Active and accumulated p53 protein is dangerous for the cell since it induces cell 
cycle arrest or apoptosis, so p53 protein levels are strictly controlled by ubiquitin 
dependent proteolysis. The main ubiquitin ligase for p53 protein is the MDM2 protein. 
The N-terminal phosphorylation of p53 disables the MDM2 binding, so increases the 
half life of p53 protein. As a negative regulator of p53 tumor suppressor, MDM2 was 
considered as a candidate oncogene. This hypothesis was proven to be true by the 
detection of amplified or overexpressed MDM2 in sarcomas and some other types of 
cancers (Momand et al. 1998). It is not very surprising that the MDM2 expression is 
under the regulation of p53 transcriptional regulation. So p53 protein levels are defined 
by a auto-regulatory feedback loop of transcriptional activation of MDM2 expression.
One of the most interesting discoveries of tumor biology in recent years is the 
description of an alternative promoter and exon within p i g e n e  (exon ip) 
(Serrano M., 2000). Since this gene product has been initiated from an alternative exon, 
the reading frame of the transcript differs from pi although the two transcripts of 
this locus are sharing 2 exons (exon 2 and exon 3). The protein product of this gene was 
14 kilodaltons in humans, so this gene is named as pl4 Alternative Reading Frame 
(p i4'^ *^^ ). The function of this protein was defined to be the inhibition of MDM2 
oncoprotein. Overexpression of was shown to stabilize p53 and activate its
downstream targets and the phenotype of knock-out mice of p i4'^’^  ^was defined to be 
developing tumors in the spectrum of p53 deficient mice. Interestingly, the promoter of 
p i4'^ '^’ is under the regulation of E2F1, which is a pRb regulated transcription factor. 
The activation of E2F1 is essential for the proceeding of cell cycle, since the 
endogenous E2F1 targets also include cyclin E, which is an essential cyclin for S phase 
progression. Rb pathway dysrégulation is a common event in cancer development as 
described in section 1-3, leading to release of E2F1. These results propose the negative 
feedback regulation of uncontrolled division through p53 activation as schematized in 
figure 1-4.
pRb E2F1
\
■> Cyclin E -► Cell cycle progression
pl4 lRF I
MDM2------ 1 p53
Figure 1-4 : The anti-mitotic effect of p53 on uncontrolled division
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The description of gross deletions covering both genes and tumor specific 
epigenetic down-regulation of pi and/or p i d e f i n e d  this locus to contain two 
tumor suppressor genes. Thus the INK4A/pl4'^’^ ’' locus was renamed as Multiple Tumor 
Suppressor (MTS) locus. This locus encodes for an Rb pathway component (p 1 
and a p53 pathway component (pl4'^'^^). As summarized at part 1-2.2.1 and 1-2.2.2, p53 
gene and pl4ARF gene are commonly deregulated tumor suppressor genes and MDM2 
is a commonly deregulated oncogene in HCC. The pathway covering pl4ARF, MDM2 
and p53 covers the activation of p53 as a result of oncogenic response and uncontrolled 
division. Although the mutation frequencies of all components of a pathway must add 
up to 100% in a specific cancer type, the frequencies of p53 pathway components do 
not add up to 100%, since p53 activation follows the route of both oncogenic activation 
and DNA damage response (figures 1 -3 and 1 -4) and the components of these pathways 
must be studied more extensively.
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CHAPTER II
THE P53 HOMOLOGUE P73 
2-1 IDENTIFICATION OF P73
P73 gene was identified by Kagdad et al., at 1997 (Kagdad et al 1997). The 
compementary DNA (cDNA) encoding p73 was discovered in a hybridization screen of 
COS cell line cDNA library using degenerate IRS-1 binding nucleotides by fortune. 
Subsequently, normal human colon cDNA library also revealed two alternative splice 
variants for p73 and named as p73a (full length p73) and p73p (exon 13 splice out 
form) (figure 2-1).
The gene encoding p73 was localized by Flourescence In Situ Hybridization 
(FISH) analysis, to the sub-telomeric, small arm of chromosome 1 (Kagdad et al 1997). 
This region is a common deletion site for different types of tumors, as also shown for 
neuroblastoma (Kagdad et al 1997), for lung (Nomoto et al., 1998), for non-astrocytic 
brain tumors (Alonso et al., 2001), and for HCC (Mihara et al., 1999). Refined 
chromosomal location of p73 gene was defined by Lo Cunsolo et al. (Lo Cunsolo et al., 
1998) and by Perri et al. (Perri et al., 1999) to be lp36.33 between markers, D1S47 and 
D1S243.
A Northern blot using the p73 central domain as a probe revealed 3 discrete 
transcripts, at 4.4 kb, 2.7 kb and 1.5 kb (Stiewe and Putzer, 2000). The major transcript 
was defined to be the 4.4 kb, which is the product of all 14 exons of the p73 gene 
(Kaghad et al., 1997). There is an extensive alternative splicing at exons at the 3’ end of 
the p73 transcript, which is not a common feature of p53 gene encoded transcript 
(Figure 2-1). Full length p73 (p73a) and the transcripts, lacking exon 13 (p73P), are the 
most common p73 transcripts in normal tissues, but cancer related changes in p73 
alternative splicing and accumulation of different transcripts were reported for several 
types of cancers (table 2-1). A descriptive study on p73 expression analysis and 
mutation detection on primary breast tumors and cell lines showed the presence of at
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least six 3’ splicing isoforms as described at figure 2-1 (Zaika et al., 1999). In this study 
normal breast was shown to be expressing low amounts of p73a and p73p, but 5 of 7 
cell lines and 30 of 77 primary breast tumors were expressing higher amounts of all six 
p73 isoforms (p73a, P, y, <|), s, 6) or combinations of these isoforms. The functions of 
some of the p73 3’ splicing variants were defined by Ueda et al. (Ueda et al., 1999). 
When the transactivation activity of p73a , p, y and s are compared with p53, p73P was 
shown to be as effective as p53, followed by p73y, p73a and p73e. The latter three p73 
forms (a, y, s) were shown to decrease endogenous p53 activity when transfected to p53 
wild-type (wt) cell line like MCF-7 or HepG2. Another study by Ueda et al. (Ueda et 
al., 2001) also showed that, inter-association of alternative splicing products of p73 may 
determine the transcription activity of p73 as a tetramer. The p73 isoforms with low 
transactivation ability (p73y, e), also decrease the transactivation ability of p53, p73a 
and p73p, since they make oligomers and tetramers with each other. These results 
provided some information to the involvement of p73 to breast carcinogenesis by an 
unknown mechanism.
A 5’ splicing product is also defined (Kaghad et al., 1997) (figure 2-1), which is 
lacking exon 2. This product is named as p73 A exon 2. The protein of this transcript is 
initiated from an alternative in-frame methionine at exon 3, so the protein is lacking the 
N-terminal 48 amino acids. Thus, this protein is deficient for the critical amino acid 
residues for the transactivation ability of p73, but DNA binding domain and 
oligomerization domains are intact (Figure 2-2). The domain structure of p73 A exon 2 
protein leads p73 investigators to propose a dominant negative function. This protein 
product of p73 gene can make tetramers with other p73 gene products and decrease the 
transactivation capability of the tetramer, or directly bind to the natural targets of p73 
gene on the genomic DNA, so occupy the promoter regions without transactivating 
them. The dominant negative function of this from has been defined recently by 
Fillipovich et al. (Fillipovich et al., 2001) and the expression was shown to be present at 
RNA level for breast cancer cell lines (Fillipovich et al., 2001) and for vulval cancer 
(O’Nions et al., 2001).
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p73 cDNA encodes for a protein having structural and functional homologous 
domains with p53 (Kagdad et al 1997). P73 and p53 share a 60% conserved DNA 
binding domain, at which most of the p53 mutations reside (Kagdad et al 1997) (Figure 
2-2). This domain of p53 is also well conserved from drosophila to men (Ollmann et al., 
2000). Moreover, p53 and p73 proteins also share conserved oligomerization (38% 
identity) and transactivation (29% identity) domains (Figure 2-2), providing some 
evidence about the function of p73, similar to p53 (Kagdad et al 1997).
p73
Transactivation
Domain
DNA Binding Oligomerization C-Terminal 
Domain Domain Domain
¡ill
itli!
P53
POTin w ¡'||||
1
Identity 29% 63% 38%
Figure 2-2 : The alignment of p73 and p53 proteins
Similar to p53, p73 protein is activated upon genotoxic stress and the activation 
mechanism was shown to involve phosphorylation by abl kinase (Agami et al., 1999, 
Gong et al., 1999, Yuan et al., 1999). The p73 protein is tightly regulated at protein 
level by degradation and it is accumulated at special occasions like DNA damage 
caused by cisplatin and ionizing radiation. Upon activation, p73 protein transactivates a 
similar set of genes, which are also transactivated by p53. The protein products of this 
set of genes are taking role in cell cycle checkpoint, apoptosis, DNA damage sensing 
and DNA repair (Yu et al., 1999), such as Bax, p21, PIG series of genes, 14-3-3c, a 
ribonucleotide reductase enzyme subunit and p57^"^  ^ (reviewed by Stiewe and Putzer, 
2002).
Unlike p53, p73 gene is rarely mutated but p73 transcription is regulated at 
epigenetic levels. There are lots of studies defining the allelic expression of p73 gene, 
but there are contradictory results. It seems that, p73 gene is expressed monoallelicly or
20
bialellicly depending on the tissue, person and the tumor (reviewed in Stiewe and 
Putzer, 2002). Some expression studies defined that there is no correlation between 
allele number and the p73 transcript levels. Cells retaining only one allele of p73 
express comparable levels of p73 with the cells having two or even three alleles of p73 
gene (Kaghad et al., 1997, Stiewe and Putzer, 2002).
Many cellular oncogenes, inducing c-myc, ras and E2F1, induce the stabilization 
and the accumulation of p53. This phenomenon is achieved, at least partially by the 
induction of p i4'^ '^ ,^ which in turn binds and blocks the ubiquitin ligase MDM2. In the 
absence of MDM2, p53 is accumulated at protein levels. Moreover, MDM2 binds to the 
transactivation domain of p53 (aminoacids: 1-27), suggesting another level of 
regulation of MDM2 on p53 activity. The amino-acid residues of p53 which are 
important for MDM2 binding are also conserved in p73. Several groups have shown 
that MDM2 and the closely related protein MDMX can bind to p73 (Ongkeko et al., 
1999, Zeng et al., 1999, Balint et al., 1999). Interestingly, MDM2 or MDMX binding 
doesn’t lead to degradation of p73, but stabilization of p73 (Zeng et al., 1999). 
However, MDM2 binding to p73a and p73p strongly reduces the transactivation 
capacity of these protein isoforms (Balint et al., 1999, Dobbelstein et al., 1999). These 
results provide some information about another type of regulation of MDM family of 
proteins on the function of p53 family proteins.
So, p73 gene encoded products are regulated at transcriptional and translational
levels.
2-2 MUTATION DETECTION STUDIES OF P73
There are lots of studies, defining the LOH at lp36 region, mutations at p73 gene 
or describing the expression pattern of this gene. More than 3000 samples were 
analyzed from different types of tumors or tumor derived cell lines, but the mutation 
frequency turned to be roughly 0.5%. A high incidence of LOH at lp36 locus has been 
described especially at neuroblastomas, lung cancers, astrocytic and non-astrocytic 
brain tumors and hepatocellular carcinomas (see table 2-1).
A total of 11 polymorphisms were defined recurrently in different types of 
cancers (table 2-2, figure 2-3). Only two asssociations of tumor progression with p73
21
allelic presence was proposed. The study by Ryan et al. (Ryan et al.,2001), the p73 
polymorphisms at the 5’ of the start codon is genotyped in oesophageal carcinoma and 
the presence of AT/AT allele (nucleotide 4 of exon2: A or G, nucleotide 14 of exon 2: T 
or C) of p73 gene was shown to be significantly less prevalent in the oesophageal 
cancer patients when compared with the normal population. Ryan et al. proposed the 
probable presence of stem like secondary structures in p73 mRNA and the structural 
changes at this stem like structure by the presence of the polymorphisms affecting the 
translational efficiency of the p73 mRNA. Another study by Hamajima et al. (Hamajima 
et al., 2002) examined the allelic frequencies of the same polymorphisms and described 
no association of these polymorphisms with the risk of digestive tract cancers in 
Japanese patients.
A total of 15 p73 gene have been mutations identified up to 15 June 2002 (table 
2-1, table 2-2, figure 2-3). Most of these mutations are point mutations leading to amino 
acid substitution. There are 3 deletion type mutations, two of which does not affect the 
reading frame. The mutation profile of p73 gene and p53 gene are quite similar. High 
percentile of point mutations leading to amino acid substitutions and microdeletions 
occuring outside of DNA biding domain are common features of p53 gene mutations 
(Greenblat et al., 1994). Interestingly, mutational hotspots of p53 gene (codons 175, 
248, 249, etc) are not mutational targets for p73 gene. Two of the mutations are 
affecting the far carboxyl-terminal portion of the p73 protein which is only present in 
p73a, indicating a specific role for this domain against tumor development. There is no 
mutation affecting the N-terminal transactivation domain, suggesting the strong 
regulation of p73 by MDM family of proteins or other factors, which reduces the 
selection for mutants at this region.
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Codons of P73 gene polymorphisms
DNA binding domain of p73 protein
=  : Oligomerization domain of p73 protein
Figure 2-3: The schematic representation of all identified mutations and 
polymorphisms of p73 gene together with corresponding domains of p73 protein.
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P73 gene deficiency causes developmental defects including, chronic infections, 
inflamations, hydrocephalus, hippocampal dysgenesis and probably some secondary 
effects like abnormalities in pheromone sensory pathway in mouse knock out model 
(Yang et al., 2000). The role of p73 in hippocampal formation of the brain is especially 
very striking since the absence of p73 leads to the loss of a discrete set of neurons that 
guide the organization of hippocampus. These results reveal a unique function of p73 in 
neurogenesis, sensory pathways and homeostatic control. Unlike p53 deficient mice, 
p73 knock out mice does not develop spontaneous tumors (Yang et al., 2000). At the 
first sight, this data argues the possible and probable tumor suppressor function of p73, 
but the knock out study also revealed another interesting feature of the p73 gene. The 
attempts of knocking out for the 5’ exons of p73 gene in mice failed since there is an 
alternative promoter within the intron 3 of p73 gene, producing a partial p73 transcript. 
With regard to the data obtained from the other p53 homologue, p63, which also had an 
internal promoter, and produce N-terminal transactivation domain lacking protein 
products, the new promoter and exon in the mouse p73 gene was characterized (Figure 
2-4) (Yang et al., 2000, Yang et al., 1998). This isoform was named as Dominant 
Negative p73 (DN-p73) and its mRNA was described to be the major transcript in 
developing and adult mouse tissues (Yang et al., 2000). The former p73 transcript was 
renamed as TA-p73, since it contains a transcription activation domain.
2-3 KNOCK OUT STUDIES OF P73
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Figure 2-4 : The mouse p73 gene and transcription initiation architecture.
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The full length of two transcripts share 11 exons but the DN-p73 lacks the first 3 
exons of TA-p73, encoding for a p53 like transactivation domain, which is necessary to 
induce cell cycle arrest and apoptosis in the presence of appropriate signals. The data 
obtained from DN-p63 suggest that DN-p73 may function as an antagonist of TA-73 so 
mouse p73 loci contains a candidate oncogene (DN-p73) and a tumor suppressor (TA- 
p73) gene isoforms. Since these two transcripts are under the regulation of two distinct 
and different promoters, their transcriptions are probably independent. The knock out 
mice for both transcripts has also partially kept the relative balance of TA and DN 
isoform. Specific knock out studies for TA and/or DN-p73 must be done to specifically 
assign the role of both of the p73 loci harboring isoforms.
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Due the structural similarity of p73 and p53, they are regarded to be redundant at 
some extent, however, DN-p73, the other product of the p73 gene, can be considered as 
a anti-p53 and anti-TA-p73 protein. From the identification of p73 gene (TA-p73, 
Kaghad et al., 1997) to the description of mouse DN-p73 isotype (Yang et ah, 2000), all 
of the functional studies assigned the probable functions of TA-p73 and its alternative 
splicing products. However, the lack of mutations in the p73 gene and the increased 
expression of TA-p73 isoforms in different types of cancers, together with the 
identification of a probable oncogenic form of p73 (DN-p73) in mice which is encoded 
from p73 locus, significantly draw the attention of tumor biologists to this interesting 
gene architecture. Now, it is quite clear that this locus produces essentially two classes 
of proteins: Those containing a transactivation domain (TA-p73 and 3’ alternative 
splicing forms) and those lacking a transactivation domain (A exon 2 splice form of TA- 
p73 together with DN-p73 and their 3’ alternative splicing forms).
2-4 FUNCTIONAL STUDIES OF P73
2-4.1 TA-p73
When endogenously expressed, TA-p73 and its alternative splicing products 
mostly resemble p53. TA-p73 protein mimics the biological function of p53 by making 
dimers and tetramers, binding to canonical p53 response elements at the target 
promoters and transactivating a series of genes taking role in cell cycle control and 
apoptosis. These genes involve p21, 14-3-3-a, PIG series (PIG3, PIG6, PIG7 and 
PIGl 1), MDM2 (Zhu et al 1998) and a ribonucleotide reductase (p53R2) (Nakano et ah, 
2000). A colony formation assay, with p53 and TA-p73 revealed no colonies after 3 
weeks, whereas mutant p53 or p53 mutant mimicking p73 harboring cells produce 
similar number of colonies, suggesting a p53 like function of TA-p73a in SK-N-AS 
cells (Kaghad et ah, 1997).
The probable pro-apoptotic and cell cycle regulatory role of TA-p73 is cell type 
dependent. TA-p73, like some other cell cycle regulatory proteins also regulates the 
differentiation state of different cell types.
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In a neuroblastoma cell line, overexpression of transcriptionally active forms of 
p73 (TA-p73) together with retinoic acid treatment, induced both morphological 
(neurite outgrowth) and biochemical (expression of neurofilaments and neural cell 
adhesion molecule (N-CAM); down-regulation of N-MYC and up-regulation of pRB) 
markers of neuronal differentiation (Del-Laurenzi et al., 2000). The induction of 
differentiation is not achieved by p53 or dominant negative forms of p73 transfection 
together with retinoic acid treatment (Del-Laurenzi et al., 2000).
The effects of TA-p73a and TA-p73p are quite similar of neuroblastoma 
overexpression results in bladder cells. The overexpression of these gene isoforms 
produced irreversable growth arrest together with the markers of replicative senescence 
in EJ bladder carcinoma cells (Fang et al., 1999).
One of the most striking results about TA-p73 may be the definition of the E2F1 
binding sites at the TA-p73 promoter and the description of the induction of TA-p73 
transcription by the E2F1 transcription factor (Sedan et al., 2002, Stiewe and Putzer, 
2000). Deregulation of E2F1 by some cellular (Ras and c-myc) and viral (ElA and v- 
abl) oncogenes have been reported (Hickman et al., 2002). Moreover, mutations at the 
Rb pathway (Rb, p i6, cdk4, cyclin D) give rise to the activation of the E2F1 
transcription factor and promotes cell cycle progression (Harbour JW and Dean DC, 
2000). As a general rule such oncogenic activities are also sensed by the general 
guardian p53 (via blocking the “p53 ubiquitination ligase, MDM2” depletion by
P I4 ARF) j j )  2000).
2-4.2 DN-p73
There are several proposed functions for DN-p73, speculated for a dominant 
negative role of this protein on TA-p73 and/or p53. Thus DN-p73 is a candidate 
oncogene. However, the human homologue of DN-p73 was not described and there was 
only one publication describing a possible function to mouse DN-p73 isotype during the 
progression of this thesis. Since the knock out study described a discrete set of changes 
in neuronal tissue, the function of mouse DN-p73 was investigated in neuronal cells of 
mouse.
Eciopic expression of DN-p73 in cell culture provided evidence for the several 
proposed in vivo functions of DN-p73. Withdrawal of Nerve Growth Factor (NGF)
32
induces a p53 dependent apoptosis in sympathetic neurons. Conversely, NGF 
withdrawal leads to a decrease of DN-p73 protein levels (Pozniak et al., 2000). This 
crude data had suggested a balance between apoptotic activity of p53 and anti-apoptotic 
activity of DN-p73. Adenoviral transfer of DN-p73 rescued the cells from apoptosis 
after NGF withdrawal. Likewise, neuronal cells didn’t under go apoptosis when infected 
with both p53 and DN-p73 adenoviral vectors. Also in vivo complexes of DN-p73 and 
p53 were shown to be present by pull down assays (Pozniak et al., 2000).
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The E2F1 mediated upregulation, c-abl dependent protein stabilization or ectopic 
overexpression of TA-p73 leads to apoptosis (Stiewe et al., 2000, Jost et al., 1997, 
Gong et al., 1999). Rb pathway dysrégulation (Rb gene mutations, pRb degradation, 
pl6 gene mutations and promoter méthylation related pl6 expression downregulation) 
is very common events in malignant transformation (Ho and Dowdy, 2002, Serrano M. 
2000) These two results propose a probable upregulation of TA-p73, together with p53, 
during tumorigenesis as a result of oncogenic activation. Except for leukemias and 
lymphomas, overexpression of TA-p73 was shown to be true for lot of cancer typès (see 
table 2-1). Prolonged overexpression of TA-p73 must, therefore, is a common event in 
tumorigenesis, which is unfavorable for cancer cells. The cells must overcome the pro- 
apoptotic activity of TA-p73. This could be achieved by p53 mutants, which could 
inhibit the putative tumor suppressor activity of TA-p73 in a dominant negative fashion 
by generating transactivation defective hetero-oligomers with TA-p73. In cotransfection 
assays, R175H and R248W mutants of p53 were shown to coimmunoprecipitate with 
TA-p73a (Di Como et al., 1999). Moreover, transactivation activity of TA-p73 is 
reduced, when cotransfected with p53 mutants, in a reporter assay (Di Como et al., 
1999) which is partially correlated with p73 dependent apoptosis. Direct protein-protein 
interaction of TA-p73 isoforms and some p53 mutants have been described (Di Como et 
al., 1999, Gaiddon et al., 2001, Marin et al., 2000). The hetero-oligomerization of p53 
family members was shown to be mediated not to occur by the oligomerization domain 
(Davison et al., 1999). Interestingly, the peptide motif, crucial for this interaction was 
identified to be in the DNA binding domain of p73, together with the oligomerization 
domain (Strano et al., 2000, Gaiddon et al., 2001). Thus, the former, non-functional 
DNA binding domain of some p53 mutants is necessary for interaction with TA-p73.
The protein-protein interaction between p73 (TA and DN) and p53 (wild type 
and mutant), would probably be a decisive event for the cell fate during tumorigenesis. 
A common p53 polymorphism at codon 72 of p53 giving rise to an arginine or a proline 
residue is characterized and proposed to take role in papiloma virus induced cervical 
cancer (Storey et al., 1998). The presence of a proline or an arginine at codon 72 was 
also proposed to affect the protein stability and development of auto-antibodies against 
p53 (Soussi T. and Beroud C. 2001). Wild type and mutant p53 containing arginine at
2-5 INHIBITION OF P73 BY P53 MUTANTS
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codon 72 was shown to bind to TA-p73 protein more efficiently than p53 containing a 
proline (Marin et al., 2000). It seems that the conformation of mutant p53 which unable 
to bind DNA, together with the presence of an arginine at codon 72, is crucial and very 
effective for the functional inactivation of TA-p73 by mutant p53. A recent report by 
Tada et al. (Tada et al., 2001), described and classified p53 mutants in two categories. 
The first category involves the mutant p53 proteins having dominant activity on the 
remaining wild type p53 (transdominant mutants). The second category involves mutant 
p53 proteins having recessive activity on wild type p53 protein, so does not affect the 
activity of p53 in tumor celts (recessive mutants). Interestingly, 85% of the mutant p53 
alleles at the first category have arginine at codon 72, whereas, the percentage of 
arginine and proline for the second category is about 50-50. These results clearly 
describe a dominant negative function for some of the mutant p53 mutants on the 
remaining, wild-type p53 (transdominant mutants), whereas the other p53 mutants, 
especially having a proline at codon 72 on p53 (recessive mutants).
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AIM AND STRATEGY OF THE STUDY
p53 is the most common mutated tumor suppressor gene (TSG) for most of the 
cancer types. Till august 1997, p53 stood alone in the tumor suppessor heaven without a 
close family member. p73 gene was identified accidentally by a group screening for IRS 
binding proteins. First studies, trying to assign a role to 73 protein defined p53 like 
functions, such as, being induced by phosphorylation following DNA damage, 
transactivation of a similar set of target genes of which the protein products have role in 
cell cycle progression, induction of apoptosis and DNA repair. Mutation detection 
studies revealed a very low mutation rate of p73 gene, at the levels of 0.5%, for 
different cancer types. Expression studies, most of which done by RT-PCR, yielded 
contradictory results, even for the same cancer type. Some of them described elevated, 
some decreased and others unchanged levels of p73 transcripts in normal-tumor paired 
tissues. The results of mutation detection studies, together with the descriptions of 
alterations in the expression pattern, proposed a non-Knudson type tumor suppressor 
function to p73.
In May 2000, together with the description of tumor-free phenotype of p73 
knock out mice, an alternative exon and an alternative promoter within p73 gene was 
described. These two products of p73 locus share 11 exons in the same reading frame, 
so most of their protein sequence is common, except for the N-terminal transactivation 
domain. Since, the second promoter is different than the first one, the expression pattern 
of the new p73 gene encoded transcript is totally different. Moreover, this product of 
the new gene of p73 locus was shown to be the prevalent product in developing and 
adult mouse tissues. The new transcript of the p73 locus can not encode for a p53 like 
transactivation domain, so, it was named as dominant-negative p73 (DN-p73), regarding 
the possible inhibitory function of the protein on p53 and former p73, which was 
renamed as TA-p73, representing the presence of transactivation domain.
CHAPTER III
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From the date of the description of p73 gene, we were concentrated to assign the 
probable function to p73 gene products in Hepatocellular Carcinoma (HCC) 
development. First of all a mutation screening study was done in Bilkent University 
Department of Molecular Biology and Genetics, which yielded to describe no 
mutations, but several polymorphisms in aflatoxin related HCC samples. This result, 
together with other studies in other cancers and HCC proved p73 gene to be an 
uncommon target for mutations during cancer development. However, the description of 
complex 3’ alternative splicing of p73 mRNA and the description of a dominant 
negative form of p73 transcript in mice provoked us to uncover the 3’ alternative 
splicing of p73 transcripts and to define the human homologue of mouse DN-p73 for 
understanding the function of p73 gene encoded products in HCC development.
For these reasons, we first aimed to make in silico analysis of the contig 
covering p73 gene for the descriptions of the promoter regions of TA and DN-p73, so as 
to compare the transcription factors binding to these promoters. As a second step we 
aimed to make expression analysis studies of p73 gene encoded transcript isotypes 
using a series of hepatoma derived cell lines and primary tumors, compared with non­
tumor and normal liver tissues. The description of TA/DN-p73 and the alterations of 3’ 
alternative splicing isotypes of p73 transcripts may correlate with other known genetic 
or epigenetic aberrations during HCC development so may enlighten the changes in 
expression patterns of p73 in normal and tumor cells as the effect or the result of 
malignant transformation.
Thus, the description and association of specific p73 transcripts with HCC 
development may have prognostic or diagnostic values. Also, correlation of the 
presence or absence of some specific p73 transcript with a described cancer related 
abnormality may enable us to identify alternative pathways that are dysregulated during 
tumorigenesis.
38
MATERIALS
AND
METHODS
39
CHAPTER IV
MATERIALS AND METHODS
4-1 Tissue Culture Studies
All cells (listed in table 4-1) were grown in media supplemented with 10% fetal 
calf serum (PCS), 1% non-essential amino acids, 100 ug/ml penicillin/streptomycin at 
37°C and 5% CO2. The cells were routinely subcultured at 2-4 day intervals depending 
on the growth rate.
4-1.1 Defrosting Cells
One vial of the frozen cell line from the nitrogen tank was taken and 
immediately put into ice. The vial was left 1 minute on the bench to allow excess 
nitrogen to evaporate and then placed into 37°C water bath until the external part of the 
cell solution is thawed (takes approximately 1-2 minutes). The cells were resuspended 
gently using a pipette and transfered immediately into a 15 ml. sterile tube containing 
10 ml cold medium. The cells were centrifuged at 1500 rpm at 4°C for 5 minutes. 
Supernatant was discarded and the pellet was resuspended in 10 ml 37°C culture 
medium to be plated into 100 mm dish. Cells were left 0/N in culture. The following 
morning culture medium was refreshed.
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Table 4-1: The cell lines used in this thesis
NAME SPECIES TISSUE/ORIGIN MEDIUM SUPP. CHEM.
COS-7 Monkey Kidney DMEM -
Huh7 Human HCC DMEM -
Hep3-BTR Human HCC DMEM -
FOCUS Human HCC DMEM -
Mahlavu Human HCC DMEM -
Hep 40 Human HCC DMEM -
НерЗВ Human HCC DMEM
HepG2 Human HCC DMEM -
PLC/PRF/5 Human HCC DMEM -
SK-Hepl Human HCC DMEM -
SNU 182 Human HCC DMEM -
SNU 387 Human HCC DMEM -
SNU 398 Human HCC DMEM -
SNU 423 Human HCC DMEM -
SNU 449 Human HCC DMEM -
SNU 475 Human HCC DMEM -
BC-1 Human HCC DMEM Insulin and 
methylprednisol
4-1.2 Subculturing Of Cells
All cells were splitted once-per-week. Culture renewal was done every three 
days. For splitting, the medium was aspirated and the cells were washed with PBS pH:
7.4 once. PBS was removed and trypsin was added to the plates. Plates were incubated 
in the incubator for 3-10 minutes until the cells are detached. Cells were plated in the 
desired dilution into new plates. For susupension cultures, cells were centrifuged at 
1500 rpm for 3 minutes and desired number of cells was resusupended in fresh medium.
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4-1.3 Freezing Cells
After defrosting a vial of cell, a few new fresh vials are immediately frozen for 
futher studies. The cells to be frozen were grown in a 150 mm cell culture dish to 70- 
80% confluency. After washed two times with PBS, the cells are trypsinized and 
detached from the plate. The suspension of cells are centrifuged at 1500 rpm for 5 
minutes and resuspended in 1.5 ml freeze medium unless otherwise indicated at ATCC 
definition. Then the cells are immediately placed to -20°C, and kept 5 hours at this 
temperature. Consequently, the cells are moved to -70°C and kept 0/N at this 
temperature and next day transferred to liquid nitrogen tank.
Freeze medium:
10% Foetal Calf Serum
10%DMSO
80% DMEM
4-2 Protein Studies
4-2.1 Protein Extraction from Cells or Tissues
4-2.1.1 Protein Extraction from Cultured Cells
Cells were grown to 70-80% confluency and washed two times with ice-cold 
PBS. Cells were scraped in ice-cold PBS and centrifuged at 1500 rpm for 5 minutes at 
4°C. Pellet was either frozen in liquid nitrigen or lysed immediately in NP-40 lysis 
buffer (150 mM NaCl, 1.0% NP-40, 50 mM Tris (pH 8.0)). For lysis, the pellet was 
resuspended in 4-5 volume of NP-40 lysis buffer and incubated in ice for 30 minutes. 
The lysate was centrifuged at 13.000 rpm for 30 minutes at 4°C. Supernatant was taken 
to a fresh tube and following protein quantitation, aliquoted and stored at -70°C.
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4-2.1.2 Protein Extraction from Tissues
The tissue is weighed and washed two times with ice-cold PBS. Four to five 
times the weight of the tissue is considered the amount of lysis buffer to be added to the 
sample (lysis buffer (150 mM NaCl, 1.0% NP-40, 50 mM Tris (pH 8.0)). For lysis, the 
tissue is homogenized with a polytron on ice for 1-2 minutes in lysis buffer. The lysate 
was centrifuged at 13.000 rpm for 30 minutes at 4°C. Supernatant was taken to a fresh 
tube and following protein quantitation, aliquoted and stored at -70“C.
4-2.2 Bradford Assay for Protein Quantitation
A standard curve was prepared by using BSA as described below:
Tubes nb.s 1 2 3 4 5 6 7 8
BSA (ul) 0 2.5 5 7.5 10 12.5 15 20
DH2O (ul) 100 97.5 95 92.5 90 87.5 85 80
Bradford (ul) 900 900 900 900 900 900 900 900
Protein samples were prepared as described below:
tubes numbers 1 2 3 4 5 6
sample(ul) 0 2 2 2 2 2
dH20(ul) 98 98 98 98 98 98
Bradford (ul) 900 900 900 900 900 900
lysis buffer 2 - - - - -
( 1= blank in both tables)
OD595 were read after samples were incubated at room temperature in dark for 5 
minutes.
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Bradford Stock Solution:
4.75ml ethanol + 250 ul dH20 (95 % ethanol) 
10 ml 85% phosphoric acid
17.5 mg Coomassie Brilliant Blue
Bradford Working Solution:
21.25 ml dH20 
0.75 ml 95% ethanol
1.5 ml 85% phosphoric acid
1.5 ml Bradford stock solution
4-2.3 SDS-Polyacrylamide Gel Electrophoresis of Proteins
The glass plates were assembled according to the manufacturer's instructions 
(EC). The volume of the gel mold was determined according to the information 
provided by the manufacturer (EC). In an Erlenmeyer flask, the appropriate volume of 
solution containing the desired concentration of acrylamide for the resolving gel was 
prepared. Effective range of separation of SDS-PAGE gels due to different acrylamide 
concentrations are summarized in table 4-2 and concentrations of components of the 
resolving gel at different concentrations are summarized in table 4-3.
Table 4-2: Effective range of separation of SDS-PAGE gels
Acrylamide concentration (%) Linear range of separation (kD)
15 12-43
10 16-68
7.5 36-94
5.0 57-212
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Without delay, the mixture was swirled rapidly and the acrylamide solution was 
poured into the gap between the glass plates. Sufficient space (the length of the teeth of 
the comb plus 1 cm.) for the stacking gel was left. The acrylamide solution was 
overlayed by using a pasteur pipette with isobutanol. The gel was placed in a vertical 
position at room temperature. After polymerization was complete, the overlay was 
poured off and the top of the gel was washed several times with deionised water to 
remove any unpolymerized acrylamide. As much fluid as possible was drained from the 
top of the gel and then any remaining water was removed with the edge of a paper 
towel. Stacking gel was prepared in a disposable plastic tube at an appropriate volume 
and at desired acrylamide concentration. Concentrations of components of the stacking 
gel at different volumes are summarized in table 4-4. Without delay, the mixture was 
swirled rapidly and the stacking gel solution was poured directly onto the surface of the 
polymerized resolving gel. The comb was immediately inserted into the stacking gel, 
being careful to avoid trapping air bubbles. The gel was placed in a vertical position at 
room temperature. While the stacking gel was polymerizing, the samples to be loaded
were prepared by heating them to lOO^C for 5 minutes in IX SDS gel-loading buffer to 
denaturate the proteins. After polymerization was complete, the comb was removed 
carefully. By using a squirt bottle, the wells were washed with deionized water to 
remove any unpolymerized acrylamide. The gel was mounted in the electrophoresis 
apparatus. Tris-glycine electrophoresis buffer was added to the top and bottom 
reservoirs. The bubbles that were trapped at the bottom of the gel between the glass 
plates were removed by a bent hypodermic needle attached to a syringe. 30-200 ug of 
protein was loaded in a predetermined order into the wells. The electrophoresis 
apparatus was attached to an electric power supply and the gel was run at 80 volts until 
the dye front has moved to the resolving gel, after the voltage was increased to 15 
V/cm, until the bromophenol blue reaches the bottom of the resolving gel. Then the 
power supply was turned off. The glass plates were removed from the electrophoresis 
apparatus and placed on a paper towel. By using a spatula, the plates were pried apart. 
Orientation of the gel was marked by cutting a corner from the bottom.
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Tris-glycine electrophoresis buffer:
25 mM Tris
250 mM glycine (electrophoresis grade)
0.1% SDS
30% mix (Acrylamide and bis-acrylamide solution)
A stock solution composed of 29% (w/v) acrylamide and 1% (w/v) bis-
acrylamide, prepared in water. Solution was stored in dark bottles at 4®C.
10% SDS
A 10% (w/v) stock solution was prepared in deionized water
APS
A small amount of 10% stock solution was prepared in deionized water and 
stored at 4®C.
5X gel loading buffer
3.8 ml distilled water
1.0 ml 0.5 MTris-HCl
0.8 ml glycerol
1.6 ml 10% SDS
0.4 ml 0.05% BPB
400 ul P-Me ethanol (added freshly)
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Table 4-3 Solution of preparing resolving gels for Tris-glycine SDS-PAGE
Solution
components
Component Volumes (ml)
6% 5 ml 10
ml
15 ml 20 ml 25 ml 30 ml 40 ml 50 ml
dH20 2.6 5.3 7.9 10.6 13.2 15.9 21.2 26.5
30% mix 1.0 2.0 3.0 4.0 5.0 6.0 8.0 10.0
1.5 M Tris (pH 8.8) 1.3 2.5 3.8 5.0 6.3 7.5 10.0 12.5
10% SDS 0.05 0.1 0.15 0.2 0.25 0.3 0.4 0.5
10% APS 0.05 0.1 0.15 0.20 0.25 0.30 0.40 0.50
TEMED 0.004 0.008 0.012 0.016 0.020 0.024 0.032 0.040
8%
(IH2 O 2.3 4.6 6.9 9.3 11.5 13.9 18.5 23.2
30% mix 1.3 2.7 4.0 5.3 6.7 8.0 10.7 13.3
1.5 M Tris (pH 8.8) 1.3 2.5 3.8 5.0 6.3 7.5 10.0 12.5
10% SDS 0.05 0.1 0.15 0.20 0.25 0.30 0.40 0.50
10% APS 0.05 0.1 0.15 0.20 0.25 0.30 0.40 0.50
TEMED 0.003 0.006 0.009 0.012 0.015 0.018 0.024 0.030
10%
dH20 1.9 4.0 5.9 7.9 9.9 11.9 15.9 19.8
30% mix 1.7 3.3 5.0 6.7 8.3 10.0 13.3 16.7
1.5 M Tris (pH 8.8) 1.3 2.5 3.8 5.0 6.3 7.5 10.0 12.5
10% SDS 0.05 0.1 0.15 0.20 0.25 0.30 0.40 0.50
10% APS 0.05 0.1 0.15 0.20 0.25 0.30 0.40 0.50
TEMED 0.002 0.004 0.006 0.008 0.010 0.012 0.016 0.020
12%
dH20 1.6 3.3 4.9 6.6 8.2 9.9 13.2 16.5
30% mix 2.0 4.0 6.0 8.0 10.0 12.0 16.0 20.0
1.5 M Tris (pH 8.8) 1.3 2.5 3.8 5.0 6.3 7.5 10.0 12.5
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10% SDS 0.05 0.1 0.15 0.20 0.25 0.30 0.40 0.50
10% APS 0.05 0.1 0.15 0.20 0.25 0.30 0.40 0.50
TEMED 0.002 0.004 0.006 0.008 0.010 0.012 0.016 0.020
15%
dH20 1.1 2.3 3.4 4.6 5.7 6.9 9.2 11.5
30% mix 2.5 5.0 7.5 10.0 12.5 15.0 20.0 25.0
1.5 M Tris (pH 8.8) 1.3 2.5 3.8 5.0 6.3 7.5 10.0 12.5
10% SDS 0.05 0.1 0.15 0.20 0.25 0.30 0.40 0.50
10% APS 0.05 0.1 0.15 0.20 0.25 0.30 0.40 0.50
TEMED 0.002 0.004 0.006 0.008 0.010 0.012 0.016 0.020
Table 4-4: Solution of preparing 5% stacking gels for Tris-glycine SDS-PAGE
Solution
components
Component Volumes (ml)
5% gel 1 ml 2 ml 3 ml 4 ml 5 ml 6 ml 8 ml 10 ml
(IH2 O 0.68 1.4 2.1 2,7 3.4 4.1 5.5 6.8
30% mix 0.17 0.33 0.50 0.67 0.83 1.0 1.3 1.7
1.0 M Tris (pH 
6.8)
0.13 0,25 0.38 0.50 0.63 0.75 1.0 1.25
10% SDS 0.01 0.02 0.03 0.04 0.05 0.06 0.08 0.1
10% APS 0.01 0.02 0.03 0.04 0.05 0.06 0.08 0.1
TEMED 0.001 0.002 0.003 0.004 0.005 0.006 0.008 0.01
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4-2.4 Transfer of Proteins from SDS-Polyacrylamide Gels to Solid Supports
As the SDS-polyacrylamide gel was approaching the end of its run, four pieces 
of Whatman 3MM paper and one piece of transfer membrane (PVDF or nitrocellulose) 
was cut to the exact size of the SDS-SDS-polyacrylamide gel by wearing gloves. One 
corner of the membrane was marked with a soft-lead pencil. The membrane was left in 
methanol for 1 minutes and then washed with deionized water and soaked into transfer 
buffer for 15-20 minutes. Meanwhile the Whatman 3MM papers were soaked into a 
shallow tray containing a small amount of transfer buffer and kept shaking for 1 
minute.
The transfer apparatus was set as follows:
- 2 layers of Whatman 3MM paper that have been soaked in transfer buffer was 
put onto the plate which will be positively charged (anode). All air bubbles were 
squeezed.
- The membrane was placed onto the Whatman 3MM papers. (The transfer 
membrane should be exactly aligned and the air bubbles trapped between it and the 
Whatman 3MM paper should be squeezed out.)
- The glass plates holding the SDS-polyacrylamide gel were removed from the 
electrophoresis tank, and the gel was transferred to a tray of deionized water.
- SDS-polyacrylamide gel was placed onto the transfer membrane. Any trapped 
air bubbles were squeezed out with a gloved hand.
- 2 layers of Whatman 3MM paper were placed to the top of the sandwich (this 
side will be negatively charged during the transfer (cathode side)).
The upper plate of the apparatus will be the cathode during the transfer. The 
electrical leads of the apparatus were connected to the power supply and the transfer 
was carried out at a current of 3.5 mA/cm^ of the gel for a period of 30-45 minutes. The 
electric current was turned of at the end of the run time and the transfer apparatus was 
disassembled from top downward, peeling off each layer in turn. The gel was 
transferred to a tray containing Coomassie Brilliant Blue and stained in order check if 
the transfer is complete or not. The top left-hand corner of the membrane was cut as 
insurance against obliteration of the pencil mark.
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Transfer Buffer:
2.9 g Glycine
5.8 g Trisma base
0.37 g SDS
200 ml methanol
Adjust volume to 1 It with ddH20
4-2.5 Staining proteins immobilized on solid surfaces with Ponceau S
The membrane onto which proteins were transferred was washed with deionized 
water and then soaked into Ponceau S. When bands of proteins become visible, the 
membrane was washed in several changes of deionized water at room temperature. The 
positions of proteins used as molecular-weight standards were marked.
Ponceau S:
10% glacial acidic acid 
5% Ponceau S 
dH20
4-2.6 Immunological detection of immobilized proteins (Western Blotting)
After staining the proteins immobilized on transfer membrane with Ponceau S, 
the membrane was washed gently with deionized water and neutralized with the 
blocking buffer for 5 minutes. In order to inhibit non-specific binding sites, the 
membrane was immersed in the blocking solution for one hour. Primary antibody (table 
4-5) was diluted according to instructions in blocking solution and incubated with the 
membrane at room temperature for one hour or at 4°C 0/N  on a slowly rotating 
platform. Afterwards the membrane was washed three times, once for 15 minutes and 
twice for 5 minutes, with TBS-T. Following the washes, the membrane was incubated 
with an appropriate secondary antibody (HRP-conjugated) which is diluted as 
recommended by the supplier in blocking solution for 1 hour at room temperature and
50
then washed three times with TBS-T. Then the membrane becomes ready for incubation 
with substrate and development
Table 4-5: The primary antibodies used in this thesis
Name Origin Against Clonality Dilution
6B10 Mouse P53 Monoclonal 1/1
15B9 Mouse P33ING1 Monoclonal 1/1
AF18 Mouse pRb Monoclonal 1/500
Abl Mouse P73 Monoclonal 1/200
Blocking Solution:
3% milk powder in 0.1% Tween 20-TBS solution
4-2.7 Detection of proteins immobilized on membranes by using the ECL Western 
Blotting kit (Amersham Life Science) (Catalog no: RPN 2106)
Detection of proteins immobilized on membranes was done by using the ECL 
Western Blotting kit (Amersham Life Science) (Catalog no: RPN 2106)
4-3 Extraction of RNA from Cells and Tissues
For the initial studies, RNA extraction was done using conventional method, 
then, faster and more reliable methods, such as TriPure and column based RNA 
extraction methods following DNAse treatment were optimized and used.
4-3.1 RNA extraction by conventional method
Conventional RNA extraction method relies on isolation of small molecular 
weight nucleic acids from a tissue or cell lysate. In this method cells were harvested 
with a guanidium thiocycnide containing high salt lysis buffer.Total cellular proteins 
and high molecular nucleic acids (DNA) were extracted by precipitation and extraction
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with phenol-chloroform-isoamyl alcohol based extraction method. The un-precipitated 
material in the soluble phase is RNA and other low molecular weight nucleic acids, 
such as plasmids. This phase is eollected and nucleic acids were precipitated with 
isopropanol. This method is appropriate for extraetion of high amounts of un-pure 
RNA. Sinee this method includes phase seperation step, contamination is possible and 
must be taken into cosideration.
The basic steps of this extraction-precipitation are as follows:
1. Cells or tissue was washed 3 times with PBS
2. 4 ml dénaturation solution was added for 10^  cells or 50mg tissue
Dénaturation solution:
Stock : 250 gr Guanidium thiocyanide is added into
293 ml dH20 and
17.6 ml 0.75M Sodium Citrate (pH: 7.0) and 
26.4 ml 10% Sarkosyl is added to the mixture.
The solution is stirred to mix at 65°C and stored for 3 months at RT.
Working : For 50 ml stock add 0.35 ml P-mercapto
ethanol
The solution must be used immediately
3. Lysate was prepared using a pipette or homogenized with a polytron ( the 
solution must be not viscous )
4. The lysate was trasfared to a 15 ml falcon
5. 0.1 volume of 2M Na-Ac was added
6. Mixture was aliquoted into 5 tubes ( 5x0.9 ml )
7. 1 ml of water saturated phenol was added
8. 0.2 volume of 49:1 chloroform/isoamyl alcohol is added
9. Tubes were stored at 4 C for 15 min, resuspended frequently.
10. Tubes were centrifuged at 10,000 rpm for 15 min at 4 °C
11. Aqueous phase was taken to a fresh tube
12. 1 volume of 100 % isopropanol is added and the mixture is stored at -20 °C 
overnight (0/N)
13. The tubes are eentrifuged at 10 000 rpm for 10 min at 4°C
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14. Supernatant (S/N) was discarded, pellet was dissolved in 300 ul denturation
solution
15. 300 ul isopropanol is added
16. Samples were stored at -20 °C 0/N
17. Tubes were centrifuged at 10 000 rpm for 10 min at 4 °C
18. S/N is discarded
19. Pellet is resuspended in 75 % ET-OH and left at RT for 15 min
20. The tubes are cenrifuged for 15 min at 4 C
21. The pellets were dried in speedvac
22. The pellets are resuspended in 100-200 ul DEPC H20
23. Samples are aliquoted and stored at -70°C
The RNA isolated with this method contains high amounts of salt and probably 
sheared genomic DNA. For these reasons, spectrophotometric analysis and 
formaldehyde containing agarose gel electrophoresis results does not give parallel 
results. For example spectrophometrically, very concentrated RNA might be 
unvisible on RNA agarose gel. Another handicap of this protocol is the time 
consumption. This method takes 3 days with only 4 hours of hands-on time.
4-3.2 RNA Isolation with TriPure Reagent
TriPure isolation reagent is a monophasic solution of phenol and guanidine 
thiocyanate for RNA, DNA and protein isolation at the same time. TriPure isolation 
reagent allows the isolation of total RNA, DNA and protein from the same sample in a 
single-step liquid-phase separation. The expected yield of RNA and DNA from various 
starting material are as follows:
RNA from tissues: liver or spleen, 6-10 pg/mg tissue; kidney, 3-4 pg/mg tissue; 
skeletal muscle or brain, 1-1.5 pg/mg tissue; placenta, 1-4 pg/mg tissue.
RNA from cultured cells: epithelial cells, 8-15 pg/106 cells; fibroblasts, 5-7 
pg/106 cells.
DNA from tissues: Liver or kidney, 3-4 pg/mg tissue; skeletal muscle, brain, or 
placenta, 2-3 pg/mg tissue.
DNA from Cultured cells: human, rat, or mouse cells, 5-7 pg/106 cells.
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The protocol for nucleic acid and protein extraction differs slightly for tissue and 
cultured cells as indicated below.
4-3.2.1 Phase Seperation Step
For 50-100 mg of tissue (or 1-5*106 cultured cells) 1 ml of TriPure reagent is 
used. Basically, the tissue is homogenized using a polytron (the cultured cells are lysed 
by pipetting or by passing though a 20 gouge 0.9 mm needle) and let stand for 5 min at 
room temperature. For each 1 ml of TriPure reagent used 0.3 ml of chloroform is added 
and mixed vigorously by shaking (not vortexing). For complete dissassociation of 
proteins and lipids, the mixture is let stand for 5 min at room temperature. The sample 
is then centrifuged for 13000 rpm at 4 degrees for 15 minutes. After this centrifugation 
there must be 3 layers formed in the tube. The upper layer is colorless and aqeous, 
containing small molecular weight nucleic acids like RNA and plasmids. The middle, 
white phase, between red, organic phenol and colorless, aqeous phase is containing 
some proteins, lipids and DNA. The lower, red phase is made of phenol and containing 
lipids and proteins. If the middle phase is thicker that 2 mm, 500 ul TriPure and 200 ul 
chloroform is added to the sample and the sample is mixed vigorously and then 
centrifuged again at 13000 rpm at 4 degrees for 15 minutes to achieve a clear 3 phase.
4-3.2.2 RNA Isolation Step
The upper aqeous phase containing small molecular weight nucleic acids are 
taken to a new tube and for each 1 ml of TriPure reagent used as starting material, 0.5 
ml of isopropanol is added to the sample. The sample is mixed briefly by inversion a 
few times and then incubated at -20 degrees for 30 min. Then the sample is centrifuged 
at 13000 rpm at 4 degrees for 10 minutes.
A white pellet containing salts and RNA must be formed after this 
centrifugation. The pellet is washed with 1 ml 80% ethanol once and recentrifuged at 
10000 rpm at 4 degrees for 10 minutes. The supernatant is discarded and the pellets 
were air dried for 5-10 minutes. The pellet is resuspended in Rnase free (DEPC treated) 
water and spectrophometrically analysed. A 260/280 ratio < 1.5 reveals the presence of 
salts, >2.0 reveals the presence of phenol or spectrophotometre dysfunction. A 260/280
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ratio >1.9 and <1.6 reveals good quality of RNA, but DNA contamination must always 
be suspected and analysed by RNA gel eleetrophoresis and RT-PCR.
4-3.3 RNA Isolation by Nucleospin-II kit
Nucleospin II RNA purification system allows the purification and extraction of 
total RNA from various sources like, cells, tissues, yeast cells, bacterial cells, body 
fluids and RNA contaminated with DNA or proteins in an aqeous solution. The 
purification system of this kit relies on the affinity of nucleic acid to positively charged 
glass beads. Briefly, the eells are lysed with 400 ul RAl (a solution containing 
Guanidine Thiocyanide and b-mercapto ethanol) and the lysate is loaded to a eolummn 
containing charged glass beads after the addition of 250 ul 100% ethanol. The nucleic 
acid components of the cell bind to the colummn material and then the colummn is 
trated with DNase (15 minutes at room temperature) so as to get rid of DNA. After the 
inactivation of DNase (by addition of 500 ul RA2) and several washes (twice with 350 
ul RA3), the only resident of the colummn, RNA, is eluted with RNase free water.
4-3.4 Formaldehyde Containing RNA Gel and RNA Electrophoresis
1% Formaldehyde containing agarose gel is prepared as follows;
11 ml 5X Forrmaldehyde gel running buffer (10 ml of 2M Sodium Aeetate, 10.3 gr 
MOPS and 390 ml DEPC treated distilled water is mixed and pH is adjusted to 7.0 with 
Sodium Hydroxide (~15 ml 5M NaOH). 5 ml, 0.5 M, pH. 8.0 EDTA is added and the 
solution is added up to 500 ml), 35 ml DEPC water and 0.5 gr agarose is added and the 
sample is heated to boil in a microwave owen. When the solution is cooled to 60-70 
degrees, 10 ml Formaldehyde is added and the gel is immediately poured into the casted 
apparatus.
RNA samples for loading are prepared as follows:
15 ul of RNA loading buffer (50% formamide, 20% Formaldehyde, 15% 5X running 
buffer, 15% glycerol-dye, premixed and stored at -20 degrees) and 5 ul of RNA sample 
is mixed, heated at 70 degrees for 5 minutes, chilled on ice.
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The prepared samples are loaded to the gel and run at 80V for 45 minutes and 
stained in Et-Br containing water for 5 min and destained overnight in distilled water.
4-4 Extraction of DNA from Cells and Tissues
The middle and bottom phases from RNA isolation (Phase seperation-as 
explained in section 4-3.2.1) were used for DNA extraction. Briefly, 0.5 m of ethanol is 
added to the middle and bottom phases. The tube is inverted several times for complete 
dissassociation of middle layer. The mixture is centrifuged for lOK rpm for 5 minutes. 
The pellet containing DNA and other impurities must be washed twice with 30% 
ethanol, 10 mM Sodium Citrate solution.
Then the pellet is resuspended in 1 ml freshly prepared digestion buffer (100 
mM Sodium Chloride, 10 mM Tris pH : 8.0, 25 mM EDTA pH : 8.0, 0.5% SDS and 0.1 
mg/ml proteinase K) and incubated overnight at 65 degrees. The protein components of 
the pellet is disassociated after 16 hours and DNA is extracted using phenol/ 
chloroform/isoamyl alcohol and precipitated with the addition of 200 ul of 7.5 M 
Ammonium acetate and 2.5 volumes of absolute ethanol. The DNA precipitate is 
resuspended in 100-200 ul of dH20 at 55 degrees for 1 hour with occasional mixing. 
The presence and the quality of DNA must be investigated with PCR using 1 -2 ul of 
DNA as template or direct agarose gel electrophoresis.
4-5 cDNA Preparation from Total RNA:
cDNA is prepared from 3-5 ug total RNA. X ul (3-5 ug) RNA, 1 ul of oligo-dT 
primer and (11-x) ul Rnase free dHaO are placed into an Rnase free tube. The tube is 
incubated at 70 degrees for 5 minutes so as to disrupt the secondary structure of RNA. 
The tube is chilled on ice and then placed to a 37 degree incubator for 5 minutes with 
the addition of 4 ul of 5X reaction buffer, 2 ul of lOmM dNTP mix and 1 ul of Rnase 
inhibitor. Then the reaction is first equilibrated and after the addition of 1 ul RT 
enzyme, incubated at 42 degrees for 1 hour. After a final incubation at 70 degrees for 10 
minutes so as to heat inactivate MMLV reverse transcriptase enzyme, 20 ul of cDNA is 
ready to use for PCR amplification.
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For a common PCR reaction with Taq polymerase, 8 components must be mixed 
and incubated at specific temperatures at specific time periods in a thermal cycler 
device. For a representative 50 ul PCR reaction, the following components must be 
mixed in a 200 ul PCR tube (Table 4-6). Please note that optimization indicates the 
probable need for optimization.
Table 4-6: The reagents of a common PCR reaction
4-6 PCR Amplification Using cDNA:
The components of a common PCR reaction using cDNA as template:
REAGENT STOCK USED VOLUME COMMENTS
dH20 32.6
PCR buffer lOX IX 5 ul
dNTP mix 2mM 200 uM 5ul
MgCb 25 mM 1.5 mM 3ul optimization
F-Primer 25 pm/ul 25 pm 1 ul optimization
F-Primer 25 pm/ul 25 pm 1 ul optimization
Taq polimerase 5U/ul 2U 0.4 ul
Template DNA (cDNA) 2 ul optimization
After mixing the components, the PCR tubes containing the reaction mixtures 
are carrried rapidly to a thermal cycler which incubates the samples at specific 
temperatures for specific time periods. A representative, 30 cycle PCR program for 
amplification of up to 1000 bp fragments is as follows:
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sox
T E M P E R A T U R E TIM E C O M M EN TS
94 5 min. Initial dénaturation
(s^ 94 30 sec. Cycle dénaturation
62 30 sec. Cycle annealing
72 30 sec. Cycle extension
72 5 min. Final extension
4 forever Waiting
4-7 Defînition of the Fidelity of Reverse Transcription and Genomic DNA 
Contamination in the cDNA:
The fidelity and genomic DNA contamination of freshly prepared cDNA must be 
checked before making expression analysis. This can be achieved by making PCR for a 
ubiquitously expressed transcript such as GAPDH, cyclophilin or beta-actin. The 
primers for this analysis must be carefully selected, so that, they must anneal to 
different exons, and produce a longer PCR product from genomic DNA covering a 
small intron. We have used GAPDH primers for this analysis, producing a 151 bp 
fragment from cDNA and 250 bp fragment from genomic DNA (for sequence of 
GAPDH primers look ‘primers used in this thesis’ section.). Making a 19-24 cycle 
GAPDH PCR using 1 ul of cDNA reveals the efficiency of cDNA synthesis and 
genomic DNA contamination.
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20 ul reaction mixture of the prepared cDNA contains 3-5 ug of total RNA, 
converted to cDNA. Using an equal amount of cDNA (such as 0.5-3 ul) for PCR 
amplifications gives comparable results at a specific number of PCR cycles. The 
number of PCR cycles is determined by an initial study for each transcript by making 
20-35 cycles of PCR with 2-4 cycle intervals. By doing such a analysis, for example, 
20, 23, 26, 29, 32, 35 cycles of PCR with an equal cDNA load defines the minimum 
number of cycle to visualize the product on agarose gel and the saturation cycle. 
Moreover, if the analysis covers a few sources, such as different cell lines and tumors, 
all samples should be analyzed initially at a high number of PCR so as to be sure at the 
presence or absence of the transcript in all samples. Semi quantitative RT-PCR can be 
achieved in 2 different approaches; comparison with GAPDH or equalizing GAPDH
4-8.1 Comparison with GAPDH
All samples are initially analyzed for their GAPDH expression at a unsaturated 
cycle, such as 19-24. Then the gene of interest is analyzed again at an unsaturated cycle. 
The band intensities of each sample is compared that of GAPDH using an image- 
analysis software. For example, p73 gene expression in sample A, B and C are 
compared. If, sample A has a GAPDH intensity of 10 and p73 intensity of 5, sample B 
has GAPDH intensity of 20 and p73 intensity of 10 and sample C has GAPDH intensity 
of 5 and p73 intensity of 10. The GAPDH versus p73 intensities are : sample A: 0.5, 
sample B: 0.5 and sample C: 2. This results mean that p73 expression levels are same 
and low in sample A and B but increased 4 times (0.5 versus 2) in sample C, although 
p73 band intensity is not 4 times increased.
4-8 Expression analysis of RNA using cDNA:
4-8.2 Equalizing GAPDH
Like method 1, all samples are initially analysed at an unsaturated cycle for 
GAPDH. IF the results are the same for samples A, B and C are 10, 20 and 5 
respectively. This means that either the RNA content or the fidelity of reverse 
transcription reaction is differing among these samples. In this method, equalizing
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GAPDH is necessary, so cDNA is diluted accordingly (A: ‘A, B: 14 and C 1/1). Using 
equal volumes of cDNA, such as 2 ul will give the same band intensities for GAPDH 
and probably will show equal and low intensity for p73 in sample A and B, but 4 times 
increase in sample C.
4-8.3 PCR amplification of selected transcripts using the optimized cDNA
The PCR reactions were carried out as described above in section 4-6. The 
transcript specific primers are summarized in table 4-7.
Table 4-7: Synthetic Oligonucleotides Used In This Study
NAME
p73L-F
p73-X14-R
p73a-R
p73p-R
GAPD-F
GAPD-R
TA-p73-F
DN-p73-F
p73-X4-R
1 6 lN IC 4 a .F
PI4ARF-F
C-R
cyclin E-F
cyclin E-R
Filip-F
Filip-R
P-actin-F
P-actin-R
p53-F
p53-R
SEQUENCE Tm (°C)
(5'-CGGCCATATTGGTGCCGCAGCCACTGGTG-3’) 64
(5’-CCTCAGTGGATCTCGGCCTC-3’) 63
(5'-GTTTGGCACCCCCAATCCTGT-3’) 61
(5'-AGGGCCCCCAGGTCCTGAGC-3') 63
(5 ’- GGCTGAGAACGGGAAGCTTGTCAT-3 ’) 64
(5 ’- CAGCCTTCTCCATGGTGGTGAAGA-3 ’) 64
(5 ’-AACCAGACAGCACCTACTTCGACC-3 ’) 62
(5 ’-ACCATGCTGTACGTCGGTGACCCC-3 ’) 62
(5 ’-GCGACATGGTGTCGAAGGTGGAGC-3 ’) 62
(5 ’- CGGAGAGGGGGAGAACAGAC-3 ’) 61
(S’- TCACCTCTGGTGCCAAAGGG -3’) 62
S’- GGCAGTTGTGGCCCTGTAGG -3’) 63
(S’-TTGACCGGTATATGGCGACACAAG -3’) 64
(S’-ATGATACAAGGCCGAAGCAGCAAG -3’) 64
(S'-GGACGGACGCCGATGCC-3') 63
(S'-GGTCCATGGTGCTGCTCAGC-3') 63
(S’-TGATATCGCCGCGCTC-3’) 59
(S’-CAGTCAGGTCCCGGCC-3’) 59
(S’-TCCCCCTTGCCGTCCCAA-3’) S8
(S’- CGTGCAAGTCACAGACTT -3’) SS
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4-9 CLONING for SEQUENCING
PCR amplified DNA fragments are cloned for sequencing for the description of 
splice acceptor and donor sites of alternative splicing products and for the description of 
a new p73 gene encoded transcript. As a vector, pGEM-T easy, T/A cloning vector was 
used (Promega). As a host for the plasmid, DH5a strain of E.coli was used.
THE GENOTYPE OF DH5a
Strain Genotype usage reference
DH5a A/acU169
i^m acZA M \5) hsdR ll recAl 
endAl gyrA96 thi-l relAl
Host for 
plasmid DNA
Hanahan
(1983)
4-9.1 Growth of E. coli strains
All strains were grown in LB medium or on LA medium supplemented with the 
appropriate antibiotic if necessary.
Solid and liquid mediums:
LB medium : 0.5% Yeast extract, 1% Bacto-tryptone, 1% NaCl.
LA medium : 0.5% Yeast extract, 1% Bacto-tryptone, 1% NaCl and 1% agar.
Antibiotics:
Ampicillin with a final concentration of 50 ug/ml was used in this study.
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Cells were made competent using a modification of the CaC12 method described 
by Maniatis et al. (Maniatis et al.„ 1982). In brief, 5 ml LB was inoculated using a 
single colony from a freshly grown plate of the E. coli strain to be used, and was 
incubated at 37°C for approximately 2 hours, until the ODeoo of the culture is 0.3-0.4. 
The culture was then cooled on ice for 5 minutes, 1 ml aliquots were added to 
microcentrifuge tubes and then the cells were pelleted by centrifugation (1 minute at 
13,000rpm ). The cells were resuspended in 0.5 ml of 50 mM CaC12 by gentle 
vortexing, before being placed on ice for 30 minutes. The cells were pelleted by 
centrifugation (1 minute at 13,000 rpm), and the supernatant was discarded. The pellet 
was resuspended in 0.1 ml of CaC12 with gentle vortexing. The cells were then stored 
on ice until required for transformation. Alternatively competent cells were prepared 
and stored at -70°C until required. 500 ml of LB was seeded with a 10 ml of overnight 
culture and grown to an OD600= 0.6. Cells were harvested by centrifugation at 5000 
rpm for 10 minutes at 4°C, before being incubated on ice for 20 minutes. The cells were 
harvested as before, resuspended in 25 ml of 50 mM CaC12 /20% glycerol and aliquoted 
into microcentrifuge tubes before being frozen. Samples were stored at -70°C and were 
viable for at least 2 months. Cells were thawed on ice prior to the addition of DNA.
4-9.2 Preparation of competent bacteria
4-9.3 Ligation
Ligation reaction is done as described in the technical manual of pGEM-T easy 
vector system handbook. This system allows the usage of unpurified PCR products in 
the ligation. Briefly, the following components were mixed and the reaction was 
incubated at room temperature for 1 hour for the ligation to proceed.
2X ligation buffer 5 ul
vector 1 ul
Insert Xul
Ligase 1 ul
dH20 3-X ul
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The DNA to be transformed (usually a 1-10 ul of ligation mixture) was added to 
the 100 ul of competent cells, mixed gently and incubated on ice for 30 minutes. The 
cells were then heat-shocked at 42°C for 90 seconds and chilled by placing on ice for 2 
minutes. 1 ml of pre-warmed LB was then added and the suspension was incubated at 
37°C for 1 hour. Each sample was pelleted by centrifugation at 13,000 rpm for 2 
minutes, resuspended in 100-200 ul of LB and plated onto selective medium and 
incubated overnight at 37 °C to allow the growth of the transformants.
4-9.4 Transformation of plasmid DNA in bacterial cells
4-9.5 Isolation of plasmid DNA from bacteria: Small scale preparation of plasmid 
DNA
This protocol is based on the alkaline lysis method of Birnboim and Doly
(1979).
The transformed bacterial strain containing the plasmid of interest was grown at 
37°C overnight in 5 ml of LB+antibiotic. 1.5 ml of the bacterial culture was pelleted by 
centrifugation for 1 minute (bench-top microfuge, 13,000 rpm) in a 1.5 ml microfuge 
tube. After the removal of the supernatant, the cells were resuspended in 0.1 ml of ice- 
cold solution I and stored for 5 minutes at room temperature. 0.2 ml of solution II was 
mixed by inversion, the tube was then stored on ice for 5 minutes. Bacterial 
chromosomal DNA and proteins were precipitated by the addition of 0.15 ml of ice-cold 
solution III. The mixture was left on ice for 5 minutes, then centrifuged at 13000 rpm in 
a bench-top centrifuge for 5 minutes to pellet the host DNA and proteins. The 
supernatant was mixed with an equal volume of phenol-chloroform (1:1) and 
centrifuged in a bench-top micro fuge at 13000 rpm for 3 minutes to separate the two 
phases. The top phase was removed and plasmid DNA was precipitated by mixing it 
with 2.5 volumes of 95% ethanol, and pelleted by centrifugation for 10 minutes (bench- 
top micro fuge, 13,000 rpm) after keeping the mixture at 4°C for 15 minutes. The 
supernatant was discarded and the pellet was left for 15-20 minutes at room temperature
63
to dry and then resuspended in 20-30 ul of TE buffer containing 10 ug/ml RNaseA. 
Samples were stored at -20 °C.
Solution I
50 mM glucose
25 mM Tris.Cl (pH 8.0) 
lOmM EDTA (pH 8.0)
Solution I can be prepared in batches of approximately 100 ml, autoclaved for 15 
minutes at 10 Ib/square in. on liquid cycle, and stored at 4oC.
Solution II
0.2M NaOH (freshly diluted from 1 M stock)
1% SDS
Solution III
5 M potassium acetate 60 ml
glacial acetic acid 11.5 ml
H20 28.5 ml
The resulting solution is 3 M with respect to potassium and 5 M with respect to acetate.
TE buffer
pH 7.4 lOmM Tris.Cl (pH 7.4) 
ImM EDTA (pH 8.0)
The results of the miniprep was quantified by spectrophotometric analysis at 
260/280nm and by agarose gel electrophoresis before the sequencing reaction.
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Restriction enzyme digestion was either used to confirm the presence of an insert 
in a plasmid or for genotyping p53 codon 72 polymorphism. DNA restriction reactions 
were carried out in a total volume of 20-100ul with 5-10 units of restriction enzyme.
The volume of the reaction buffers were arranged to be IX and the enzyme volume was 
never greater than 1/10th of the reaction volume so as to prevent star activity due to the 
high glycerol concentration. Analytical studies for detection of the presence of an insert 
in a plasmid was achieved with a two hour restriction, whereas, the genotyping studies 
was achieved with an overnight digestion of the PCR amplified DNA so as to achieve 
100% restriction. A typical 20 ul restriction reaction was described below.
4-9.6 Restriction enzyme analysis
Component volume Unit
H20 13 ul -
DNA 5 ul -
lOX buffer 2 ul -
Enzyme 1 ul lOU
The restriction enzymes were obtained from MBI Fermentas (Lithuania).
4-10 Analysis of DNA using agarose gele electrophoresis
The agarose gel electrophoresis of DNA was carried out using the instructions 
defined by Maniatis et al. (Maniatis et al., 1988) and using the mini, midi and maxi 
systems of EC.
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CHAPTER V
THE DESCRIPTION AND ANALYSIS OF P73 GENE ENCODED 
TRANSCRIPTS AND PROTEINS
We have started to investigate the probable role of p73 in liver carcinogenesis, 
just after the description of the p73 gene, in late 1997. The role of p53 in the 
ethiopathology of HCC is well defined so its structural and functional homologue p73 
gene was suspected to be structurally inactivated during HCC development. A group of 
scientists, under the supervision of Prof Mehmet Ozturk were organized to look for 
mutations in the DNA binding domain of p73, especially to the codons corresponding to 
the mutational hotspots of the p53 tumor suppressor. The results of this study revealed 
no mutations but several polymorphisms in a set of primary liver cancer samples so the 
role of p73 on liver carcinogenesis was described to be different than the other family 
member, p53 (Ozdag et al., unpublished data).
With the clues of this initial study, we have suspected changes in the expression 
pattern of p73 gene during liver carcinogenesis so we planned to work with HCC 
derived cell lines for characterization of p73 gene encoded transcripts. We knew that 
p73 gene encodes for at least 2 major transcripts, namely p73a and p73p. The 
difference of these two transcripts is that p73p, lacking exon 13. Since other groups 
stated that p73 mRNA levels are very low (Zaika et al., 1999), we planned to describe 
all 3’ alternative splicing forms by a 2 step PCR as described in figure 5-2. Thus we 
have extracted total RNA from 10 HCC cell lines, namely Huh7, Hep3-BTR, Focus, 
Mahlavu, Hep40, Hep3B, HepG2, PLC/PRF/5, BC-1 and SK-Hepl and a normal liver 
by conventional method. The 260/280 nm. Optical Density (OD) of these samples were 
between 1.8 and 2.0, and the concentrations were between 0.8 to 1.5 ug/ul.
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cDNA from these samples were prepared by using 5 ug of total RNA, by oligo- 
dT primer. The reaction volume of cDNA preparation is 20 ul and 1 ul from each 
sample is used for P-actin amplification for the control of the quality and the quantity of 
cDNA (Figure 5-1).
5-1 cDNA preparation and P-actin PCR results
1 7 8 10 11 12
P-actin
Figure 5-1: The RT-PCR picture of P-actin of 10 HCC cell lines and a normal liver.
Lanes: 1: marker, 2: Huh7, 3: Hep3-BTR, 4: Focus, 5: Mahlavu, 6: Hep40, 7: Hep3B, 8: 
HepG2, 9: PLC/PRF/5, 10: BC-1, 11: SK-Hepl and 12: Normal Liver
5-2 Description of 3’ end alternative splicing forms of p73 transcripts by 2 
round PCR amplification
The two round PCR strategy was used to detect the p73 encoded transcripts is 
schematized in figure 5-2. First, a PCR using p73L-F and p73-X14-R was performed 
from all samples, using 2.5 ul of cDNA as a template. The result of this amplification 
did not produce a visible band on ethidium bromide stained agarose gel. However, the 
second round PCR, using 5 ul of product from first PCR as template and p73L-F as the 
forward and p73a-R and p73p-R as the specific reverse primers yielded positive and 
comparable results, as shown in figures 5-3 and 5-4.
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Figure 5-2 : The schematic representation of the approach: Two round PCR based 
detection of 3’ alternative splicing products of p73 transcripts
-p73 -a
Figure 5-3 : Second round PCR results of p73a specific PCR of 10 HCC cell lines 
and a normal liver.
Lanes; 1: marker, 2; Huh7, 3: Hep3-BTR, 4: Focus, 5: Mahlavu, 6: Hep40, 7: Hep3B, 8: 
HepG2, 9: PLC/PRF/5, 10: BC-1, 11; SK-Hepl and 12: Normal Liver. The band 
indicated with below the a  transcript is a non-specific band
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p73 -p
Figure 5-4 : Second round PCR results of p73P specific PCR of 10 HCC cell lines 
and a normal liver.
Lanes: 1: marker, 2: Huh7, 3: Hep3-BTR, 4: Focus, 5: Mahlavu, 6: Hep40, 7: Hep3B, 8: 
HepG2, 9: PLC/PRF/5, 10: BC-1, 11: SK-Hepl and 12: Normal Liver
5-4 Identification of consistently amplified smaller bands as new transcript 
isoforms and cloning of the new transcripts
The PCR results for some cell lines, produced consistent and small amplification 
products, which can not be diminished by changing the annealing temperature and 
magnesium concentration (Figure 5-4, lane 6). Therefore these products were suspected 
to be specific products of the PCR reaction, so alternative splicing was taken under 
consideration. As suspected, the sizes of smaller amplicons were matching the probable 
size of candidate splicing products. The candidate alternative splicing forms are lacking 
one or more exons so with the approach defined in figure 5-2 the relative sizes of the 
probable bands that can be obtained with our experimental system are summarized in 
table 5-1.
Table 5-1: The probable product size of a  and p specific second round PCR reactions, 
as calculated by the lack of one or a combination of more than one exons.
a  specific second round PCR produce 
p73a : 383 bp 
p73y : 235 bp 
p73e : 97 bp
P specific second round PCR produces 
p73p:369 bp 
p73(j): 221 bp
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All of the PCR products from a  and p specific reactions were excised from 
agarose gel, purified and ligated to pGEM-T-easy, T/A cloning vector. The ligation 
products were transformed to DHsa strain of E.coli and selected for ampicilin 
resistancy on LA plates. The colonies formed were inoculated into LB-ampicilin 
medium and minipreps were prepared (Figure 5-5). Candidate clones were digested with 
EcoRI, which takes the insert out (Figure 5-6).
1 7 8 9 10 11
Figure 5-5: A representative miniprep results of several p73 alternative splicing 
products
Lanes: Lmarker, 2,3,4,5: candidate clones from p73a, 6; A blue colony, 7,8,9,10,11: 
candidate clones from p73p
1 4 5 7 8
Figure 5-6 : Restriction of miniprep results of several p73 alternative splicing 
products with EcoRI
7]
Lanes: 1; Ikb marker, 2: empty pGEM-T-easy, 3: p73p, 4:p73(]), 5: p73y, 6: p73s, 7: 
p73a, 8: lOObp DNA ladder
5-5 Sequencing results and the description of exon-exon boundaries of 
alternative splicing products
New minipreps were prepared and phenol-ehloroform treatment was done so as 
to be sure that plasmids are ready for sequencing. Sequencing results showed the 
authenticity of a , p, y, (j) and s forms with exon-exon junctions (Figure 5-7). Through 
the progression of these studies, Zaika et al. (Zaika et al., 1999), described the presence 
of all probable splicing forms of p73 transcripts in breast cancer cell lines and primary 
breast cancer tissues, including the ones we have described (Figure 2-1). Our results 
correlate well with the data obtained from breast cancer samples, which proposed the 
expression of p73a and p73p as major transcripts in normal breast tissue, but cancer 
related changes in the alternative splicing give rise to different p73 gene encoded 
transcripts through the progression of carcinogenesis. Our results showed the presence 
of p73a and p73p in normal liver and the acquired expression of a combination of least 
5 different p73 3’ alternative splicing forms in HOC derived cell lines.
Figure 5-7: The sequencing results of the plasmid clones containing the different 
splicing products of p73.
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5-6 Identification of a new exon and a promoter region within intron 3 of p73 
gene
After the Human Genome Project was finished, all the sequence of human 
cluomosomes entered to the public database. In silico analysis of the contig harboring 
human p73 gene yielded the identification of a promoter like DNA fragment, at which 
different transcription factors bind. Moreover, the promoter like DNA fragment 
contained a putative exon, transcription initiation site, translation initiation site, an open 
reading frame at considerable length and a splicing acceptor site (Figure 5-8). These 
results lead us to propose the initiation of a new transcript fi'om intron 3 of human p73 
gene. The new exon in the intron 3 of p73 was called as exon 3’, regarding the 
nomenclature of p63 and mouse DN-p73 (Yang et al., 1998, Yang et al., 2000)
1__CCTGCTTCCAGGGGGACTCGGGCCCCTCTGCCAGGGTCAACTTTGTACCCAAGACGGCTGAAATACAATG
7 1 GAAATTCAGACGGCCCAACAGGGAGTGGCAGTCACCTCAAAGGCCCCACTAGACGGGTGCGGGGCACCA
140__CTGCAGAGCCCCTCCCTGGCTGTGCCAAGGCCGTCCACGCCTGCAGGGGGCCCCACTGCCGGGCTGTT
2 19 __Ci^CKSCAUfCAGTGGCTTGTCCCTGTTTCCTGGGGGCTTGGCCAGTGCCAGGGTGGGCTCCAAACGCA
287__CGGCTCTGGGCTCTTGGACTCACCCCTGCTTTGGGCAGGCAGTGGAAGGCAGGCCCCACAAGAGCTGC
355__TCACTCCCGTCACCTGTCTCCCTCGGGGGTCTAGGGTCGAACCTCCTGTGAGCCCCTCCTCTCCATGC
423__^AGCCCTTGGACTGGTCCTGGCGGACCACCGAGTTCCCCGCGCAGGGGGCAGGTGCGCCCCACCTGGGT
491 GCCAAGGGAGGCGACACCATCTCTCCCCCTTGGGGTGGCCCAGCCTTGCCTACCATGATCTCCAGGGC 
559_]ICGGGGCTCAGCCCTCATGCCTGGGAACAGAGGCTGCTTTACGGGGTGAGGGCCTGGGGCCCCCCGAGC
627__CTTCCCCAGGCAGGCAGCATCTCGGAAGGAGCCCTGGTGGGTTTAATTATGGAGCCGGCGCTGACCGG
695__CGTCCeWSO^
p r e d ic t e d  D N -p73 prom oter
7 3 2__CCAACACATCACCGGGCAAGCTGAGGCCTGCCCCGGACTT06ft.YGRftTACTCATGAGGAATAAAGGGG
800 YgGGClB^afllGTTTTGTTGTTGGATTCAGCCAGTTGACAGAACTAAGGGAGATGGGAAAAGCGAAAAT
868__GCCAACAAACGGCCCGCATGTTCCCCAGCATCCTCGGCTCCTGCCTCACTAGCTGCGGAGCCTCTCCC
936__GCTCGGTCCACGCTGCCGGGCGGCCACGACCGTGACCCTTCCCCTCGGGCCGCCCAGATCCATGCCTC
1004__GTCCCACGGGACACCGTTCCCTGGCGTGTGCAGACCCCCCGGCGCCTACCATGCTGTACGTCGGTGG
10 7 1 ACCCCGCACGGCACCTCGCCACGGTAGGTGTGACGCGCCATTCATAGGATCTCTTCGGGGACTTTG
underlines^ probable DN-p73 promoter
bold “T” in the underlined region^ probable transcription initiation site 
letters on grey background= probable first exon of DN-p73 (exon 3’) 
the bold “GT” at the end of exon= splicing signal
bhlC probable ST AT binding site (100% match)
glWpB iii|№ibtl"^probable spl binding site((100% match)also found in mouse e2fl
promoter). Hsiao et al., 1994
y i^ w  WegWights^probable spl binding site((100% match)also found in human 
glycophorin B promoter). Rahuel et al., 1992.
QllllllflllBI^^ spl binding site((100% match)also found in human cdc2
promoter). Shimizu et al., 1995.
Figure 5-8 ; The analysis of the contig, covering a putative promoter, binding sites for 
transcription factors, a putative exon, transcription and translation initiation sites and 
a splice donor site.
5-7 Description of the transcript from the new promoter containing the new
exon
Primers were designed from exon 3’ and exon 4 to amplify the putative p73 
transcript (now called as DN-p73), but not the former p73 transcript (now called as TA- 
p73). The initial amplification trials using SNU398 cell line cDNA revealed a band at 
expected size (Figure 5-9).
200 bp
100 bp
DN-p73
Figure 5-9: The PCR result of exon 3’-exon 4 which is specific for DN-p73 but not 
TA-p73.
Lanes; 1; 100 bp marker, 2: DN-p73 PCR result of SNU 398 (expected to be 186 bp)
5-8 Cloning and sequencing of the new transcript
The new transcript was ligated to pGEM-T-easy, T/A cloning vector. The 
ligation products were transformed to DHsa strain of E.coli and selected for ampicilin 
resistancy on LA plates. The colonies formed were inoculated into LB-ampicilin 
medium and minipreps were prepared for sequencing. The results of sequencing 
revealed the exon-exon boundries of exon 3’ to exon 4 as shown in Figure 5-10.
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Figure 5-10: The sequencing result of a DN-p73 clone
The bold letters indicate the putative exon 3’ of DN-p73 and the underlined letters 
indicate the former exon 4 of p73
5-9 RNA isolation by TriPure reagent and purification by MN Nucleospin II kit 
from 15 HCC derived cell line, 7 primary HCC tumor, 1 correspoding non-tumor 
liver and 1 normal liver
The expression profile of the new transcript, together with the former one and 
the 3 ’ end alternative splicing isoforms must be studied in a series of HCC cell lines and 
primary tumors in comparison with non-tumor liver tissue and normal liver, in order to 
assign a role to p73 in hepatocarcinogenesis. The most common method for such studies 
is semi-quantitative RT-PCR method. Since this method is very sensitive, it requires 
highly pure, DNAse treated RNA. For this reason, 15 HCC derived cell lines, namely 
Huh7, Hep3BTR, FOCUS, Mahlavu, Hep40, Hep3B, HepG2, PLC/PRF/5, SK-Hepl, 
SNU 182, SNU 387, SNU 398, SNU 423, SNU 449 and SNU 475 were grown to 70% 
confluency in 150 mm tissue culture plates and their RNA is isolated by TriPure RNA 
isolation reagent and then purified with MN Nucleospin II RNA isolation kit, including 
DNAse treatment. RNA from a normal liver sample was used previously in the 
description of 3’ alternative splicing products. This RNA was further purified by MN 
Necleospin II RNA isolation kit and DNAse treatment is done. All the samples from 
cell lines and normal liver were subjected to spectrophotometric analysis and RNA gel 
electrophoresis (Figure 5-11).
The isolated RNA is aliquoted and snap frozen with liquid nitrogen immediately 
except for 1 aliquot. 5 ul of RNA from the unfrozen aliquot was mixed with RNA 
loading buffer, heated at 70°C for 5 min, cooled on ice and loaded to the formaldehyde 
containing agarose gel. 4 ul of RNA from the unfrozen aliquot was diluted in 396 ul of 
DEPC treated water and spectrophotometrically analyzed.
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Figure 5-11 RNA electrophoresis of purified RNA from 15 cell lines and normal 
liver
Lanes: 1: Huh7, 2: Hep3BTR, 3: FOCUS, 4: Mahlavu, 5: Hep40, 6: Hep3B, 7: HepG2, 
8: PLC/PRF/5, 9: SK-Hepl, 10: SNU 182, 11: SNU 387, 12: SNU 398, 13: SNU 423, 
14: SNU 449, 15: SNU 475, 16: Normal liver
7 primary HCC tumors and 1 corresponding non-tumor tissue were chosen from 
the archives of Prof. Mehmet Ozturk, homogenized with a polytron in TriPure RNA 
isolation reagent and their RNA is isolated. Following the purification of RNA by MN 
Necleospin II RNA isolation kit and DNAse treatment, the samples were subjected to 
RNA electrophoresis, together with spectrophotometric analysis (Figure 5-12).
Figure 5-12 : The purified total RNA of the 7 archival HCC tumors and 1 
corresponding non-tumor tissue
Lanes: 1: non-tumor 1, 2: tumorl, 3: tumor 2, 4: tumor3, 5: tumor 4, 6: tumor 5, 7: 
tumor 6, 8: tumor 7
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5-10 cDNA preparation and GAPDH PCR results
cDNA is prepared from 3-5 ug of total RNA by oligo-dT primer following the 
instructons of the cDNA preparation kit (MBI, #K1622). The quality of cDNA, for 
semi-quantitative PCR analysis can only be described by a semi-quantitative PCR for a 
ubiquotously expressed transcript like GAPDH, P-actin or cyclophilin. We have 
previously used P-actin to analyze cDNA synthesis efficiency, but, we have been 
informed the presence of pseudo-genes of actin in human genome which does not 
contain any introns (genbank no: D50658). If RNA is not treated with DNAse, the 
sample will contain some DNA contamination. The contaminant DNA not only will 
interfere with the cDNA preparation reaction, but also the pseudo-genes from the 
genomic DNA will produce fake amplicons, which can not be distinguished from the 
amplifications from cDNA by their size. For this purpose, we have switched to a 2 step 
RNA isolation and purification step with DNAse treatment, and we have also switched 
to‘ GAPDH as the internal control, for which no pseudo-gene reported to be present in 
human genome. The primers for amplification of GAPDH were designed from different 
exons, so the PCR reaction will produce a band at 250bp from the genomic DNA, 
covering a small intron and 151 bp from the cDNA. This also allowed us to detect the 
probable genomic DNA contamination of our samples.
Semi-quantitative RT-PCR is optimized according to a constant load of cDNA 
(such as 1 ul/ 50 ul PCR reaction) and increasing number of PCR cycles. The aim of 
this optimization is to obtain an unsaturated but visible PCR yield. For this reason, an 
initial study of 30 cycles RT-PCR was done for 5 representative samples. The samples 
with the minimum and the maximum yield were taken to a further analysis. These 
samples were tested for increasing number of PCR cycles as described in figure 5-13.
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Figure 5-13: The strategy of semi-quantitative PCR optimization
The cycle number of the minimum number of cycle necessary for a visible but 
an unsaturated band is obtained for each transcript. First and most importantly, such a 
study for GAPDH was done and the optimum cycle range for GAPDH was determined 
to be 22-24.
1 2 3 4 5 6 1 8
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Figure 5-14: Cycle optimization of GAPDH RT-PCR
Lanes: 1: Marker, 2: 19 cycle, 3: 20 cycle, 4: 21 cycle, 5: 22 cycle, 6: 23 cycle, 7: 24 
cycle, 8: 25 cycle
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After optimization, all cell lines, normal liver, tumor and non-tumor samples 
were tested and equalized with 24 cycles of GAPDH PCR (Figure 5-15 and 5-16). 20% 
of the yield of a 50 ul PCR reaction was loaded to the ethidium bromide stained agarose 
gel.
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17
Figure 5-15: The 24 cycle GAPDH PCR results from all cell lines and the normal 
liver
Lanes : LMarker, 2:Huh7, 3:Hep3BTR, 4:FOCUS, 5:Mahlavu, 6:Hep40, 7:Hep3B, 
8:HepG2, 9:PLC/PRF/5, 10:SK-Hepl, lliSNU 182, 12:SNU 387, 13:SNU 398, 14:SNU 
423, 15:SNU449, 16: SNU475, 17:Normal liver
1 7 8
Figure 5-16: The GAPDH PCR results of archival tumors and the non-tumor
Lanes: 1: non-tumorl, 2: tumor 1, 3: tumor 2, 4: tumor 3, 5: tumor 4, 6:tumor 5, 7: 
tumor 6, 8: tumor 7, 9: negative control
5-11 Description of 3’ end alternative splicing forms of p73 in 15 HCC cell lines 
compared to a normal liver by semi-quantitative PCR
After the cDNA is qualified for semi quantitative PCR, we have optimized the 
conditions for p73a and p73|3 specific semi quantitative PCR reactions (The second 
step PCR of Figure 5-2). Since the two step PCR was incompatible for a semi- 
quantitative PCR analysis, we tried to optimize our conditions for a single step PCR to 
detect p73a, p73y, p73e with p73L-F-p73a-R and p73p and p73(j) with p73L-F-p73p-R
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primer pairs (Figure 5-2). The optimum cycle for p73a specific PCR appeared to be 33 
and p73p specific PCR to be 34 cycles (Figure 5-17 and Figure 5-18).
Figure 5-17 : Cycle optimization of p73a semi-quantitative RT-PCR
Lanes; 1; Marker, 2: 32 cycle, 3; 34 cycle, 4: 36 cycle, 5: 38 cycle
4 5
Figure 5-18 : Cycle optimization of p73p semi-quantitative RT-PCR
Lanes: 1: Marker, 2: 30, 3: 32 cycle, 3: 34 cycle, 4: 36 cycle, 5: 38 cycle
The set of 15 HCC cell lines and a normal liver was analyzed at the optimized 
conditions. The p73a specific PCR resulted with the description of p73a and p73y 
increased in most of the cell lines, when compered with normal liver (Figure 5-19). The 
result of p73p specific PCR was also very striking since the expression of p73p and 
p73(|) was deviated in positive (Figure 5-20, lane 7) and negative manner (Figure 5-20, 
lane 5) when compared with normal liver, depending on the cell line (Figure 5-20).
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1 2 7 8 9 10 11 12 13 14 15 16 17
p73 -a 
p73 -Y
Figure 5-19 : Semi quantitative PCR results of p73a specific PCR
Lanes : 1 .-Marker, 2:Huh7, 3:Hep3BTR, 4;FOCUS, 5:Mahlavu, 6:Hep40, 7:Hep3B, 
8:HepG2, 9:PLC/PRF/5, 10:SK-Hepl, ILSNU 182, 12:SNU 387, 13:SNU 398, 14:SNU 
423, 15:SNU 449, 16: SNU 475, 17:Normal liver
1 2 5 6 7 8 9 10 11 12 13 14 15 16 17
Figure 5-20 : Semi quantitative PCR results of p73P specific PCR
Lanes ; LMarker, 2;Huh7, 3:Hep3BTR, 4:FOCUS, 5;Mahlavu, 6:Hep40, 7:Hep3B, 
8:HepG2, 9:PLC/PRF/5, 10:SK-Hepl, ILSNU 182, 12:SNU 387, 13;SNU 398, 14:SNU 
423, 15:SNU449, 16: SNU 475, 17:Normal liver
5-12 Densitometrie analysis of the p73, 3’ end splicing isoforms, compared to 
normal liver.
The agarose gel pictures were analysed with an image analysis software (Multi- 
Analyst, Beckman Instruments), and then bands are compared with their relative 
intensities. The area under the curve provides information of total band intertsity, 
whereas the peak point of the curve defines the maximum intensity. The intensity can 
get values between 0-255, 0 to be extreme white and 255 to be the extreme black. The 
interval of 1-254 yields different intensities of gray. Each picture contains 3 windows. 
The first window is the result of a-specific PCR, which yields p73a and p73y. The 
second window shows the result of ß-specific PCR, ehich yields p73ß and p73(j). The
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third window provides the result of equal template loading control, GAPDH. Each 
picture is background subtracted before the image analysis, meaning the reduction of a 
constant number of intensity from all the pixels of a figure. This is done to normalize all 
the samples to a common background and setting “0” to be the absolute white. Figure 5- 
21 describes the analysis of 3 representative samples (Huh7, Hep40 and Hep3B) and the 
normal liver.
Figure 5-21: The densitométrie analysis of three representative HCC cell lines of 
p73 3’ end alternative splicing isoforms compared to normal liver
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5-13 Description of TA and DN-p73 transcript isotypes by semi- 
quantitative PCR in 15 HCC cell lines and primary HCC samples
The 5’ end differing transcripts of p73, namely TA-p73 and DN-p73 were 
also detected by semi-quantitative PCR. For each analysis, an initial study of 30- 
38 cycles were done and optimum cycle was determined using an adequate 
sample cDNA. Although these two products are under the regulation of different 
promoters, the optimum cycle number for TA-p73 and DN-p73 PCR appeared to 
be both 35 (Figures 5-22 and 5-23).
1 2
- -  I
6
Figure 5-22 : Cycle optimization of TA-p73 semi-quantitative RT-PCR
Lanes : 1: marker, 2: 32 cycle, 3: 33 cycle, 4: 34 cycle, 5; 35 cycle, 6 : 36 cycle
Figure 5-23 : Cycle optimization of DN-p73 semi-quantitative RT-PCR
Lanes : 1: marker, 2: 33 cycle, 3: 34 cycle, 4: 35 cycle, 5: 36 cycle, 6 : 37 cycle
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Figure 5-24: Semi quantitative PCR results of TA-p73 speciflc PCR for 15 
HCC cell lines and a normal liver
Lanes : LMarker, 2:Huh7, 3:Hep3BTR, 4:FOCUS, 5:Mahlavu, 6:Hep40, 
7:Hep3B, 8:HepG2, 9:PLC/PRF/5, 10:SK-Hepl, 11:SNU 182, 12:SNU 387, 
13:SNU 398, 14:SNU 423, 15:SNU 449, 16: SNU 475, 17:Normal liver
3 4 5 6 7 8 9 10 11 12 13 14 15 16 17
Figure 5-25: Semi quantitative PCR results of DN-p73 specific PCR for 15 
HCC cell lines and a normal liver
Lanes : LMarker, 2:Huh7, 3:Hep3BTR, 4:FOCUS, 5;Mahlavu, 6:Hep40, 
7:Hep3B, 8:HepG2, 9:PLC/PRF/5, 10:SK-Hepl, ILSNU 182, 12:SNU 387, 
13:SNU398, 14:SNU 423, 15:SNU449, 16: SNU 475, 17:NormaI liver
The results of TA-p73 and DN-p73 expression in HCC derived cell lines 
showed that DN-p73 is expressed at a uniform level in all samples. However, we 
could not detect any TA-p73 expression in normal liver. So the major p73 
transcript in normal liver appeared to be DN-p73. There is an acquired expression 
of TA-p73 in 14/15 HCC derived cell lines. These results are the first description 
of the TA and DN p73-p73 gene isoform expression in a cancer. This data have 
been partially confirmed by earlier studies which showed an increased expression 
of p73 (now named as TA-p73) in different cancer types, as summarized at table 
2-1. With the lack of the knowledge of the presence of DN-p73, the former 
studies could only detect TA-p73 transcript (if they have amplified exon 1-3 of
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TA-p73) or the total levels of TA and DN-p73 (if they have amplified the exons 
4-14 of p73). A very niee example to this diserepeney could be the contradictory 
results obtained from HCC samples. The study of Mihara et al. (Mihara et ah, 
1999) described similar levels of p73 transcripts in non-tumor and tumor liver 
samples. Hovewer, the studies of Herath et al. (Herath et al., 2000) and Tannapfel 
et al. (Tannapfel et al., 1999) described an elevation in p73 transcript levels. 
These results were in apparent contradiction before the description of TA-p73 and 
DN-p73 but they are all true. Mihara et al. had studied p73 expression using 
primers located at the 3’ end of transcript so described TA-p73 and DN-p73 
together. Our results showed the presence of DN-p73 in normal liver and the 
presence of DN-p73 together with TA-p73 in HCC tumors. Thus it is plausible 
that the total DN and TA-p73 levels are similar in non-tumor and tumor liver 
tissue respectively. Herath et al. and Tannapfel et al. have described the 
expression of p73 using oligomers to the extreme 5’ end of the transcript, so 
detected only the expression of TA-p73, but not DN-p73. Their results were also 
correct and they described the acquired expression of TA-p73 in tumor cells but 
not in the normal cells of liver.
Figure 5-26; Semi quantitative PCR results of TA-p73 specific PCR for 7 
primary HCC samples and a noq-tumor liver
Lanes: l:non-tumor 1, 2: tumor 1, 3: tumor 2, 4: tumor 3, 5: tumor 4, 6: tumor 5, 
7: tumor 6, 8: tumor 7. 9: negative control
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Figure 5-27: Semi quantitative PCR results of DN-p73 specific PCR for 7 
primary HCC samples and a non-tumor liver
Lanes: l:non-tumor 1, 2: tumor 1, 3: tumor 2, 4: tumor 3, 5:tumor 4, 6:tumor 5, 
7:tumor 6, 8:tumor 7. 9: negative control (no template DNA)
The results of TA-p73 and DN-p73 expression in primary HCC tumors and 
the non-tumor tissue were in correlation with the results of HCC derived cell lines. 
DN-p73 was expressed at similar and comparable levels in tumor and non-tumor 
liver tissues but TA-p73 was not expressed in the non-tumor liver. Interestingly, the 
percentile of TA-p73 expression changed significantly when cell lines (14/15) were 
compared with primary tumors (3/7). This alteration could be the results of the 
heterogeneity of the tumorous cells in the total tumor cell population since the whole 
population of a cell line is composed of rapidly proliferating cells, whereas primary 
tumors contain a portion of normal or non-tumor cells.
5-14 : The description of the presence of endogenous DN-p73 protein 
in a HCC derived cell line.
The presence of the DN-p73 transcript was described in RNA level by 
semi-quantitative PCR, but the presence of RNA does not prove evidence for the 
presence of DN-p73 protein. We have analyzed the mouse homologue of DN-p73 
together with the predicted amino acid composition of human DN-p73 and 
calculated the molecular weight of DN-p73 to be 62 kDa. Since there is an 
extensive alternative splicing of p73 encoded transcripts, we have chosen an 
antibody recognizing only p73a. The western blot using 300-500 ug of total 
protein yielded 2 bands coresponding to the molecular weight of TA and DN- 
p73a proteins (Figure 5-28). The lysate of COS7 cell line was used as a positive 
control for TA-p73a protein.
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Figure 5-28: Western blot using the ER13 antibody, which recognizes a 
epitope against the carboxyl-end of the p73 protein.
Lanes: 1: SNU398, 2: COS7
This result is the first description of endogenous human DN-p73 protein. This 
result also provided information about the importance of DN-p73 and TA-p73 during 
tumorigenesis. First of all, TA-p73 expression was shown to be a cancer related 
event for HCC. Of great interest, the acquired expression of TA-p73 is an unexpected 
event during carcinogenesis when the structural and functional similarity of p53 
tumor suppressor and TA-p73 are concerned. The description of E2F1 transcription 
factor binding sites in TA-p73 promoter and the induction of TA-p73 by exogenous 
E2F1 expression (Stiewe and Putzer, 2000) lead us to propose a relationship between 
the Rb pathway dysrégulation and TA-p73 expression. The results of the experiments 
for the description of the status of Rb pathway components and the evidence for the 
transcriptional activity of E2F1 transcription factor are provided in the next chapter.
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CHAPTER VI
THE STATUS OF RB PATHWAY COMPONENTS AND THE EVIDENCE 
FOR THE ACTIVITY OF E2F1 TRANSCRIPTION FACTOR
The retinoblastoma gene was identified as a locus involved with the 
development of an inherited eye tumor (Knudson AG, 1971). Further studies 
revealed the presence of mutations in this gene in different cancer types and the 
proof of the tumor suppressor idea (Knudson AG., 1971, Friend et al., 1986). The 
E2F family of transcription factors were defined to be the key molecules associated 
with the growth suppressive activity of Rb protein (pRb) (Chelappan et al., 1991). 
E2F proteins are a family of transcription factors, composed of at least 5 members, 
having role in the transactivation of cell cycle regulatory genes, that are especially 
necessary for S phase progression (Nevins JR, 1998). Thus, the main role of pRb was 
the sequestering of E2F family of proteins.
pRB is the natural substrate of cyclin dependent kinases-cyclin complexes. As 
the name implies, cyclin dependent kinases are phosphorylating enzymes that are 
under the regulation of cyclin proteins (reviewed by Sherr and Roberts 1999). The 
sequestering activity of pRb on E2F proteins is regulated by phosphorylation of pRb 
by cyclin D-CDK4 complex at multiple positions (reviewed by Sherr and Roberts 
1999). Upon phosphorylation, pRb releases E2F proteins to initiate the cell cycle. 
The restriction point or point of no-retum was described as the key point in the G1 
phase-S phase progression of cell cycle, which was associated with the release of 
E2F1 transcription factor from pRb (reviewed by Sherr and Roberts 1999).
The initiation of the cell cycle, thus the phosphorylation status of pRb was 
strictly controlled by cyclin dependent kinase inhibitors (CKI) (Lundberg and 
Weinberg, 1998). The major inhibitors of CDK4-cyclin D complex are the INK4 
family of CKIs especially (Nevins JR, 2001).
Thus, there are positive regulators (cyclin D, CDK4, E2F1) and negative 
regulators (pRb, p i6) of cell cycle initiation and S phase progression, collectively
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named as the Rb pathway. There are mutations, virus related interferences and 
epigenetic regulations of the components of Rb pathway, defined for almost each 
component in different types of cancers (Nevins JR, 2001). With the description of 
E2F1, as a transactivator of TA-p73, we have suspected the acquired expression of 
TA-p73 to be a result of Rb pathway inactivation.
E2F1 dysregulation is the ultimate result of Rb pathway disruption, but 
demonstration of pRb bound and unbound fraction of E2F1 protein is out of our 
technical limits so we aimed to look at pRb protein levels and p i t r a n s c r i p t  
levels for characterization of Rb pathway. We would also like to prove the Rb 
pathway inactivation by detection of endogenous targets of E2F1 transcription factor, 
such as cyclin E and correlate the results with the expression of the recently
described p53 homologue, TA-p73.
6-1 Description of pl6 transcripts by semi-quantitative PCR in 15 HCC 
cell lines
pl6iNK4A resides in the MTS locus which is harboring both the
pl6iNi^4A genes. These two genes share 2 of their 3 exons, but the first
exons, thus the promoter regions are totally different. Since this locus harbors two 
tumor suppressor genes, the allelic or total deletions are commonly seen in 
cancers. Inherited mutations of plb^^ '^*'  ^gene were described in the familial cases 
of Melanoma, with the absence of Rb gene mutations, suggesting the functional 
loss of p i a s  a functionally equivalent event for tumor progression 
(reviewed by Nevins JR, 2001). Moreover epigenetic modifications of promoter 
region of p 1 gene is also seen through the progression of almost all cancers 
at different frequencies (Serrano M, 2000). For the reasons I have described 
above, we aimed to analyze the p i e x p r e s s i o n  in RNA level by semi 
quantitative RT-PCR method. RNA isolation, pufication and cDNA synthesis 
were done as described for TA-p73 expression analysis. GAPDH amplification 
was done prior to this analysis as an equal template loading control. After an 
initial study for identification of the logarithmic phase of amplification for pl6 
PCR (Figure 6-1), we have decided to make the final experiment at 34 cycles 
(Figure 6-2). This result indicates a probable deletion of MTS locus in 3 of 15
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(SNU 387, SNU 449 and SK-Hepl) and probably méthylation related decreased
expression of plb*'^ expression in 4/15 (SNU 398, SNU 423, SNU 475 and 
PLC/PRF/5) HCC derived cell lines.
Figure 6-1 : Cycle optimization for pl6, semi quantitative RT-PCR.
Lanes : 1: marker, 2: 30 cycle, 3: 32 cycle, 4: 34 cycle, 5: 36 cycle, 6 : 38 cycle
10 11 12 13 14 15
Figure 6-2 : Semi-quantitative pl6 PCR results of 15 HCC cell lines
Lanes : 1: Mahlavu, 2; Hep3B, 3:SNU 182, 4: SNU 387, 5: SNU 398, 6: SNU 
423, 7: SNU 449, 8: SNU 475, 9: Huh7, 10: Hep3BTR, 11; FOCUS, 12: Hep40, 
13: HepG2, 14: PLC/PRF/5, 15: SK-Hepl
6-2 The description of retinoblastoma protein (pRb) in HCC cell lines
Retinoblastoma gene product is the major component of Rb pathway. The 
epigenetic modifications leading to decreased Rb mRNA expression, truncation 
mutations leading to small and unstable pRb derived peptide and increased 
expression of pRb-protease targetting molecules such as gankryn are common 
events leading to the loss of functional Rb protein in HCC. Thus pRb is the 
ultimate Rb gene encoded product to describe for detection of functional
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inactivation. For these purposes, we have extracted protein from all cell lines and 
made western blots for the detection of pRb. Initially, we have tested the presence 
of proteins by Ponceau S staining after the transfer to nitrocellulose or PVDF 
membrane, and then make an initial western blot for an equal loading eontrol. 
Our previous studies yielded p33INGl as a good internal control for equal protein 
loading (Figure 6-3).
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Figure 6-3 : Anti-p33INGl western blot results of 15 HCC cell lines
Lanes : l:Huh7, 2:Hep3BTR, 3:FOCUS, 4:Mahlavu, 5:Hep40, 6:Hep3B, 
7:HepG2, 8:PLC/PRF/5, 9:SK-Hepl, lOiSNU 182, ILSNU 387, 12:SNU 398  ^
13:SNU 423, 14:SNU 449, 15: SNU 475, 16:positive control
After an initial optimization study for antibody dilution and protein 
concentration, we made the pRb western by using 50 ug of total protein (Figure
6-4). AF18, anti pRb antibody was used to probe the membranes at a dilution of 
1/500. The upper band in the western blot is the pRB and the band denoted with 
an asterix (*) is a previously defined non-specific band (Morel et al., 2000). 
There is a lost or decreased pRb expression in 6/15 (40%) of HCC derived cell 
lines (НерЗВ, SNU 423, SNU 449, Hep3BTR, FOCUS, Hep40).
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Figure 6-4 : Anti pRb western blot results of 15 HCC cell lines
Lanes: 1: Mahlavu, 2: Hep3B, 3:SNU 182, 4:SNU 387, 5:SNU 398, 6:SNU 423, 
7.-SNU 449, 8: SNU 475, 9:Huh7, 10:Hep3BTR, ILFOCUS, 12: Hep40, 
13:HepG2, 14:PLC/PRF/5, 15:SK-Hepl
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These data together with p i6 RT-PCR results provide us the 
information of Rb pathway dysrégulation. We have observed Rb pathway 
dysrégulation in 11/15 HCC cell lines (Table 6-1). The result of RB pathway 
inactivation is the activation of E2F1 responsive genes thus this correlation was 
also described with the data of cyclin E, p l4  and TA-p73 RT-PCR results in table
6-1 at the end of this chapter.
6-3 THE DESCRIPTION OF ENDOGENOUS E2F1 TARGETS, 
and CYCLIN E
The activation of endogenous E2F1 transcription factor targets is a clue for 
Rb pathway dysrégulation. These genes include, Matrix Métalloprotéase 6 
(MMP6), Bak, Bad, Bid (Apoptotic genes), TA-p73 and cyclin E and many others 
(Stanelle et al., 2002). We have chosen to study the expression of cyclin E and 
pl4ARF as the proof of active E2F1. Cyclin E is a late G1 phase to late S phase 
cyclin and the presence of cyclin E is necessary for the activation of CDK2, thus 
the progression of cell cycle. is the other product of MTS locus, which is
functioning as p53-ubiqutin ligase, MDM2 blocker, so p53 activator
(pl4Alternaive Reading Frame) (Kamijo et al., 1998). This gene was reported to 
be upregulated by E2F1 transcription factor. TA-p73 was also defined to be a 
responsive gene for E2F1 mediated transactivation. We have made expression 
analysis of several transcripts, namely p i4'^ *^' and cyclin E, to correlate with TA- 
p73 expression the results of TA-p73 expression and other E2F1 targets are co­
summarized with Rb pathway components in table 6-1, at the end of this chapter.
We have initially studied for the description of the logarithmic phase of 
amplification for cyclin E and pl4ARF transcripts In this study, 32-33 cycle was 
observed to be in the logaritmic phase of amplification (Figure 6-5), so 33 cycles 
was chosen for semi-quantitative PCR of cyclin E experiments. Such a study also
revealed 34 cycles for the semi-quantitative analysis of p l4  
(Figure 6-6).
ARF PCR experiments
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Figure 6-5 : Cycle optimization for cyclin E, semi quantitative RT-PCR.
Lanes ; 1: marker, 2; 29 cycle, 3: 31 cycle, 4: 33 cycle, 5: 35 cycle, 6 : 37 cycle
Figure 6-6 : Cycle optimization for pl4, semi quantitative RT-PCR.
Lanes : 1: marker, 2: 28 cycle, 3: 30 cycle, 4: 32 cycle, 5: 34 cycle, 6 : 36 cycle
The cDNA synthesized and equalized for the description of TA-p73, DN- 
p73 expression was used as a template to test the semi-quantitative expression of 
cyclin E and pl4ARF transcripts in HCC derived cell lines, normal liver, primary 
tumors and non-tumor tissue. The results of cyclin E PCR of HCC cell lines 
revealed a similar and comparable of cyclin E transcripts in all cell lines, which is 
slightly more than that of normal liver (Figure 6-7). Since cell lines are 
homogenous populations of dividing cells, this result is not unexpected. 
Interestingly, the semi-quantitative RT-PCR results of primary tumors and the 
non tumor liver tissue pointed out the dysrégulation of Rb pathway to be present 
in 3 of 7 tumors (43%).
94
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17
Figure 6-7 : Semi-quantitative Cyclin E PCR results of 15 HCC cell lines and 
a normal liver
Lanes: 1: Normal liver, 2: SNU 475, 3: SNU 449, 4: SNU 423, 5: SNU 398, 6: 
SNU 387, 7; SNU 182, 8: SK-Hepl, 9: PLC/PRF/5, 10: HepG2, 11: Hep3B, 12: 
Hep40, 13: Mahlavu, 14: FOCUS, 15: FIep3BTR, 16: Huh7, 17: negative control 
(no template DNA)
8 9
Figure 6-8 : Semi-quantitative cyclin E PCR results of a non-tumor liver and 
7 HCC tumors
Lanes: 1: non-tumorl, 2: tumorl, 3: tumor 2, 4: tumor3, 5:tumor4, 6:tumor5, 
7:tumor6, 8:tumor7. 9: negative control (no template DNA)
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Figure 6-9 : Semi-quantitative pl4 PCR results of 15 HCC cell lines and a 
normal liver
Lanes : l:Huh7, 2:Hep3BTR, 3:FOCUS, 4:Mahlavu, 5:Hep40, 6:Hep3B, 
7:HepG2, 8:PLC/PRF/5, 9:SK-Hepl, 10:SNU 182, 11:SNU 387, 12:SNU 398, 
13:SNU 423, 14:SNU 449, 15: SNU 475, 16:Normal liver
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Figure 6-10: Semi-quantitative pl4 PCR results of a non-tumor liver and 7 
HCC tumors
Lanes: 1: non-tumorl, 2; tumor 1, 3: tumor 2, 4; tumor 3, 5: tumor 4, 6: tumor 5, 
7: tumor 6, 8: tumor 7. 9: negative control (no template DNA)
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THE PROTEIN STATUS AND CODON 72 GENOTYPING OF P53 GENE
Mutation of the p53 gene is the most common event in cancer 
development. As the central player of the tumor suppressor team, p53 protein has 
interesting properties. Unlike the other tumor suppressor genes, most of the 
mutations of p53 gene give rise to functionally inactive but more stable protein 
products (Blagosklonny MV, 2000). Thus the presence of a mutant p53 protein is 
favorable for a tumor cell. Such mutant proteins were thought to be functioning 
in a dominant negative manner to inactivate the remaining p53 protein by hetero­
oligomerization (Blagosklonny MV., 2000). However, the descriptions of a 
mutant p53 gene together with the deletion of the other p53 allele raised the 
question of the function of the “mutant p53”. A codon specific p53 mutation was 
identified as the first carcinogen specific hotspot mutation, and associated with 
ingestion of a fungal toxin (Bressac et al., 1991, Hsu et al., 1991). Therefore, the 
presences of mutant p53 proteins are specifically important for HCC cells.
The probable function of mutant p53 proteins was proposed to interact 
with TA-p73 and regulate its death inducing activity (Marin et al., 2000). 
Generally p53 mutations give rise to conformationally improper or DNA binding 
deficient p53 proteins. Such proteins can not bind to DNA and transactivate its 
negative feedback loop component MDM2. The downregulation of MDM2 
expression results in the accumulation of mutant p53 proteins. The activation 
mechanisms of both p53 and p73 rely on tetramerization so accumulated p53 
mutant proteins could easily take few role of the p73 tetramer.
The study of Marin et al. defined the presence of a hetero-oligomerization 
of TA-p73 with different mutant forms of p53 proteins (Marin et al., 2000). 
Moreover, this study also provided evidence for the strength of this interaction to
CHAPTER VII
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be regulated by a common polymorphism of p53 gene (arginine or proline at 
codon 72, R72P). Thus we aimed to describe the relevance of these data in HCC 
samples.
7-1 Western blot for p53 protein for 15 HCC cell lines
After an initial study for the definition of optimum antibody dilution and 
antigen concentration, p53 western is done by using 30 ug uf total protein to 
discriminate mutant and wild type p53 proteins. 6B10, anti-p53 antibody 
(hybridoma supernatant) was used to probe the membranes at a dilution of 1/1 
(Figure 7-1).
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Figure 7-1 : Anti p53 western blot results of 15 HCC cell lines
Lanes : 1: HepG2, 2: SK-Hepl, 3: FOCUS, 4: SNU 387, 5: SNU 398, 6: Hep3B, 
7: Hep3BTR, 8: Hep40, 9: Mahlavu, 10: PLC/PRF/5, 11: SNU 423, 12: SNU 449, 
13: Huh7, 14: SNU 182, 15: SNU 475
Previous published data (Puisieux et ah, 1993, Hsu et al., 1993) together 
with figure 7-1 suggests the presence of p53 gene mutations at least 13/15 HCC 
derived cell lines (with the exception of HepG2 and Sk-Hepl). We could not 
detect p53 protein in 5 cell lines (Hep3B, Hep3BTR, FOCUS, SNU 387 and SNU 
398), probably because of gene deletions.
7-2 Genotyping the codon 72 Arg/Pro polymorphisms of p53 from HCC 
cell lines
Marin et al. (Marin et al., 2000) suggested a possible role of mutant p53 
for the inhibition of the apoptotic activity of TA-p73. Moreover, the inhibition 
was shown to be dependent to a polymorphism at codon 72 of p53. It was also
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suggested that mutant p53 proteins having an arginine at codon 72 instead of a 
proline was more capable of inactivating the apoptotic activity of TA-p73. 
Therefore, we have decided to genotype the p53 expressing HCC cell lines for the 
codon 72 polymorphism. This genotyping strategy is based on amplification of 
the 5’ 470bp of p53 and restriction of the PCR product with an enzyme (FnuDII, 
MBI Fermentas) recognizing the polymorphic site if it encodes for an arginine. 
The arginine restriction yields 250 and 220bp products and the proline restriction 
produces the unaffected 470 bp band (Figure 7-2)
10 11
Figure 7-2 : The restriction products of p53 PCR revealing the R/P status of 
codon72
Lanes; 1: 100 bp DNA ladder, 2: Huh7, 3: Mahlavu, 4: Hep40, 5: HepG2, 6: 
PLC/PRF/5, 7: SK-Hepl, 8: SNU 182, 9: SNU 423, 10: SNU 449, 11: SNU 475
Our results showed that 6/10 (60%) of the p53 protein expressing HCC 
cell lines encode for a p53, having a proline at codon 72 and 4/10 (40%) encode 
for a p53 having an arginine at codon 72. These results are in contradiction with 
the data presented by Marin et a l, since the number of cell lines with a mutant 
p53 containing a proline (n=5; Mahlavu, Hep40, PLC/PRF/5, SNU 423, SNU 
449) are less abundant than the number of cell lines with a mutant p53 containing 
an arginine (n=3; Huh7, SNU 182, Snu 475). If mutant p53 with arginine at codon 
72 had an antagonistic effect of TA-73, most of the cell lines will have arginine, 
instead of proline.
100
CHAPTER VIII
THE SUMMARY OF RESULTS
In this thesis we firstly aimed to define a function for the p73 gene encoded 
transcripts in Hepatocellular Carcinoma. As a second step, we tried to correlate our 
results with a known cancer related dysrégulation, so make p73 a component of a 
commonly dysregulated pathway.
For this reason, we have tried to describe all 3’ alternative splicing forms of 
p73 transcripts. We have identified p73y, p73(|) and p73e in addition to the known 
p73 forms p73a and p73p. We also described the cancer related alteration at the 3’ 
alternative splicing of p73 by semi-quantitative RT-PCR method, with comparison to 
a normal liver sample.
With the description of an alternative promoter within the mouse p73 gene 
and the clues of the other p53 homologue, p63, we made an in silico study to define 
the human form of mouse DN-p73. Our studies revealed the in vivo presence of the 
in silico data. Thus we have specifically analyzed the expression of DN-p73 and TA- 
p73 by semi-quantitative RT-PCR method in HCC cells. Our results were very 
interesting since we have detected an acquired and cancer related expression of TA- 
p73 in HCC cells, whereas the DN-p73 expression was moderate in tumor and non­
tumor liver cells. If the pro-apoptotic and cell cycle regulatory function of TA-p73 
was concerned, the cancer related TA-p73 expression could easily be illustrated as an 
unwanted event for tumor cells. However, the identification of E2F1 transcription 
factor binding sites in the promoter region of TA-p73 and the description of the 
induced TA-p73 expression by ectopic E2F1 expression rerouted us to correlate our 
data with a probable Rb pathway inactivation. The expression and status of Rb 
pathway (pRb and p i c o m p o n e n t s  were investigated together with the E2F1 
activation related changes in gene expression (pH '^^ and cyclin E expression). Our
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results revealed a partial correlation with Rb pathway inactivation and induction of 
TA-p73 expression in HCC derived cell lines and primary HCC tumors.
Mutant p53 proteins are retained in cancer cells, thus they acquire a function 
favoring the tumor cells. The probability of hetero-oligomerization of mutant p53 
and TA-p73 which would result in functional inactivation of TA-p73 thus could be a 
result of the presence of mutant p53 proteins in cancer cells. We have investigated 
the levels of p53 protein and the presence of the incidence of a p53 gene 
polymorphism, which was proposed to take a role in p53-p73 interaction. Our results 
showed the presence of mutant p53 in more than half and showed the diminished p53 
expression in more than 30% of our samples. We have also defined the p53 
polymorphism as an irrelevant correlation to justify the functional inactivation of 
TA-p73 expression.
The description of new human p73 gene encoded product (DN-p73), the 
expression analysis of DN-p73 and TA-p73, p53, Rb pathway components and E2F1 
transcription factor regulated genes were published in the journal “Oncogene” at 23 
August 2001.
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CHAPTER IX
DISCUSSION
The studies presented in this thesis describe the identification of the 
human homologue of mouse DN-p73, and the cancer related changes in the 
expression profile of p73 locus harboring genes.
p73 gene was identified at 1997 to encode for a new structural and 
functional homologue of the p53 protein, which is considered the guardian of the 
genome. p73 gene was localized to lp36.3, which is a common site for deletions 
for different cancer types, especially neuroblastoma and Hepatocellular 
Carcinoma (HCC). The studies trying to assign a “p53 like” inactivation profile to 
p73 failed because of the lack of a significant number of mutations in the p73 
gene coding region (see table 2-1). However, functional studies, done either by 
inducing the endogenous p73 or ectopic expression of p73 containing plasmid in 
mammalian cells described the structural homologues having similar effects on 
cell fate. The decisive events induced by p73 on cell fate are cell cycle arrest and 
apoptosis, just like p53. Expression analysis studies mostly defined increased 
expression of p73 when compared with the corresponding non-tumor counterpart, 
which is an unexpected situation, when the p53 like function of p73 is regarded. 
Another difference of p53 and p73 was identified with the description of 
extensive alternative splicing at 3’ end of p73 gene encoded transcripts, which is 
not a common feature of p53. These transcripts were shown to have different 
transactivation capabilities.
The mouse knock-out study of p73 gene led the identification of a new 
transcript from the same locus. This transcript was shown to be originated from 
an alternative promoter and the transcription was initiated from a hidden exon 
(exon 3’) within the intron 3 of mouse p73 gene. Since the protein of this new 
mRNA was lacking the p53 transactivation homology domain, it was named as
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DN-p73. The former p73 isoform, whieh was only called as “p73” was renamed 
as TA-p73. TA and DN-p73 gene isotypes share in-frame 11 exons, so most of 
their protein products were the same. So, their real function can only be 
discriminated by the help of their different N-Terminal domains.
The function of TA-p73 (former p73) was defined to be similar with that 
of p53 (Figure 9-1). When activated, TA-p73 transactivates a set of genes having 
role in cell cycly regulation and induction of apoptosis. The function of DN-p73 
however, was defined recently, just before the submission of this thesis to be an 
anti-apoptotic protein (Stiewe et al. 2002).
There were several proposed functions for human DN-p73, which of most 
describing a dominant negative role of this protein on TA-p73 and/or p53. Thus 
DN-p73 was a candidate oncogene. The oncogenic capacity of this protein was 
proposed to happen in two different approaches, but the role of DN-p73 in 
neutralizing TA-p73 or p53 might involve both (Figure 9-1). The first approach 
relied on the possibility that DN-p73 tetramers can bind to the p53 responsive 
elements, so p53 or TA-p73 can not bind to them. The second approach relied on 
the probability of oligomerization of different p73 isoforms (a, P, (j), etc) and p73 
isotypes (TA-p73 and DN-p73) within each other or with p53. The final 
tranactivation ability of p53 family aggregates will be defined by the 
transactivation domain containing (TA-p73 or p53) and transactivation deficient 
(DN-p73 or A exon 2-p73) composition of the hetero-tetramer.
Both of these possibilities were proven to be true by Stiewe et al. (Stiewe 
et al., 2002). For the description of the first hypothesis, Stiewe et al. tested the 
DNA binding ability of DN-p73 by Electro Mobility Shift Assay (EMSA), since 
DN-p73 was a protein containing DNA binding domain. The labeled p53 
consensus oligonucleotides were bound to and supershifted with DN-p73 at a 
comparable affinity and this binding was reversed with competing 
oligonucleotides. Secondly, Stiewe et al. tested the transactivation ability of TA 
and DN p73 isoforms and described the incapability of DN-p73, but not TA-p73 
or p53 on p53 responsive-luciferase reporter activity. These results show that DN- 
p73 alone could bind to the promoters of p53 responsive genes and block their
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transactivation. Stiewe et al. described the second hypothesis of hetero­
oligomerization, by cotransfection of p53-responsive luciferase reporter and DN- 
p73, together with TA-p73 or p53 at increasing plasmid concentrations and 
assaying for the luciferase activity. The results of this study revealed the dose 
dependent inhibition of wild type p53 activity by DN-p73, so the second 
hypothesis.
Figure 9-1 ; Linking the Rb pathway and p53 pathway components through pl4'^‘^  ^
and TA-p73.
The proteins indicated with red are commonly mutated genes during tumor 
progression. TA-p73 is indicated with purple color and DN-p73 is indicated with 
green color.
Our first aim was to define the alterations in the p73 locus originated 
transcripts in HCC as compared with non-tumor and normal liver cells. The 
differences in the expression profile of TA and DN-p73, in combinations of 3’ 
alternative splicing forms may lead to the production of different p53 like proteins 
under the name of TA and DN-p73 with different transactivation capabilities. The 
complexity of the scheme is increased when the probability of these proteins is 
considered to make heterodimers and heterotetramers with each other and with 
mutant p53.
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Our results support the presence of a complex 3’ alternative splicing, which 
may produce at least 5 proteins with different carboxyl-ends. In normal liver we have 
only observed the presence of a, p and (j) forms, whereas we have detected a 
combination of a, P, y, (j) and e forms but mainly an increase in a, y and e forms and 
either increase or decrease in p and (j) forms in HOC derived cell lines. Except for the 
transcriptionally very active p and active a  forms, all other splicing variants have 
very low or no transactivation activity.
In additions to the alterations in the 3’ alternative splicing pattern of p73, the 
expression changes due to direct transcriptional regulation of TA and DN promoter, 
together with the changes in 5’ alternative splicing of TA-p73 produces more 
decisive transactivation capable and transactivation deficient p73 gene derived 
proteins. In fact, the studies concerning the 5’ region of p73 must be the first choice 
for description of the transactivation abilities of p73 gene encoded proteins, since the 
3’ alternative splicing does not give a DN-transcript the transactivation ability. This 
is the case for normal liver, which produces DN-p73 and its alternative splicing 
products, but no TA-p73. So the function of p73 gene encoded proteins in normal 
liver is mainly anti-apoptotic.
As a conclusion, there are gross changes in the expression profile of p73 in 
HCC derived samples. First of all 3’ alternative splicing pattern of p73 was altered to 
produce different levels of a, P and (j) forms in addition to cancer related expression 
of y and 8 forms. Human DN-p73 is defined to be expressed at comparable levels in 
normal, non-tumor and tumor tissues of liver. The computer based promoter analysis 
revealed the binding of ubiquitous transcription factors to the promoter of DN-p73, 
such as Sp-1, so we have confirmed our in silico data which correlates with our in 
vivo data obtained from liver derived tissues. Interestingly, we have also defined the 
induction of TA-p73 expression at transcription level in 14 of 15 HCC cell lines and 
3 of 7 primary HCC tumors. The earlier promoter analysis studies described the 
presence of E2F1 transcription binding sites in the TA-p73 promoter and TA-p73 
was shown to be induced by in vitro ectopic E2F1 expression by several groups 
(Selean et al., 2002, Stiewe and Putzer, 2000). The absence of TA-p73 in normal and
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non-tumor liver as well as the cancer related expression of TA-p73 led us to correlate 
the in vitro data obtained by other groups by induction of TA-p73 by overexpression 
of E2F1 transcription factor and in vivo data obtained by us about the description of 
the induction of TA-p73 in a panel of HCC samples. Since the Rb protein functions 
to block E2F1 transcription factor, we have proposed the acquired expression of TA- 
p73 as an indicator of Rb pathway dysrégulation, which is a common event for HCC. 
The Rb pathway dysrégulation includes the mutations in Rb gene, functional 
inactivation of Rb protein, mutational inactivation of pl6 gene and epigenetic 
downregulation of p i6 mRNA expression (see Figure 9-1). So, we aimed to prove 
that Rb pathway is dysregulated, both by showing the overexpression of endogenous 
targets of E2F1 (TA-p73, pl4 and cyclin E) and describing the pl6 and Rb status of 
our HCC derived samples (Figure 9-1). We planned to experiment our aim by 
studying the expression natural E2F1 target genes, namely p i6, p i4, cyclin E and 
TA-p73 by semi quantitative RT-PCR and describing the cellular status of Rb protein 
by western blot.
Our results clearly showed that Rb pathway is non-functional in at least 80% 
of HCC cell lines and 45% of primary tumors (table 6-1). Moreover, the acquired 
expression of TA-p73 was partially correlated with activation of endogenous E2F1. 
These results are the first correlation study concerning the description of Rb pathway 
dysrégulation and expression of TA-p73 in cancer samples.
This data is very important when the therapeutic approaches are concerned. 
First of all, p53 gene mutations and Rb pathway dysrégulation (which induces TA- 
p73) are common events in cancer development. It seems that p53 is the most 
specialized member of the family, being mutated in 50% of all cancer types, being 
induced by a variety of oncogenic signals and genotoxic drugs. Thus, most of the 
therapeutic approaches for cancer involve the activation of endogenous, wild type 
p53. The first leakage of this approach is the possibility of the status of p53. Since 
p53 gene is mutated in 50% of the tumors, such therapies are unlikely to produce a 
curative result in the tumors with mutant p53, so 50% of the patients. The remaining 
50% of tumors with wild type p53 respond to the high genotoxic stress induced by 
drugs such as cisplatin or by y-irradiation. The second leakage of this approach 
appears in this step, at which, not only the normal cells are killed, but also a selection
108
on cancer cells, for the ones containing mutant p53 was induced. So even the tumor 
of the patient contains a wild type p53, a very strong selection is introduced to select 
the tumor cells with mutant p53. This is why, the relapse of tumor is followed by a 
gain of a more aggressive tumor, which is resistant to a variety of genotoxic drugs 
most of the time. Thus the cancer therapy approaches are not convenient if they are 
only relying on the function of wild type p53.
When p73 gene encoded proteins are regarded as target molecules for tumor 
therapy, there are two aspects, defined by the two major transcripts of this gene, TA- 
p73 and DN-p73. The proteins of these two transcripts have opposing functions. TA- 
p73 can be regarded to function as a tumor suppressor and DN-p73 as an oncogene. I 
will mention the strategies for both of them separately.
In the absence of functional p53, TA-p73 may compensate for the function 
of it partially. The presence of TA-p73 transcript is not an indicator of a functional 
p73 protein, but the induction and stabilization of TA-p73 protein by genotoxic drugs 
such as cisplatin or by inducing the cellular tyrosine kinase, c-abl may be good 
approaches to selectively eliminate tumor cells. Moreover, the identification of new 
drugs that are stabilizing and activating TA-p73 protein will be an important 
improvement of tumor pharmacology. Another approach for inducing TA-p73, even 
in the absence of RB pathway dysrégulation may be introduction and expression of 
the E2F1 transcription factor to the tumor cells by means of gene therapy 
approaches. Such a transfer, together with treatment with a TA-p73 protein inducing 
genotoxic agent, will define the fate of cancer cells, independent of the p53 status of 
tumor cell population. The strategy presented in this thesis must also be reproduced 
for other cancer types, so as to describe alternative pathways to eliminate cancer cells 
in the absence of p53.
The oncogenic product of p73 locus, DN-p73, may also be targeted as an 
anti-p53 protein in cancer therapy. DN-p73 was shown to be major p73 gene product 
in normal physiological condition in developing and adult mouse tissues. Moreover, 
we have shown the presence of DN, but not TA form of p73 mRNA in normal and 
non-tumor liver by semi-quantitative RT-PCR method. These data, together with the 
knowledge of the ubiquitous and low levels of expression of p53 in normal tissues
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propose a balance between DN-p73 and p53. Since the main function of DN-p73 
was shown to block the apoptotic activity of p53 and TA-p73, its activity must be 
down-regulated together with the activation of p53 or TA-p73 for inducing a higher 
degree of apoptosis. This could be achieved by targeting the DN-p73 promoter for 
downregulation of mRNA expression, or targeting the very N-terminal of DN-p73 
protein for rapid degradation. We have also shown the presence of similar levels of 
DN and TA-p73 proteins in a HCC derived cell line with no functional p53 protein. 
This result may be the answer of how acquired expression of TA-p73 is tolerated by 
tumor cells. The presence of low and ubiquitous levels of DN-p73 might be the 
major opposing force against the tumor related presence of TA-p73.
A common polymorphism at codon 72 of p53 was proposed to alter the 
binding ability of p53 mutants to wild type p53 proteins or TA-p73. The p53 
molecule having an arginine at codon 72 was shown to be binding to TA-p73 more 
efficiently than the one having a proline at this position (Marin et al., 2000). This 
binding was also shown to inhibit the apoptotic activity of TA-p73 and wild type p53 
(Marin et al., 2000). We have shown the presence of TA-p73 transcript in 14/15 
HCC cell lines. If this hypothesis is true, then most of the HCC derived cell lines 
would have mutant p53 molecule with an arginine at codon 72, instead of a proline. 
However, our data on p53 Arginine/Proline genotyping and protein expression did 
not support for the selection of mutant p53 with the arginine allele. This discrepancy 
could be for few reasons. Firstly, our cell lines were originated from different 
regional and etiological background. We have some cell lines originated from Korea, 
Japan, USA and African countries. Since the allelic frequency of Arginine/Proline 
changes dramatically with race background, the data from cell lines may not be used 
as a random population. Secondly, the ethiology of HCC, so the timing of p53 
mutation may be important. P53 gene mutations in aflatoxin related HCC is a very 
early event, however, the functional inactivation of p53 by viral proteins followed by 
structural inactivation of p53 is seen in virus related HCC development, which is a 
late event. Thus the etiology of HCC may be decisive for the selection of p53 alleles. 
Unfortunately, we do not have enough HCC samples from different etiological 
backgrounds to make a correlation study. ·
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The description of p73 isoforms in different tissues, cancers and pathologies 
will allow us to make reasoning for the physiological functions of these isoforms and 
the phenotype -  cell contex correlation for combinations of p73 gene products. Such 
studies, together with the functional description of p73 gene derived products and 
identification of p73 targeting molecules may provide different approaches for the 
cure of different pathologies.
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CHAPTER X
FUTURE PERSPECTIVES
This study was the first in vivo correlation study for the demostration of the 
Rb pathway dysrégulation and TA-p73 transactivation. Our results were promising 
since we have defined the cancer related expression of a p53 functional homologue 
(TA-p73). If activated properly, TA-p73 protein would accumulate, and drive the 
cancerous cells to apoptosis. One of the major implications of the use of TA-p73 in 
tumor therapy is the tumor specific effect of TA-p73, unlike other approaches such 
as the use of cysplatin and radiation to induce p53 dependent apoptosis. The TA-p73 
protein would be present in only Rb pathway dysregulated cells, which are the cancer 
cells of a tumor mass. Therefore new drugs that are specifically inducing the stability 
of TA-p73 protein must be discovered as soon as possible.
The expression of DN-p73 was described to be at similar levels in all 
normal and tumor derived cell populations studied. Also DN-p73 was defined to be 
present in all developing and adult tissues of mouse. Thus it is anticipated to be 
present in most of the human tissues. It is currently not known whether DN-p73 
mRNA expression or protein levels are regulated. Moreover, due to the presence of 
DN-p73 at almost all cell types make things harder, since the description of a model 
system lacking DN and/or TA-p73 expression but harboring a wild type p73 gene is 
necessary. In our department, such a study is proceeding under the supervision of 
Prof Mehmet Ozturk, paralel with our studies. We have initally described 2 breast 
cancer cell lines with the absence of any p73 gene product. Our initial results of 
E2F1 transcription factor transfection recovered TA-p73 expression, together with a 
lower DN-p73 expression. My collègue Ozgur Karakuzu is now investigating the 
time dependent activation of TA and DN-p73 in response to E2F1 activation. These 
results are important for the description of TA and DN-p73 regulation by ectopic 
E2F1 expression.
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Acquired expression of transcriptionally active p73 in hepatocellular 
carcinoma cells
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p53 and p73 proteins activate similar target genes and 
induce apoptosis and cell cycle arrest. However, p53, but 
not p73 is considered a tumour-suppressor gene. Unlike 
p53, p73 deficiency in mice does not lead to a cancer- 
prone phenotype, and p73 gene is not mutated in human 
cancers, including hepatocellular carcinoma. Here we 
report that normal liver cells express only AN-p73 
transcript forms giving rise to the synthesis of N- 
terminally truncated, transcriptionally inactive and 
dominant negative p73 proteins. In contrast, most 
hepatocellular carcinoma cells express TA-p73 transcript 
forms encoding full-length and transcriptionally active 
p73 proteins, in addition to AN-p73. We also show that 
together with the acquired expression of TA-p73, the 
r^etinoblastoma pathway’ is inactivated, and E2Fl-target 
genes including cyclin E and are activated in
hepatocellular carcinoma. However, there was no full 
correlation between ‘retinoblastoma pathway’ inactiva­
tion and TA-p73 expression. Most TA-p73-expressing 
hepatocellular carcinoma cells have also lost p53 function 
either by lack of expression or missense mutations. The 
p73 gene, encoding only AN-p73 protein, may function 
as a tumour promoter rather than a tumour suppressor in 
liver tissue. This may be one reason why p73 is not a 
mutation target in hepatocellular carcinoma. Oncogene 
(2001) 20, 5111-5117.
Keywords: liver cancer; p73; retinoblastoma; 
pl4ARi·; cyclin E
Introduction
The p53 and its newly discovered homologues, 
namely p73 and p63 form a family of genes that 
activate similar target genes, and induce apoptosis 
and cell cycle arrest (Marin and Kaelin, 2000; 
Lohrum and Vousden, 2000). However, p53, but 
not the other family members, is considered a 
tumour-suppressor gene. For example, unlike p53, 
p73 deficiency in mice does not lead to a cancer- 
prone phenotype (Yang et al, 2000), and p73 gene is 
not mutated in human tumours, including hepatocel­
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lular carcinoma (HCC) (Marin and Kaelin, 2000; 
Mihara et ai, 1999). Presently, the reasons for this 
discrepancy are not known. One of the major 
differences between p53 and the two other family 
members is the ability of p63 and p73 genes to 
encode multiple transcript isoforms (Marin and 
Kaelin, 2000; Lohrum and Vousden, 2000). Different 
p63 and p73 C-termini are generated as a result of 
alternative splicing between exons 10-15 and 10-14, 
respectively (Marin and Kaelin, 2000). In addition, 
p63 utilizes a cryptic promoter located in intron 3 to 
generate additional transcripts called AN-p63 iso­
forms (Yang et ai, 1998).
Our knowledge on truncated AN-p73 isoforms is 
scarce, but AN-p73 transcripts lacking transactivation 
domain were proposed to be predominant p73 gene 
products in some mouse tissues (Yang et ai, 2000). 
Pozniak et al. (2000) have recently demonstrated that 
p73 is primarily present in developing neurons as a 
truncated AN-p73 isoform in mouse. Like the tran­
scripts encoding AN-p63 (Yang et al., 1998), murine 
AN-p73 messages were derived from an alternative 
promoter located in intron 3, and AN-p73 failed to 
activate transcription from a p53-reporter gene, but 
suppressed the transactivation activity of both TA- 
p73a and wild-type p53 (Yang et al., 2000; Pozniak et 
al., 2000). On the other hand, most, if not all reported 
studies on the expression of p73 in different cancers did 
not distinguish between AN-p73 and TA-p73 isoforms 
(reviewed in Marin and Kaelin, 2000; Lohrum and 
Vousden, 2000).
With regard to p73 implications in liver malig­
nancy, Tannapfel et al. (1999a,b) have reported that 
both p73 transcripts and protein were undetectable in 
most normal liver cells, but p73 protein was over- 
expressed in a subset of HCCs, and could serve as an 
indicator of poor prognosis (Tannapfel et al., 1999b). 
On the other hand, Mihara et al. (1999) reported the 
absence of mutation, as well as absence of over­
expression of p73 gene in HCC. These observations 
were in apparent contradiction and they did not 
provide evidence about the mechanisms of p73 
involvement in liver malignancy. These reports, 
together with the identification AN-p73 in some 
mouse tissues (Yang et al., 2000; Pozniak et al., 
2000), led us to test whether p73 expression in 
normal liver and HCC differs in terms of AN-p73 
and TA-p73 isoforms. We also compared p73
if) Truncated p73 in liver and full-length p73 in hepatomaAE Sayan et al
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expression in HCC cells with the status of ‘retino­
blastoma pathway’ and p53.
Results
By comparison of murine p73 cDNA sequences with 
that of human p73 gene, we developed assays for 
identification and detection of AN-p73 and TA-p73 
transcript isoforms (Figure la). Initial RT-PCR 
assays and nucleic acid sequencing identified AN-p73 
isoform in SNU 398 HCC cell line (Figure lb). The 
AN-p73 was also detected uniformly in mouse, rat 
(data not shown) and human liver tissues, as well as 
HCC cell lines (Figure Ic). In contrast, TA-p73 was 
not detectable in normal liver, but it was present in 14/ 
15 (93%) of HCC cell lines. However, TA-p73 bands 
displayed various intensities. They were at the limit of 
detection in cDNAs from SNU 182 and SNU 423 cell 
lines, and there was no detectable TA-p73 expression in 
Mahlavu cell line (Figure Ic). p73 transcripts also differ 
in their 3' regions because of alternative splicing 
between exons 10 to 14, giving rise to a, /i, y, S, e 
and (j) isoforms (Zaika et ai, 1999). p73 transcripts 
expressed in normal liver and HCC cell lines were 
mainly a, (i and (j) isoforms (data not shown). To 
confirm the expression of AN-p73 and TA-p73, we 
tested the presence of these protein isoforms in SNU 
398 as compared to COS7 (Figure Id), using ER 13 
monoclonal antibody against amino acids 495-636 of 
p73-a (Oncogene Research Products, MA, USA). This 
antibody was shown to react with the a, but not P 
isoform of p73 protein (Marin et ai, \9%). As shown 
in Figure Id, ER13 antibody reacted with full-length 
p73-a (i.e. TA-p73-a) in COS7 cell line which was used 
as a positive control (Marin et al., 1998). SNU 398 cell 
line expressed TA-p73-a similar to COS7, but also a 
shorter polypeptide with an apparent molecular weight 
of 62 kD. This polypeptide can not be p73-/? because 
of ER 13 specificity. Its apparent molecular weight 
correlates with that of mouse AN-p73-a described by 
Pozniak et al. (2000). Since, SNU 398 express both 
TA-p73 and AN-p73 transcripts (Figure Ic), the 
presence of both TA-p73 and AN-p73 proteins in this 
cell line is expected.
Next, p73 expression was studied in primary HCC 
tumours. As shown in Figure le, all tumours, as well 
as non tumour liver samples expressed AN-p73 
isoform. In addition, two of seven (29%) HCC tumour 
samples expressed TA-p73 isoform. An additional 
tumour (Tl) displayed a weakly positive TA-p73 band. 
There was no detectable TA-p73 in the remaining T3, 
T4, T6 and T7 tumours, as well as in non tumour liver 
NTl. Thus, acquired expression of TA-p73 in HCC 
was demonstrated in both primary HCC tumours and 
HCC-derived cell lines. However, the presence of TA- 
p73 was more frequent in cell lines than primary 
tumours. The TA-p73 transcripts shown in Figure 1 
were tested with a primer pair located on exons 3 and 
4, respectively. It has recently been described that, in 
some breast carcinoma cell lines overexpressing TA­
p73, a transactivation-deficient splice variant lacking 
exon 2 (p73Aexon2) is also detected (Fillippovich et ai, 
2001). Since our TA-p73 transcript test system would 
not distinguish between TA-p73 and p73Aexon2, we 
performed additional RT-PCR experiments. Using a 
forward primer located on exon 1 together with a 
reverse primer located on exon 4 (Fillippovich et al., 
2001), we detected mainly TA-p73 transcripts in both 
primary HCC and cell lines (data not shown). This 
confirms that TA-p73 forms described in Figure 1 are 
indeed full-length forms, even though one can not rule 
out a weak expression of p73Aexon2 form in some cell 
lines.
Induced expression of TA-p73 in some HCCs 
suggested that its expression is acquired during 
malignant transformation of hepatocytes. Recently, 
E2F1 transcription factor has been shown to activate 
p73 transcription through E2F1-binding motifs around 
non-coding exon 1 of p73 gene (Stiewe and Putzer 
2000; Lissy et al., 2000; Irwin et al., 2000; Zaika et ai, 
2001). E2F1-responsive p73 gene products have been 
identified as full-length p73a and p73/i proteins (Stiewe 
and Putzer, 2000; Lissy et al., 2000; Irwin et al., 2000) 
that can be encoded by TA-p73, but not AN-p73 
transcript isoforms (Figure la). Thus, we hypothesized 
that the selective induction of TA-p73 expression in 
HCC tumours is due to E2F1 activation. Therefore, we 
also tested the expression of E2F1 target genes 
and CCNEl encoding cyclin E (Dyson, 1998). As 
shown in Figure le, the expression of cyclin E was 
induced in three tumours (Tl, T2, T5), as compared to 
non tumour liver tissue NTl. The expression of p i4'^ '^ '' 
was also induced in two tumours (Tl and T2). It was 
also noteworthy that in TA-p73-positive T2 and T5 
tumours, cyclin E expression was also induced, but 
only T2 showed p i4'^ ’^ ’· induction. Thus, three E2F1 
target genes (i.e. p73, Cyclin E and p lV ^’) were 
induced in some HCC tumours. However, there was 
no full correlation between their expression patterns in 
different tumours. This could be due to the quality of 
RNA extracted from these archival tumour tissues. 
(We were not able to test additional samples, because 
HCC is a rarely operated tumour). Alternatively, the 
expression of these E2F1 target genes in HCC may be 
under the influence of additional factors.
As the activity of E2F1 is controlled by the protein 
product of retinoblastoma (RBI) gene (pRb) (Dyson, 
1998), we studied whether the induction of TA-p73 
expression is related to the inactivation of ‘retinoblas­
toma pathway’ in HCC cells. The ‘retinoblastoma 
pathway’ in cancer cells is altered mainly by inactiva­
tion of either RBI or gene (Dyson, 1998). In
HCC, RBI mutations are rare, but allelic loss and 
decreased pRb levels occur frequently (reviewed in 
Ozturk, 1999), which may be due to overexpression of 
gankyrin that reduces the stability of pRb, and releases 
‘free E2F1’ (Higashitsuji et al., 2000). Loss of p i6'^ '^ ·^ “ 
expression by gene deletion or promoter méthylation is 
also common in HCC (see Ozturk, 1999; Baek et al., 
2000). Therefore, we compared the expression of TA- 
p73 with the expression of pRb protein and
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TA-p73 Primer TAP Primer R
- El -0 —
AN-p73
Primer DNF
Exon 3 T Exon 4
(aa 50-64)
(aa 1-15)
(aa 1-15)
GAC GTC TTC GAG CTG GAG GGO ATG ACT ACA TCT GTC ATG GCC CAGD V F H L E G M T T S V M A Q
ATG CTG TAG GTG GGT
Exon 3' 
GAC CGC GCA CGG CAC CTC GCC
T Exon 4 
ACG GCC GAGM L y V G D P A R H L A T A Q
ATG CTT TAG GTC GGT
Exon 3^
GAC CCC ATG AGA CAC CTC GCC
T Exon 4 
ACG GCC CAGM L Y V G D P M R H L A T A Q
TA-p73
TA-P73 ^  
AN-p73 ^
MW (kD) 
119
87
46.5
A TA-p7Z 
4 AN-p73
4  CyclinE
4
4 GAPDH
Figure 1 Identification of TA-p73 and AN-p73 transcripts and their expression in normal liver, HCC cell lines and primary HCC 
tumours, as compared to E2F1 target genes cyclin E and p i ( a )  Exon-intron structure of 5' coding region of human p73 gene 
showing the transcription start sites and splicing events leading to TA-p73 and AN-p73 isoforms. Initiation of transcription in exon 
1 produces the TA-isoforms, containing the transactivation (TA) domain (previously called p73), while initiation in exon 3' gives rise 
to the AN-isoforms without the TA domain. The putative transcriptional start site and exon 3' for AN-p73 were identified by in 
silico analysis of human p73 gene, as compared to mouse AN-p73 transcript sequence. Primers TAP and DNF indicate the positions 
of isoform-specific forward primers used to identify respectively TA-p73 and AN-p73 transcripts, in combination with Primer R 
common to both isoforms, (b) Partial nucleotide and amino acid sequences of human TA-p73 and AN-p73 transcript isoforms as 
compared to mouse AN-p73 isoform. Data for human AN-p73 was obtained from direct sequencing of a 186 bp RT-PCR product 
obtained from SNU 398 HCC cell line, using DNF and R primer pair, (c) As compared to normal liver (NL), the expression of TA- 
p73, but not AN-p73 is induced strongly in 14 out of 15 (93%) HCC cell lines. TA-p73 and AN-p73 isoforms were tested as 
described in a. GAPDH was used as a control for equal template loading in PCR. Neg; negative control, (d) Western blot analysis 
of p73 protein in SNU 398 and COS7 reveals the presence of a ~62 kD polypeptide (presumably AN-p73 according to Pozniak et 
al., 2000) in SNU 398, in addition to TA-p73 protein present in both cell lines. Five-hundred f.ig total protein was analysed with 
anti-p73 ER13 monoclonal antibody which recognizes p73-a, but not p73-/i isoforms (Marin et al., 1998). (e) Expression of TA-p73, 
AN-p73, cyclin E and transcripts in primary HCC tumours. RT-PCR analysis using oligonucleotide primers shown in a,
reveals the expression of AN-p73 in all samples tested. TA-p73 is easily detected in two out of seven tumours (T2, T5), T1 shows 
only weak expression, non tumour liver NTl (counterpart of Tl) is negative. Similarly, cyclin E expression is also induced in Tl, T2, 
and T5, but p i4 ·^^  ^ transcripts are induced only in Tl and T2. GAPDH was used as a control for equal template loading in PCR. 
Neg; negative control
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transcripts in HCC cell lines. The expression of either 
pRb or plb'^ ·^ *^ “ was lost in six cell lines, and 
significantly decreased in five others. Thus, ‘retinoblas­
toma pathway’ appeared to be inactivated in at least 11 
out of 15 (73%) cell lines (Figure 2a). Indeed, this 
inactivation has previously been reported for eight of 
these cell lines (Morel et ai, 2000; Baek et al., 2000; 
Puisieux et al., 1993; Suh et al., 2000). In support of 
this conclusion, the expression of E2F1 target genes 
cyclin E and were also induced in all cell lines,
except three for (Figure 2b), due to CDKN2A
gene deletion in SNU 387 and SNU 449 (Baek et al., 
2000), and probably in SK-Hepl. These studies showed 
that both the inactivation of ‘retinoblastoma pathway’
and the induction of TA-p73 expression are relatively 
common events in HCC cell lines. However, our 
observations do not allow establishing a direct 
correlation between these two events. Additional 
studies are needed to address this issue.
The overexpression of TA-p73 is not compatible 
with cellular growth (Marin and Kaelin, 2000; Fang et 
al., 1999), but HCC cells can apparently tolerate TA- 
p73 expression (Figure Ic). The AN-p73, co-expressed 
in these cells, is known to suppress both TA-p73 and 
p53 acfivities (Yang et al., 2000; Pozniak et al., 2000). 
In addition, some tumour-derived p53 mutant proteins 
were shown to bind and inactivate TA-p73 protein 
(Marin and Kaelin, 2000; Di Como et al., 1999; Strano
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Figure 2 Comparative analysis of the status of retinoblastoma pathway (pRb and E2F1 target (cyclin E and )
and p53 genes in HCC cell lines, (a) Either pRb or p i e x p r e s s i o n  is totally lost (Hep3B, SNU 387, SNU 449, Hep3B-TR, 
Hep40, SK-Hepl), or significantly decreased (SNU 398, SNU 423, SNU 475, FOCUS, PLC/PRF/5) in 11 out of 15 (73%) cell lines 
tested. Western blot analysis using antibody IF8 reveals that pRb protein is not detectable in HepB3, Hep3B-TR and Hep40, or 
weakly positive in SNU 423, SNU 449 and FOCUS. The asterix (*) denotes a non-pRb cross-reactive antigen (Morel et al., 2000), 
serving as a loading control for Western blot assay. RT-PCR analysis shows that pl6'^'^'^“ is not detectable in SNU 387, SNU 449 
and SK-Hepl, or weakly positive in SNU 398, SNU 423, SNU 475 and PLC/PRF/5. See Figure Ic for template loading control 
using GAPDH. Negative control for p i6*^ *^ '*“ RT-PCR is not shown, (b) The expression of E2F1 target cyclin E and pl4'^‘^*^‘ genes 
is induced in HCC cell lines. RT-PCR analysis of cyclin E transcripts reveals that their expression is uniformly induced in all cell 
lines tested, as compared to normal liver (NL). The induction of pl4'^‘^ *^ expression is detectable in all but three cell lines. The lack 
of expression in SNU 449 and SNU 387 (see Baek et al., 2000), and probably SK-Hepl (notice the lack of both p i a n d  
PI4ARF expression) is due to CDKN2A gene deletion. See Figure Ic for the use of GAPDH as template loading control. Negative 
control is not shown, (c) Western blot assay for p53 shows no expression in FOCUS, SNU 387, SNU 398, Hep3B, Hep3B-TR, and 
high levels in Hep40, Mahlavu, PLC/PRF/5, SNU 423, SNU 449, Huh7, SNU 475 cell lines. Mahlavu and PLC/PRF/5 display 
Arg249Ser, and Huh7 Tyr220Cys mutations. HepG2 and SK-Hepl express wild-type p53 (Puisieux et al., 1993; Hsu et al., 1993). 
pRb Western blot data was used as a loading control (as in a)
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et aL, 2000; Marin et ai, 2000; Gaiddon et ai, 2001). 
Therefore, we tested whether there was a correlation 
between TA-p73 expression and p53 gene status in 
HCC cells. As shown in Figure 2c, p53 protein was 
either lost or mutant in at least eight out of 15 (53%) 
cell lines tested.
Discussion
Our observations demonstrate that p73 gene in normal 
liver cells encodes only truncated AN-p73 transcript 
isoform. In mouse, this isoform was shown to code for 
an inactive p73 protein, acting as a dominant negative 
form on the activities of full-length TA-p73 as well as 
wild-type p53 proteins (Yang et aL, 2000; Pozniak et 
ai, 2000). The dominant expression of AN-p73 
transcript isoform was demonstrated in normal liver 
tissues from human, mouse as well as rat organisms 
(see Figure lc,e for human liver, other data not 
shown). In contrast, p73 gene encodes both TA-p73 
and AN-p73 isoforms in most HCC cell lines and some 
primary tumours. The acquired expression of TA-p73 
in HCC cells appears to be transformation-related 
rather than proliferation-related, since Mahlavu cells 
did not express detectable TA-p73 transcripts, while 
expressing AN-p73 isoform (Figure Ic). We also 
detected AN-p73, but not TA-p73 transcripts in 
proliferating normal human fibroblast cell line MRC5 
(data not shown).
Separate analysis of AN-p73 and TA-p73 tran­
scripts in liver and HCC has not been reported yet. 
However, Tannapfel et al. (1999a) reported the 
absence of p73 expression in normal hepatocytes, 
using an antibody directed against amino acid 
residues encoded by exon 3 of p73, which is absent 
in AN-p73, but present in TA-p73 transcripts (see 
Figure lb). Studies with this antibody (together with 
another anti-p73 antibody directed against a region 
common to both TA-p73 and AN-p73 proteins) also 
demonstrated that the p73 protein was negative in 
non tumour liver tissues, but positive in 32% of 
HCCs (Tannapfel et al., 1999b). Based on observa­
tions described here, it now appears that p73 detected 
in these HCCs is the TA-p73 form, although this 
requires a separate confirmation analysis with the 
TA-p73-specific antibody alone.
The induction of TA-p73 and the ‘retinoblastoma 
pathway’ inactivation was common in HCC cell lines 
(Table 1). However, comparative studies did not allow 
us to establish a link between the induction of TA-p73 
expression and the inactivation of ‘retinoblastoma 
pathway’. For example, the expression of E2F1-target 
genes was also induced in cell lines with apparently 
normal pRb and expression. Nevertheless, our
results indicate that ‘retinoblastoma pathway’ inactiva­
tion is common in HCC cell lines and it is 
accompanied by an induction of E2F1 target genes 
(i.e. p73, cyclin E and in most HCCs. This may
suggest that the acquired expression of TA-p73 in some 
HCC cell lines is due to the inactivation of ‘retino-
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blastoma pathway’. However, this remains to be 
demonstrated with further studies.
The expression of AN-p73 in normal liver, and the 
acquired expression of TA-p73 in HCC reveal new 
implications for p73 in tumour biology. The p73 gene, 
encoding only AN-p73 transcripts in normal liver, may 
function as a tumour promoter rather than a tumour 
suppressor in this tissue, by interfering with wild-type 
p53 function (Yang et ai, 2000; Pozniak et ai, 2000). 
This could explain why p73 is not mutated in HCC 
(Mihara et al., 1999). However, p53 gene is frequently 
mutated in HCC (Ozturk, 1999), as also demonstrated 
here in HCC-derived cell lines (Figure 2c). Thus, AN- 
p73 protein may not completely neutralize wild-type 
p53 activity. Alternatively, the induction of TA-p73 
transcription in tumour cells may redirect AN-p73 
protein from wild-type p53 to newly expressed TA-p73 
proteins.
On the other hand, the expression of TA-p73 
transcripts in HCC cells is puzzling, based on the fact 
that TA-p73 overexpression is known to induce growth 
arrest and apoptosis (Marin and Kaelin, 2000; Lohrum 
and Vousden, 2000). Therefore, HCC cells expressing 
TA-p73 need to equip themselves with mechanism(s) to 
tolerate TA-p73 protein expression. In addition to a 
possible role of AN-p73 protein for TA-p73 inactiva­
tion (Yang et ai, 2000; Pozniak et al., 2000), mutant 
p53 proteins may also inactivate TA-p73, as reported 
previously (Di Como et al., 1999; Strano et al., 2000; 
Marin et al., 2000; Gaiddon et al., 2001). Accordingly, 
several HCC cell lines reported here (Mahlavu, PLC/ 
PRF/5, Huh7 etc.) express mutant p53 proteins that 
may inactivate TA-p73 protein. However, some other 
cell lines (FOCUS, Hep3B, SNU 387, SNU 398 etc.) 
have lost p53 expression. In this later group of cell 
lines, the tolerance of TA-p73 expression may require 
mutant p53-independent mechanisms. One additional 
hypothesis is that TA-p73 protein levels and/or its 
growth suppressive activities are regulated by post- 
translational mechanisms, independent of both AN-p73 
and mutant p53. For example, endogenous p73 protein 
in a tumour cell line was shown to be stabilized by 
cisplatin and by c-Abl kinase, with no change in p73 
transcript levels (Gong et al., 1999). Moreover, the 
apoptosis-inducing function of p73 was demonstrated 
to be dependent to or enhanced by the c-Abl kinase in 
different cell types (Yuan et al., 1999; Agami et al., 
1999; Gong et al., 1999). Thus, some HCC cell lines 
may tolerate TA-p73 expression, if, for example, they 
are deficient in c-Abl kinase activity.
Materials and methods
Tissue.s and cell lines
Normal liver tissues from Balb/c mice and Sprague-Dawley 
rats were obtained after ether anaesthesia. Normal human 
liver tissue was obtained from discarded surgical material 
from a patient operated for hepatic hydatid cyst. Primary 
HCC tumours and non tumour liver were freshly frozen
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Table 1 Comparative analysis of TA-p73 induction, E2F1 target gene activation and the retinoblastoma (RB/) pathway inactivation in HCC
cell lines
Cel! lines
Group I: Inactivated RBI pathway 
hep3B 
Hep3B-TR 
hep40 
FOCUS 
SNU-449 
SNU-387 
SK-hepl 
PLC/PRF/5 
SNU-475 
SNU-398 
SNU-423
Group II: Normal RBI pathway 
Mahlavu 
SNU-182 
HepG2 
Huh-7
RBI pathway genes
pRb
ND
ND
ND
T races
Positive
Positive
Positive
Positive
Positive
Positive
T races
Positive
Positive
Positive
Positive
Positive
Positive
Positive
Positive
ND
ND
ND
Traces
T races
Traces
T races
Positive
Positive
Positive
Positive
TA-p73
Positive 
Positive 
Positive 
Positive 
Positive 
Positive 
Positive 
Positive 
Positive 
Positive 
T races
ND
Traces
Positive
Positive
EF2I target genes
p j 4 A R F
Positive
Positive
Positive
Positive
ND
ND
ND
Positive
Positive
Positive
Positive
Positive
Positive
Positive
Positive
Cyclin E
Positive
Positive
Positive
Positive
Positive
Positive
Positive
Positive
Positive
Positive
Positive
Positive
Positive
Positive
Positive
ND: not detected
archival materials. Fifteen human hepatoma-derived cell lines 
(14 HCC and one hepatoblastoma), MRC5 and COS7 were 
grown in culture as described (Morel et ai, 2000). Most cell 
lines were from ATCC, the others have been previously 
described (Morel et al., 2000; Baek et ai, 2000; Puisieux et 
al., 1993; Bouzahzah et al., 1995).
RNA and cDNA preparations
Total RNA from cell lines and tissues was extracted using 
NucleoSpin RNA II Kit (MN Macherey-Nagel, Duren, 
Germany) and TriPure reagent (Boehringer Mannheim, 
Indianapolis, IN, USA), respectively. The cDNAs were 
prepared from total RNA (5 pg) using RevertAid First 
Strand cDNA Synthesis Kit (MBI-Fermentas, Vilnius, 
Lithuania).
Tran.script analysis by RT-PCR
For the identification of TA-p73 and AN-p73 forms, we used 
the available human p73 genomic sequence and mouse AN- 
p73 cDNA sequence data and designed two forward and one 
reverse (Primer R; 5'-GCGACATGGTGTCGAAGGTG- 
GAGC-3') primers to specifically amplify these forms from 
human, mouse and rat tissues. These sequences were selected 
on the basis of highest homology between mouse and human 
DNA sequences (maximum one mismatch, data not shown). 
The forward primers TAF (5'- AACCAGACAGCACCT- 
ACTTCGACC-3') and DNF (5'-ACCATGCTG TAC- 
GTCGGTGACCCC-3') were used for specific amplification 
of TA-p73 and AN-p73 forms, respectively. For the detection 
of p73 isoforms generated by differential splicing between 
exons 10 to 14, a forward primer from exon 10 (5'- 
CGGCCATATT GGTGCCGCAGCCACTGGTG-3') and 
two different reverse primers were used. A reverse primer 
from exon 13 (5'-GTTTGGCACCCCCAATCCTGT-3') was 
used for specific amplification of transcripts containing this 
exon, i.e. p73a, p73e, and p73y (see Zaika et al., 1999 for 
terminology). Another reverse primer, encompassing se­
quences from exon 12 followed by exon 14 (5'-AGGGCCCC- 
CAGGTCCTGAGC-3'), was used for specific amplification 
of p73/f and pl3(j) isoforms (Zaika et al., 1999) that contain
this particular sequence, plb'^ *^ ·^ ·' and pi4'^ '^ '^ RT-PCRs were 
done using a specific forward primer for each transcript (5'- 
CGGAGAGGGGGAGAACAGAC-3' for pl6""^ '^ and 5'- 
TCACCTCTGGTGCCAAAGGG-3' for pi 4'^ *^ '^) and a 
common reverse primer (5'-GGCAGTTGTGGCCCTG- 
TAGG-3'). For the detection of cyclin E mRNA levels, 
cyclin E-F (5'-TTGACCGGTATATGGCGACACAAG-3') 
and cyclin E-R (5'-ATGATACAAGGCCGAAGCAG- 
CAAG-3') primers were used. All RT-PCR reactions were 
done using appropriate annealing and extension conditions 
(additional information is available upon request). Equal 
amount of RNA was used in cDNA synthesis and the 
quality of cDNA was initially tested by GAPDH RT-PCR 
amplification with primer pair F (5'-GGCTGAGAACGG- 
GAAGCTTGTCAT-3') and R (5'-CAGCCTTCTCCAT- 
GGTGGTGAAGA-3'), using 1/40 vol-ume of cDNA 
preparation. Further PCR studies were performed with 
cDNA preparations yielding equal amounts of GAPDH 
amplification products. Total PCR cycle numbers have been 
defined following an initial study at 22, 26, 30 and 34 
cycles, in order to remain in the logarithmic phase of 
amplification. All RT-PCR results have been repeated 
several times from different batches of RNA preparations 
except primary tumours for which single RNA preparations 
were used. The expression of TA-p73 isoform was 
confirmed with an additional pair of primers, as described 
by Fillippovich et al. (2001). The identity of different p73 
isoforms (TA-p73, AN-p73, p73a, p73/i, p73y, p73(/;) has 
been confirmed by restriction enzyme mapping and 
automated sequencing (PE, ABI PRISM 377 automated 
sequencer) techniques.
Western blotting
The expression of retinoblastoma (pRb) and p53 proteins in 
different cell lines was studied by Western blotting, using 
anti-pRb IF8 (SC 102, Santa Cruz Biotechnology) and anti- 
p53 6B10 (Yolcu et al., 2001) monoclonal antibodies, 
respectively, as described previously (Morel et al., 2000). 
Equal protein loading was confirmed by blotting with control 
antibody against cytokeratin 18 (JAR 13 clone, gift from D 
Bellet, Institut Gustave Roussy, France). p73 protein Western
Oncogene
blot assays were done with ER13 (Ab-1, Oncogene Research 
Products, MA, USA) using the experimental procedure 
described by Marin et al. (1998).
Abbreviations
HCC, hepatocellular carcinoma; RBI, 
gene; pRb, retinoblastoma protein.
retinoblastoma
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ÑAPO as a novel marker for apoptosis
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A poptosis or programmed cell death plays a pivotal role in embryonic development and maintenance of homeostasis. It is also Involved In the etiology of pathophysiological conditions such as cancer, neurode- 
generatlve, autoimmune, infectious, and heart diseases. 
Consequently, the study of apoptosis Is now at center of 
both basic and clinical research applications. Therefore, 
sensitive and simple apoptosis detection techniques are 
required. Here we describe a monoclonal antibody-defined
novel antigen, namely NAPO (negative In apoptosis), 
which is specifically lost during apoptosis. The anti-NAPO  
antibody recognizes two nuclear polypeptides of 60 and 
70 kD. The antigen is maintained in quiescent and senescent 
cells, as well as in different phases of the cell cycle. Including 
mitosis. Thus, immunodetection of NAPO antigen provides 
a specific, sensitive, and easy method for differential 
identification of apoptotic and nonapoptotic cells.
Introduction
During the last decade, apoptosis has become a major focus of 
interest for many fields of biomedical research. Programmed 
cell death is required for proper embryonic development as 
well as for the maintenance of homeostasis in adult tissues 
(Vaux and Korsmeyer, 1999; Wyllie and Golstein, 2001). 
Moreover, apoptosis is involved in the etiology and patho­
physiology of a variety of diseases, such as cancer, neuro- 
degenerative, autoimmune, infectious, and heart diseases 
(Chervonsky, 1999; Roulston et al., 1999; Mattson, 2000; 
Narula et al., 2000; Reed, 2000). Apoptotic cell death is 
characterized by a series of morphological changes, including 
cell shrinkage, nuclear condensation, chromatin segregation, 
membrane blebbing, formation of membrane-bound apoptotic 
bodies, and internucleosomal DNA cleavage (Saraste and 
Pulkki, 2000). These morphological changes result from 
a series of genetically programmed biochemical changes 
initiated by either the activation of death receptors or in­
tracellular stress conditions such as DNA damage. These 
proapoptotic signals are conveyed to mitochondria to cause 
the release of caspase-activating factors from this organelle, 
followed by a cascade of caspase activation which leads to 
cell death (Earnshaw et al., 1999; Gottlieb, 2000).
Apoptosis, as a critical component of life in multicellular 
organisms, is a target subject for understanding cellular 
mechanisms of many diseases, as well as for developing new
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drugs that interfere with either proapoptotic or antiapoptotic 
molecular networks. Consequently, it has become important 
to develop reliable assays to measure cell death. Techniques 
currently available for apoptosis detection are based on the 
study of morphology of apoptotic cells (light and fluores­
cence microscopy coupled to nuclear staining with specific 
dyes and electron microscopy), DNA fragmentation detected 
by terminal transferase-mediated dUTP nick-end labeling 
(TUNEL)* and similar techniques, membrane changes 
detected by annexin V in vivo labeling, and on immunological 
assays using antibodies directed to apoptosis-related proteins 
(Stadelmann and Lassmann, 2000). Essential requirements 
for apoptosis detection techniques include high sensitivity 
for apoptotic cells, the ability to differentiate between 
apoptosis and other forms of cellular changes, as well as 
distinction between different stages of the cell death process. 
However, we are facing a relative paucity for simple tech­
niques fulfilling these requirements, and furthermore allowing 
quantitative analysis (van Heerde et al., 2000). Immunological 
detection of apoptosis-related proteins is probably the best 
approach to overcome this obstacle, but there are only a few 
known apoptosis marker antigens (Stadelmann and Lass­
mann, 2000).
Here we describe a mouse monoclonal antibody-defined 
nuclear antigen composed of two polypeptides that we call 
NAPO  (for negative in apoptosis), which is strongly expressed 
in cells under many conditions (proliferation, quiescence, mi­
tosis, and senescence) except apoptosis. The immunoreactivity 
of the antigen, as tested by immunofluorescence technique.
*Abbreviations used in this paper: TUNEL, terminal transferase-medi­
ated dUTP nick-end labeling.
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Figure 1. initial characterization of NAPO antigen. Anii-NAPO  
monoclonal antibody recognizes two bands migrating at ~60 and 
70 kD. P^Slmethionine-labeled Huh7 cells were subjected to 
immunoprécipitation with anti-N/\PO antibody (+). ( - )  is a 
negative control (A). Immunofluorescence staining of Huh7 cells 
with anti-NAPO antibody indicates that NAPO is a nuclear antigen 
(B). Hoechst 33258 counterstain for nuclear DNA (C). NAPO 
Immunofluorescence staining of SNU 398 cells growing In standard 
culture medium indicates that the majority of cell nuclei are 
positive, but occasionally some cells with small nuclei (presumably 
apoptotic) are negative (D), as indicated by white arrows in nuclear 
DNA staining (E). /VAPO antigen is negative In apoptotic SNU 398 
cells which are induced by growth in serum-free medium (F). 
Apoptotic cells are indicated by white arrows In Hoechst 33258 
counterstainIng (G).
is lost in apoptotic cells in a way opposite to TUNEL and 
annexin V staining. Thus, NAPO antigen may serve as a reli­
able marker for apoptosis.
Results and discussion
Biochemical characterization of the N A P O antigen
A mouse IgG monoclonal antibody (named anú-NAPO an­
tibody) was generated against a nuclear antigen after immu­
nization with human colorectal cell line COLO 320. Deter­
gent-soluble proteins were prepared from metabolically 
labeled Huh7 cells and subjected to immunoprécipitation 
with anti-NAPO antibody. As shown in Fig. 1 A, anti- 
NAPO antibody recognized two proteins migrating at ^^60
: y  ·
A :·■·-
f
Figure 2. Identification of NAPO as a common apoptosis marker.
NAPO is negative in 100 )jlM H202-treated apoptotic Huh7 cells 
(A), In contrast to positive staining with TUNEL (C). NAPO is also 
lost in Fas-mediated apoptosis in jurkat cells (E), H202-mediated 
apoptosis in 293 cells (G), and UV-C-mediated apoptosis in MRC-5 
cells (I). B, D, F, H, and J show Hoechst 33258 counterstain ing.
and 70 kD, respectively. Immunofluorescence studies re­
vealed with the same cell line indicated that NAPO was a 
nuclear antigen (Fig. 1, B and C). This antibody was specific 
for human and monkey NAPOy since all human cell lines 
and monkey COS-7 showed positive immunostaining, but 
mouse (HC 11), rat (IAR-6), and hamster (CHOK-I) cell 
lines were negative (unpublished data).
Although NAPO antigen was ubiquitously present in all 
human cell lines so far tested, small nuclear fragments which 
are occasionally observed with some cell lines under normal 
culture conditions were negative (Fig. 1, D and E as an ex­
ample). This suggested to us that NAPO antigen could be 
lost during apoptosis.
Identification of N A P O as an apoptotic marker
Hepatocellular carcinoma-derived SNU 398 cells, which 
undergo apoptosis when grown under serum-free conditions 
were serum starved for three days and tested for NAPO anti­
gen immunoreactivity. Cells displaying morphological char-
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Table I. List of cell lines tested for loss of NAPO immunoreactivity 
after induction of apoptosis by various stimuli
Cell line Origin Morphology Apoptosis stimuli
Huh 7
SNU 398
MCF7
HeLa
SW480
LNCaP
U20S
A375
Jurkat
MRC-5
293
HCC
HCC
Breast cancer 
Cervix cancer 
Colon cancer 
Prostate cancer 
Osteosarcoma 
Melanoma 
TCL 
Lung
Embryonal kidney
Epithelial
Epithelial
Epithelial
Epithelial
Epithelial
Epithelial
Epithelial
Epithelial
Lymphoid
Fibroblastic
Epithelial
H2O2
Serum starvation
TNF-a, UV-C
UV-C
UV-C
UV-C
UV-C
UV-C
Anti-Fas, UV-C 
UV-C
Cisplatin, H2O2
HCC, hepatocellular carcinoma; TCL, acute T cell leukemia.
acteristics of apoptosis (cell shrinkage, nuclear condensation, 
and fragmentation) displayed negative NAPO staining in 
contrast to positive nuclear staining of all nonapoptotic cells 
(Fig. 1, F and G).
To confirm the loss of NAPO antigen during apoptosis in 
another cellular system, hepatocellular carcinoma-derived 
Fiuh7 cells were used. H 2O 2 (100 piM) treatment of these 
cells induce apoptosis under serum-deficient (0.1% FCS) 
conditions (unpublished data). As shown in Fig. 2 A, NAPO 
antigen was negative in apoptotic Huh7 cells that are identi­
fied as cells with small nuclei by Hoechst 33258 counter- 
staining (Fig. 2 B). To test whether the loss of NAPO expres­
sion is specific to this antigen, rather than a common feature 
shared by nuclear proteins, we also tested Huh7 cells for p53 
protein immunoreactivity under similar conditions. Huh7 
cells express a mutant p53 protein that accumulate in their 
nuclei (Volkmann et al., 1994). Both apoptotic and nonap­
optotic Huh7 cells displayed positive staining for p53 protein. 
Indeed, apoptotic cells displayed a stronger p53 immunore­
activity when compared with nonapoptotic cells (unpub­
lished data). This indicated that the loss of NAPO immu­
noreactivity in apoptotic Huh7 cells was specific to this 
antigen rather than a common feature of nuclear proteins.
For further characterization of NAPO as an apoptosis 
marker, additional studies were performed in different cell 
lines treated with different apoptosis stimuli. For all experi­
ments NAPO tests were run in parallel to TUNEL or an- 
nexin V staining (TUNEL data for Huh7 shown in Fig. 2 C 
as an example). To show whether NAPO antigen is lost dur­
ing death receptor-mediated apoptosis, TNF-a-treated 
MCF 7 and anti-Fas antibody-treated Jurkat cells were used. 
NAPO was lost in apoptotic Jurkat (Fig. 2 E) as well as 
MCF-7 cells (unpublished data). To test whether NAPO loss 
during apoptosis was common to cells of different origin, ad­
ditional tumor-derived (HeLa, U20S, A375, SW480, LN­
CaP) as well as normal tissue-derived (293 and MRC-5) cell 
lines were induced to undergo apoptosis by H 2O 2, UV-C, or 
cisplatin treatment (Table I). NAPO staining was lost in all 
apoptotic cells in contrast to strong nuclear staining of the 
nonapoptotic counterparts (example data on 293 and MRC-5 
cells are shown in Fig. 2, G and I, respectively).
These results demonstrate that NAPO is ubiquitously ex­
pressed in living cells, but lost during apoptosis independent 
of the apoptosis activating pathway (Table I). The loss of
.· r .
I I » » ·  
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Figure 3. NAPO antigen is positive in quiescent cells. MRC-5 cells 
were tested in parallel for BrdU incorporation (A and E) or NAPO 
antigen (C and G). Cells in A -D  were grown under standard culture 
conditions. Cells In panels E-H were serum starved for 3 d to induce 
a quiescent state, as indicated by negative BrdU staining in E. Note 
that both actively growing (C) and quiescent cells (G) are positive 
for NAPO. B, D, F, and FI show Hoechst 33258 counterstaining.
NAPO during apoptosis strongly suggests that this antigen is 
a nuclear caspase substrate. The epitope recognized by anti- 
NAPO antibody on this antigen is probably lost as a result of 
caspase-mediated protein cleavage. However, it is presently 
unclear whether any of 60- and 70-kD polypeptides of the 
NAPO antigen are known caspase substrates. To our knowl­
edge, proteins with similar molecular weight have not been 
described previously as apoptosis-associated proteins. Thus, 
NAPO appears to be a novel marker for apoptosis that could 
serve to distinguish apoptotic from nonapoptotic cells. How­
ever, it was important to know whether the antigenic reactiv­
ity is modified under different growth conditions such as 
quiescence, cell cycle (especially mitosis), and senescence.
Expression of the N A P O antigen in quiescent cells
MRC-5 human embryonic lung fibroblast cells (passage 18) 
were grown to confluency and serum starved for 3 d to in­
duce quiescence. To show that these cells are indeed quies­
cent, BrdU incorporation was also tested. Our results indi­
cate that '^ 1 5 % of asynchronously growing MRC-5 cells are 
positive for BrdU i.e., in S phase (Fig. 3 A), whereas no 
BrdU labeling was observed in quiescent cells (Fig. 3 E). 
Under both conditions, all cells displayed a similarly positive 
nuclear staining for NAPO (Fig. 3, C and G). These obser-
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Figure 4. NAPO expression during cell cycle. Huh7 cells were 
synchronized by nocodazole treatment, followed by mitotic shake- 
off. Freshly collected cells were then grown in culture for up to 
36 h. The S phase was identified by BrdU incorporation assay. Time 
points between 0-16, 20-32, and 36 h were evaluated respectively 
as G l, S, and G2 phases according to the BrdU incorporation index 
(A). NAPO and BrdU staining were performed at 4 h intervals. B, D, 
F, and H illustrate NAPO staining of cells at mitotic arrest (B), 8 h 
(D), 24 h (F), and 36 h (H), respectively. C, E, G, and I show 
Hoechst 33258 counterstaining. Note diffused NAPO staining in 
mitotically arrested Huh7 cells (B and C) which were digitally 
magnified threefold for better visualization.
vations indicated that NAPO expression is not lost in nondi­
viding quiescent cells.
Expression of the N A P O antigen during cell cycle
We also analyzed the expression pattern of NAPO in syn­
chronized cells in order to follow its positivity during differ­
ent phases of the cell cycle. For this purpose Huh7 cells were 
treated with nocodazole and mitotic cells were collected by 
mitotic shake-off and plated onto coverslips. Synchronized 
Huh7 cells were tested every 4 h for 36 h of culture for both 
BrdU incorporation and NAPO staining. BrdU incorpora­
tion was minimal until 16 h after the release from mitotic ar­
rest with a maximum of BrdU incorporation at 24 h, fol­
lowed by a significant decrease at 36 h (Fig. 4 A). According 
to BrdU incorporation index, cells at time points before 16 h 
were evaluated as G l phase cells, cells between time points
20 and 32 h as S phase cells, and those at time point 36 h as 
G2 phase cells. Mitotically arrested cells showed a diffusely 
positive (nuclear and cytoplasmic) NAPO staining (Fig. 4 B). 
NAPO-stamm^ pattern was nuclear throughout the cell cy­
cle, at all time points (time points 8, 24, and 36 h are shown 
in Figs. 4, D, F, and H, respectively). Thus, NAPO staining 
was always positive during the cell cycle, the only noticeable 
change being a diffuse staining during mitosis, in contrast to 
strictly nuclear staining in other phases of the cell cycle.
Expression of the /VAPO antigen in senescent cells
To test whether NAPO antigen expression is modified dur­
ing senescence, MRC-5 cells were grown until passage 40, at 
which point they remain alive and attached to cell plate, but 
they stop dividing, a characteristic feature of senescence 
(Fulder and Holliday, 1975).The senescence is often accom­
panied by a positive SA-(3-gal activity, which is negative in 
presenescent cells (Dimri et al., 1995). As shown in Fig. 5, 
in contrast to presenescent MRC-5 cells at passage 18 (Fig.
5 A), senescent MRC-5 cells at passage 40 were positive 
for SA-p-gal activity (Fig. 5 B). Immunofluorescence data 
shown in Fig. 5, C and D, indicated that both presenescent 
and senescent MRC-5 cells were positive for NAPO antigen 
immunoreactivity, demonstrating that NAPO expression is 
not lost in senescent cells.
Our obseiwations demonstrate that NAPO is present in liv­
ing cells in all phases of the cell cycle as well as during senes­
cence and quiescence, getting lost only during apoptosis. 
When compared with other available apoptosis detection sys­
tems, NAPO test is highly specific for apoptosis and offers the 
simplicity of antibody-based assays. The anú-NAPO anti­
body can be used for detection of apoptotic cells under differ­
ent conditions, such as in situ staining of cells and tissue sec­
tions, and for flow cytometry. TUNEL assay (Gavrieli et al., 
1992) is widely used for the identification of apoptotic cells, 
even though it requires several cumbersome experimental 
steps. As NAPO and TUNEL assays provide exclusive nuclear 
staining of alive and apoptotic cells, respectively, we believe 
that both assays may be combined for better identification of 
apoptosis. Moreover, NAPO assay may detect apoptotic cells 
before DNA fragmentation and it does not require special 
pretreatment of assay samples. NAPO may also be used in 
combination with annexin V staining (Martin et al., 1995). 
NAPO  differs from previously identified and antibody- 
defined apoptosis markers (Grand et al., 1995; Zhang et al., 
1996; Hammond et al., 1998; Srinivasan et al., 1998; Leers 
et al., 1999) by its exclusive loss in apoptotic cells, but not in 
quiescent, proliferating, senescent, or even mitotic cells. We 
believe that this antibody will be veiy helpful for develop­
ment of simple and easy immunoassays for measurement of 
apoptosis in both cell lines and tissue samples.
Materials and methods
Monoclonal antibody production
10,000,000 COLO 320 cells were lysed in 2 ml PBS and 0.5 ml of lysate 
was injected into tail vein of Balb/c mice. 1 mo later, mice were immu­
nized twice more at 1 wk intervals, hybridomas were prepared from 
splenic cells, and antibody-producing clones were selected as described 
previously (Ozturk et al., 1989). One of the antibodies of IgG isotype, 
named anti-NAPO, was used for further studies.
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Figure 5. NAPO antigen is positive in senescent cells. Presenescent 
(A, C, and E) and senescent (B, D, and F) MRC-5 cells were stained 
for senescence-associated (3-gaIactosidase activity (A and B), NAPO 
immunoreactivity (C and D), and Hoechst 33258 DNA staining 
(E and F). Note that senescence-associated (3-galactosidase-positive 
cells are also positive for NAPO antigen.
Tissue culture
Huh7, SNU 398, COLO 320, MCF-7, HeLa, U20S, SW480, A375, 293, 
MRC-5, COS7, IAR-6, and CFIOK-I cells were grown in DME (Biochrome 
or GIBCO BRL). FICl 1 was grown in RPMI 1640 (Biological Industries) 
supplemented with 10 ng/ml EGF (Sigma-Aldrich) and 5 p-g/ml insulin 
(Sigma-Aldrich). Jurkat and LNCaP cells were grown in RPMI 1640. All 
cells were grown in media supplemented with 1 0 %  FCS, 1 %  nonessential 
amino acids, 100 p-g/ml penicillin/streptomycin at 37°C and 5 %  CO 2 .
Induction of apoptosis
Apoptotic cell death was induced by either serum starvation or treatment 
with H2O 2, UV-C, cisplatin, anti-Fas antibody or TNF-a treatment. SNU 
398 hepatocellular carcinoma cells were induced in serum-free medium 
for 3 d and tested for apoptosis. For oxidative stress-induced apoptosis, 
Fluh7 cells were incubated in a culture medium containing 0 .1 %  FCS for 
72 h, and treated with freshly prepared 100 /xM H2O 2 for at least 4 h be­
fore apoptosis assay. 293 cells were treated with 200 jxM H2O 2 or 100 jxM 
cisplatin. MCF-7, FleLa, U 20S, A375, SW480, LNCaP, Jurkat, and MRC-5 
cells were treated with U V-C irradiation (60-120 mj/cm“). For physiologi­
cally induced apoptosis studies, TNF-a-treated (Boehringer; 50 ng/ml for 
72 h) MCF-7 and anti-fas antibody-treated (Upstate Biotechnology; clone 
CF111, 25 ng/ml for 24 h) jurkat cells were used.
Induction of quiescence
Presenescent MRC-5 cells (passage 18) were grown to confluency on cov- 
erslips and serum starved for 3 d. At the end of 3 d, one set of cells was 
tested for BrdU labeling and the other set was subjected to immunofluores­
cence for the expression of the N A P O  antigen as described later. Asynchro­
nously growing MRC-5 cells of the same passage were used as a control.
Mitotic arrest and cell cycle synchronization
Huh7 cells were grown to 60% confluency and incubated with 50 ng/ml 
nocodazole (Sigma-Aldrich) for 18 h. Mitotic cells were collected by mi­
totic shake-off and replated onto coverslips. At indicated time points (be­
tween 4 and 36 h), one set of cells was tested for BrdU labeling, and the 
other set was subjected to immunofluorescence for the expression of the 
N A P O  antigen.
Immunoprécipitation
F1uh7 cells grown to 7 0 %  confluency were starved in DME lacking me­
thionine (Sigma-Aldrich) and labeled with 200 pCi P^SJmethionine (Amer-
sham Pharmacia Biotech) per 4 ml medium for 2 h. Cells were scraped in 
ice-cold PBS and lysed in NP-40 lysis buffer (150 mM NaCI, 1 .0 %  NP-40, 
50 rnM Tris pH 8.0, protease inhibitor cocktail; Roche), and centrifuged at 
13,000 rpm at 4°C  for 30 min. The cell lysate was incubated with anti- 
N A P O  antibody for 2 h and the N A P O  antigen was immunoprecipitated 
by using protein G sepharose (Amersham Pharmacia Biotech).
Immunofluorescence
Cells were grown on coverslips and fixed with 10 0 %  ice-cold acetone for 
1 mm or by 4 %  paraformaldehyde for 1 h. When paraformaldehyde was 
used, cells were permeabilized for 3 min with 0 .1 %  Triton X-100 in 0 .1 %  
sodium citrate. After saturation with 3 %  BSA in PBS-T (0.1%) for 15 min 
fixed cells were incubated with anti-NAPO antibody for 1 h at room tem­
perature. FITC-conjugated goat anti-mouse antibody (Dako) was used as 
the secondary antibody and diluted as recommended by the supplier. The 
immunofluorescence staining of Huh7 cells for p53 protein was tested us­
ing 6B10 monoclonal antibody (Yolcu et al., 2001). Nuclear DNA was vi­
sualized by incubation with 3 p,g/ml Hoechst 33258 (Sigma-Aldrich) for 5 
min in the dark. Cover slips were then rinsed with distilled water, mounted 
on glass microscopic slides in 5 0 %  glycerol, and examined under fluores­
cent microscope (ZEISS), jurkat cells were cytospinned (Shandon) for 3 
min at 200 rpm before immunofluorescence procedures.
TUNEL and annexin V stainings
The TUNEL assay was performed using an in situ cell death detection kit 
(Roche), according to manufacturer's recommendations. The annexin V 
assay was performed by annexin V-PE reagent (PharMingen), according to 
manufacturer's recommendations, and cells were fixed in ethanol. After 
TUNEL and annexin V assays, cells were counterstained with Hoechst 
33258 and examined as described.
BrdU labeling and identification of S phase cells
For BrdU incorporation, cells were incubated with 30 fxM BrdU for 1 h be­
fore fixation with ice-cold 7 0 %  ethanol for 10 min. After DNA dénatur­
ation in 2 N FICl for 20 min, cells were incubated with FITC-conjugated 
anti-BrdU antibody (Dako) in the dilution as recommended by the sup­
plier, cells were counterstained with Hoechst 33258 and examined as de­
scribed.
Senescence-associated (3-galactosidase assay
MRC-5 cells were grown to passage 40 and subjected to senescence-asso­
ciated p-galactosidase (SA p-gal) assay, as described by Dimri et al. 
(1995). Briefly, cells were fixed in 3 %  formaldehyde for 5 min and incu­
bated with SA p-gal solution (40 mM citric acid/sodium phosphate buffer, 
pH 6.0, 5 mM potassium ferro cyanide, 5 mM potassium ferric cyanide, 
150 mM NaCI, 2 mM MgCl2 , and 1 mg/ml X-Gal) for up to 12 h, and ex­
amined under light microscope.
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